Thus,O
",",O
to,O
better,O
understand,O
the,O
emergence,O
of,O
the,O
recent,O
SARS‐CoV‐2,O
epidemic,O
in,O
Italy,O
",",O
we,O
analyzed,O
a,O
larger,O
and,O
updated,O
dataset,O
of,O
recently,O
released,O
data,O
of,O
the,O
COVID‐2019,O
epidemic,O
to,O
improve,O
more,O
effective,O
intervention,O
strategies,O
.,O
The,O
dataset,O
comprised,O
(,O
n,O
 ,O
=,O
 ,O
141,O
),O
complete,O
genomes,O
sequences,O
from,O
the,O
current,O
(,O
2019‐2020,O
),O
SARS‐CoV‐2,O
epidemic,O
retrieved,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
database,O
.,O
The,O
complete,O
dataset,O
was,O
assessed,O
for,O
the,O
presence,O
of,O
phylogenetic,O
signal,O
by,O
applying,O
the,O
likelihood,O
mapping,O
analysis,O
implemented,O
in,O
the,O
IQ‐TREE,O
1.6.8,O
software,O
(,O
http://www.iqtree.org,O
),O
.,O
To,O
better,O
understand,O
the,O
establishment,O
and,O
transmission,O
of,O
the,O
novel,O
SARS‐CoV‐2,O
in,O
Italy,O
",",O
the,O
recent,O
Italian,O
genomes,O
available,O
on,O
the,O
GISAID,S-Dataset
 ,O
database,O
were,O
added,O
to,O
a,O
dataset,O
of,O
138,O
SARS‐CoV‐2,O
genomes,O
from,O
the,O
global,O
epidemic,O
.,O
Phylogenetic,O
inference,O
robustness,O
will,O
be,O
improved,O
if,O
other,O
genomic,O
sequences,O
will,O
be,O
available,O
to,O
build,O
an,O
even,O
more,O
informative,O
dataset,O
despite,O
the,O
low,O
heterogeneity,O
of,O
the,O
sequenced,O
strains,O
.,O
It,O
was,O
designated,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
[,O
3,O
],O
.,O
In,O
late,O
January,O
2020,O
",",O
WHO,O
declared,O
the,O
outbreak,O
a,O
global,O
pandemic,O
with,O
cases,O
in,O
more,O
than,O
45,O
countries,O
where,O
the,O
COVID-19,O
was,O
spreading,O
fast,O
outside,O
China,O
",",O
most,O
significantly,O
in,O
South,O
Korea,O
",",O
Italy,O
",",O
and,O
Iran,O
with,O
over,O
"2,924",O
deaths,O
and,O
"85,212",O
cases,O
confirmed,O
while,O
"39,537",O
recovered,O
on,O
29,O
February,O
2020,O
",",O
06:05,O
 ,O
AM,O
(,O
GMT,O
),O
.,O
COVID-19,O
is,O
a,O
positive,O
-,O
sense,O
single,O
-,O
stranded,O
RNA,O
virus,O
(,O
+,O
ssRNA,O
),O
.,O
The,O
phylogenetic,O
analysis,O
indicates,O
that,O
COVID-19,O
likely,O
originated,O
from,O
bats,O
[,O
15,O
],O
.,O
The,O
sequence,O
of,O
COVID-19,O
RBD,O
",",O
together,O
with,O
its,O
RBM,O
that,O
contacts,O
receptor,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
",",O
was,O
found,O
similar,O
to,O
that,O
of,O
SARS,O
coronavirus,O
.,O
In,O
January,O
2020,O
",",O
a,O
group,O
of,O
scientists,O
demonstrated,O
that,O
ACE2,O
could,O
act,O
as,O
the,O
receptor,O
for,O
COVID-19,O
[,O
17–21,O
],O
.,O
However,O
",",O
COVID-19,O
differs,O
from,O
other,O
previous,O
strains,O
in,O
having,O
several,O
critical,O
residues,O
at,O
the,O
2019,O
-,O
nCoV,O
receptor,O
-,O
binding,O
motif,O
(,O
particularly,O
Gln493,O
),O
which,O
provide,O
advantageous,O
interactions,O
with,O
human,O
ACE2,O
[,O
15,O
],O
.,O
At,O
present,O
",",O
there,O
is,O
no,O
vaccine,O
or,O
approved,O
treatment,O
for,O
humans,O
",",O
but,O
Chinese,O
traditional,O
medicines,O
",",O
such,O
as,O
ShuFengJieDu,O
capsules,O
and,O
Lianhuaqingwen,O
capsules,O
",",O
could,O
be,O
possible,O
treatments,O
for,O
COVID-19,O
.,O
Sequences,O
of,O
proposed,O
epitopes,O
were,O
selected,O
from,O
the,O
COVID-19,O
reference,O
sequence,O
using,O
UCSF,O
Chimera,O
1.10,O
and,O
saved,O
as,O
a,O
PDB,S-Repository
 ,O
file,O
.,O
Sequence,O
alignment,O
of,O
the,O
COVID-19,O
envelope,O
protein,O
was,O
done,O
using,O
BioEdit,O
software,O
which,O
shows,O
total,O
conservation,O
across,O
four,O
sequences,O
which,O
were,O
retrieved,O
from,O
China,O
and,O
the,O
USA,O
(,O
Figure,O
3,O
),O
.,O
Applying,O
the,O
advanced,O
bioinformatics,O
tools,O
and,O
databases,O
",",O
various,O
peptide,O
-,O
based,O
vaccines,O
could,O
be,O
designed,O
where,O
the,O
peptides,O
act,O
as,O
ligands,O
[,O
61–63,O
],O
.,O
The,O
COVID-19,O
is,O
an,O
RNA,O
virus,O
which,O
tends,O
to,O
mutate,O
more,O
commonly,O
than,O
the,O
DNA,O
viruses,O
[,O
67,O
],O
.,O
These,O
mutations,O
lie,O
on,O
the,O
surface,O
of,O
the,O
protein,O
",",O
which,O
makes,O
COVID-19,O
more,O
superior,O
than,O
other,O
previous,O
strains,O
by,O
inducing,O
its,O
sustainability,O
leaving,O
the,O
immune,O
system,O
in,O
a,O
blind,O
spot,O
[,O
68,O
],O
.,O
In,O
our,O
present,O
work,O
",",O
different,O
peptides,O
were,O
proposed,O
for,O
designing,O
a,O
vaccine,O
against,O
COVID-19,O
(,O
Figure,O
1,O
),O
.,O
In,O
the,O
beginning,O
",",O
the,O
whole,O
genome,O
of,O
COVID-19,O
was,O
analyzed,O
by,O
a,O
comparative,O
genomic,O
approach,O
to,O
determine,O
the,O
potential,O
antigenic,O
target,O
[,O
69,O
],O
.,O
The,O
Artemis,O
Comparison,O
Tool,O
(,O
ACT,O
),O
was,O
used,O
to,O
analyze,O
human,O
coronavirus,O
(,O
HCoV,O
-,O
HKU1,O
),O
reference,O
sequence,O
vs.,O
Wuhan,O
-,O
Hu-1,O
COVID-19,O
.,O
New,O
genes,O
(,O
ORF8,O
and,O
ORF6,O
),O
were,O
found,O
inserted,O
in,O
COVID-19,O
which,O
were,O
absent,O
in,O
HCoV,O
-,O
HKU1,O
that,O
might,O
be,O
acquired,O
by,O
the,O
horizontal,O
gene,O
transmission,O
[,O
70,O
],O
.,O
Multiple,O
sequence,O
alignment,O
(,O
MSA,O
),O
was,O
performed,O
using,O
ClustalW,O
for,O
the,O
seven,O
strains,O
of,O
coronavirus,O
",",O
which,O
are,O
COVID-19,O
(,O
NC_04551,S-AccessionNumber
),O
",",O
SARS,O
-,O
CoV,O
(,O
FJ211859,S-AccessionNumber
),O
",",O
MESA,O
-,O
CoV,O
(,O
NC_019843,S-AccessionNumber
),O
",",O
HCoV,O
-,O
HKU1,O
(,O
AY884001,S-AccessionNumber
),O
",",O
HCoV,O
-,O
OC43,O
(,O
KF923903,S-AccessionNumber
),O
",",O
HCoV,O
-,O
NL63,O
(,O
NC_005831,S-AccessionNumber
),O
",",O
and,O
HCoV-229E,O
(,O
KY983587,S-AccessionNumber
),O
.,O
The,O
maximum,O
likelihood,O
phylogenetic,O
tree,O
revealed,O
that,O
COVID-19,O
is,O
found,O
in,O
the,O
same,O
clade,O
of,O
SARS,O
-,O
CoV,O
;,O
thus,O
",",O
the,O
two,O
strains,O
are,O
highly,O
related,O
to,O
each,O
other,O
(,O
Figure,O
4,O
),O
.,O
Unfortunately,O
",",O
IEDB,S-Repository
 ,O
did,O
not,O
give,O
any,O
result,O
for,O
B,O
-,O
cell,O
epitopes,O
;,O
this,O
might,O
be,O
due,O
to,O
the,O
length,O
of,O
the,O
COVID-19,O
(,O
75,O
amino,O
acids,O
),O
.,O
Although,O
both,O
flu,O
and,O
anti,O
-,O
HIV,O
drugs,O
are,O
used,O
currently,O
in,O
China,O
for,O
treatment,O
of,O
COVID-19,O
",",O
chloroquine,O
phosphate,O
",",O
an,O
old,O
drug,O
for,O
treatment,O
of,O
malaria,O
",",O
has,O
recently,O
been,O
found,O
to,O
have,O
apparent,O
efficacy,O
and,O
acceptable,O
safety,O
against,O
COVID-19,O
[,O
77,O
",",O
78,O
],O
;,O
nevertheless,O
",",O
more,O
studies,O
are,O
required,O
to,O
standardize,O
these,O
therapies,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
this,O
is,O
the,O
first,O
study,O
to,O
identify,O
certain,O
peptides,O
in,O
the,O
envelope,O
(,O
E,O
),O
protein,O
as,O
candidates,O
for,O
COVID-19,O
.,O
Within,O
few,O
weeks,O
",",O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
announced,O
a,O
novel,O
coronavirus,O
designated,O
as,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Currently,O
",",O
there,O
is,O
no,O
vaccine,O
or,O
approved,O
treatment,O
for,O
this,O
emerging,O
infection,O
;,O
thus,O
",",O
the,O
objective,O
of,O
this,O
study,O
is,O
to,O
design,O
a,O
multiepitope,O
peptide,O
vaccine,O
against,O
COVID-19,O
using,O
an,O
immunoinformatics,O
approach,O
.,O
Results,O
 ,O
Extensive,O
mutations,O
",",O
insertion,O
",",O
and,O
deletion,O
were,O
discovered,O
with,O
comparative,O
sequencing,O
in,O
the,O
COVID-19,O
strain,O
.,O
The,O
T,O
-,O
cell,O
epitope,O
-,O
based,O
peptide,O
vaccine,O
was,O
designed,O
for,O
COVID-19,O
using,O
the,O
envelope,O
protein,O
as,O
an,O
immunogenic,O
target,O
.,O
With,O
the,O
raging,O
COVID-19,O
pandemic,O
ongoing,O
",",O
the,O
interaction,O
between,O
aging,O
and,O
immune,O
response,O
to,O
the,O
pathogen,O
SARS,O
-,O
CoV-2,O
has,O
attracted,O
great,O
attention,O
.,O
It,O
has,O
been,O
widely,O
reported,O
that,O
elderly,O
people,O
are,O
more,O
susceptible,O
to,O
COVID-19,O
and,O
",",O
once,O
infected,O
",",O
the,O
consequence,O
is,O
much,O
more,O
severe,O
.,O
The,O
deaths,O
associated,O
with,O
COVID-19,O
have,O
been,O
largely,O
attributed,O
to,O
respiratory,O
failure,O
",",O
sepsis,O
",",O
cardiac,O
failure,O
",",O
kidney,O
injury,O
",",O
or,O
coagulopathy,O
.,O
Having,O
quantified,O
the,O
changes,O
in,O
PBMC,O
due,O
to,O
aging,O
",",O
the,O
authors,O
went,O
on,O
to,O
analyze,O
the,O
interaction,O
between,O
aging,O
and,O
COVID-19,O
.,O
Through,O
a,O
four,O
-,O
way,O
comparison,O
of,O
young,O
and,O
old,O
subjects,O
with,O
and,O
without,O
COVID-19,O
",",O
the,O
authors,O
found,O
that,O
COVID-19,O
infections,O
lead,O
to,O
a,O
depletion,O
of,O
TC,O
and,O
an,O
increase,O
of,O
MC,O
population,O
",",O
and,O
in,O
particular,O
a,O
depletion,O
of,O
CD4,O
+,O
naive,O
TC,O
and,O
increase,O
of,O
CD16,O
+,O
MC,O
",",O
and,O
that,O
aged,O
subjects,O
with,O
COVID-19,O
further,O
exacerbated,O
these,O
trends,O
.,O
Since,O
CD16,O
+,O
MC,O
has,O
highly,O
pro,O
-,O
inflammatory,O
properties,O
(,O
e.g.,O
",",O
high,O
expression,O
of,O
proinflammatory,O
cytokines,O
),O
compared,O
with,O
the,O
non,O
-,O
CD16,O
expressing,O
classic,O
monocytes,O
and,O
are,O
expanded,O
in,O
various,O
inflammatory,O
diseases,O
(,O
Ziegler,O
-,O
Heitbrock,O
",",O
2007,O
),O
",",O
the,O
observation,O
of,O
Zheng,O
et,O
al,O
.,O
",",O
suggests,O
that,O
aging,O
and,O
COVID-19,O
act,O
synergistically,O
to,O
drain,O
the,O
adaptive,O
immune,O
system,O
and,O
to,O
exacerbate,O
the,O
overly,O
inflammatory,O
response,O
that,O
may,O
be,O
partially,O
responsible,O
for,O
the,O
severity,O
of,O
the,O
infection,O
in,O
aged,O
patients,O
.,O
Future,O
studies,O
should,O
examine,O
the,O
interactions,O
between,O
aging,O
and,O
other,O
viral,O
infections,O
using,O
a,O
similar,O
approach,O
",",O
to,O
see,O
whether,O
the,O
observed,O
effect,O
is,O
general,O
or,O
specific,O
to,O
COVID-19,O
.,O
Three,O
genetic,O
-,O
related,O
models,O
for,O
predisposition,O
to,O
COVID-19,O
could,O
be,O
described,O
:,O
1,O
-,O
Common,O
variants,O
in,O
multiple,O
loci,O
that,O
have,O
weak,O
effect,O
through,O
single,O
contribution,O
.,O
2,O
-,O
Moderately,O
rare,O
variants,O
in,O
limited,O
genes,O
are,O
expected,O
to,O
have,O
strong,O
effects,O
",",O
and,O
thus,O
be,O
highly,O
penetrant,O
and,O
even,O
dominant,O
trait,O
as,O
long,O
as,O
COVID-19,O
infection,O
is,O
considered,O
.,O
The,O
concept,O
of,O
susceptibility,O
to,O
COVID-19,O
is,O
getting,O
more,O
and,O
more,O
complex,O
when,O
gene,O
interactions,O
with,O
environment,O
factors,O
",",O
such,O
as,O
smoking,O
",",O
are,O
considered,O
(,O
see,O
Fig,O
.,O
1,O
),O
.,O
The,O
receptor,O
-,O
binding,O
domain,O
(,O
RBD,O
),O
of,O
the,O
COVID-19,O
spike,O
-,O
protein,O
shows,O
strong,O
interaction,O
with,O
human,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
receptor,O
.,O
Consequently,O
",",O
ACE2,O
genetic,O
variants,O
that,O
could,O
affect,O
its,O
gene,O
expression,O
",",O
protein,O
conformation,O
",",O
and,O
protein,O
stability,O
are,O
the,O
one,O
of,O
most,O
questionable,O
underlying,O
factors,O
involving,O
in,O
genetic,O
predisposition,O
to,O
COVID-19,O
infection,O
[,O
1,O
],O
.,O
It,O
might,O
be,O
a,O
clue,O
to,O
the,O
higher,O
prevalence,O
and,O
severity,O
of,O
COVID-19,O
in,O
men,O
than,O
in,O
women,O
[,O
2,O
],O
.,O
The,O
immune,O
-,O
related,O
genetic,O
variants,O
involving,O
the,O
prior,O
strain,O
of,O
coronavirus,O
",",O
namely,O
SARS,O
-,O
CoV,O
",",O
are,O
suspected,O
to,O
have,O
roles,O
in,O
genetic,O
predisposition,O
of,O
COVID-19,O
infection,O
[,O
3,O
],O
",",O
[,O
4,O
],O
",",O
since,O
COVID-19,O
has,O
80,O
%,O
genetic,O
identity,O
to,O
SARS,O
-,O
CoV,O
[,O
5,O
],O
.,O
COVID-19,O
appears,O
to,O
be,O
less,O
severe,O
in,O
children,O
[,O
10,O
],O
.,O
For,O
membrane,O
fusion,O
to,O
occur,O
–,O
in,O
comparison,O
with,O
other,O
class,O
-,O
I,O
fusion,O
proteins,O
and,O
as,O
described,O
in,O
coronavirus,O
post,O
-,O
fusion,O
structures,O
–,O
the,O
S2,O
component,O
is,O
likely,O
to,O
undergo,O
a,O
major,O
helical,O
rearrangement,O
",",O
in,O
which,O
the,O
long,O
trimer,O
interface,O
helix,O
(,O
spanning,O
residues,O
990–1035,O
),O
grows,O
and,O
extends,O
",",O
by,O
incorporating,O
the,O
refolded,O
turn,O
and,O
helix,O
from,O
the,O
N,O
-,O
terminal,O
portion,O
of,O
HR1,O
",",O
and,O
projects,O
the,O
fusion,O
peptide,O
towards,O
the,O
host,O
cell,O
membrane,O
.,O
Abstract,O
 ,O
Detection,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
is,O
a,O
crucial,O
tool,O
for,O
fighting,O
the,O
COVID‐19,O
pandemic,O
.,O
This,O
dataset,O
brief,O
presents,O
the,O
exploration,O
of,O
a,O
shotgun,O
proteomics,O
dataset,O
acquired,O
on,O
SARS‐CoV‐2,O
infected,O
Vero,O
cells,O
.,O
The,O
number,O
and,O
proportion,O
of,O
persons,O
infected,O
with,O
COVID-19,O
are,O
mainly,O
determined,O
based,O
on,O
individual,O
testing,O
and,O
laboratory,O
-,O
based,O
bio,O
-,O
molecular,O
diagnostics,O
using,O
",",O
e.g.,O
",",O
reverse,O
transcription,O
-,O
quantitative,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
-,O
qPCR,O
),O
.,O
COVID-19,O
cases,O
are,O
reported,O
by,O
regional,O
health,O
authorities,O
and,O
aggregated,O
on,O
the,O
level,O
of,O
",",O
e.g.,O
",",O
the,O
Federal,O
States,O
in,O
Germany,O
",",O
as,O
well,O
as,O
on,O
a,O
national,O
level,O
(,O
RKI,O
",",O
2020,O
),O
.,O
Medema,O
et,O
al,O
.,O
(,O
2020,O
),O
have,O
shown,O
a,O
good,O
correlation,O
between,O
the,O
number,O
of,O
COVID-19,O
cases,O
and,O
the,O
gene,O
concentration,O
in,O
the,O
wastewater,O
of,O
different,O
Dutch,O
cities,O
.,O
Sequences,O
were,O
identified,O
in,O
terms,O
of,O
the,O
closest,O
homology,O
sequence,O
using,O
BLAST,O
",",O
https://blast.ncbi.nlm.nih.gov/Blast.cgi,O
(,O
database,O
Nucleotide,O
collection,O
(,O
nr,O
/,O
nt,O
),O
using,O
Blastn,O
(,O
optimized,O
for,O
somewhat,O
similar,O
sequences,O
),O
or,O
Megablast,O
(,O
optimized,O
for,O
highly,O
similar,O
sequences,O
),O
),O
.,O
In,O
Germany,O
",",O
local,O
health,O
authorities,O
report,O
the,O
number,O
of,O
COVID-19,O
cases,O
confirmed,O
by,O
laboratory,O
diagnosis,O
after,O
aggregation,O
from,O
the,O
community,O
to,O
district,O
level,O
to,O
state,O
and,O
federal,O
authorities,O
.,O
Whenever,O
available,O
",",O
the,O
cumulative,O
prevalence,O
and,O
the,O
cumulative,O
number,O
of,O
COVID-19,O
patients,O
recovered,O
and,O
deceased,O
were,O
obtained,O
from,O
community,O
-,O
level,O
reports,O
published,O
on,O
the,O
homepages,O
of,O
the,O
responsible,O
local,O
health,O
authorities,O
on,O
April,O
9th,O
",",O
2020,O
.,O
Previous,O
evaluation,O
of,O
the,O
primers,O
and,O
probe,O
within,O
a,O
different,O
test,O
setting,O
analysing,O
patient,O
material,O
or,O
cell,O
culture,O
-,O
derived,O
SARS,O
-,O
CoV-2,O
showed,O
minor,O
cross,O
-,O
reactivity,O
with,O
other,O
human,O
coronaviruses,O
(,O
data,O
not,O
shown,O
),O
.,O
While,O
the,O
sequence,O
of,O
the,O
P12,O
PCR,O
product,O
showed,O
significant,O
similarity,O
to,O
SARS,O
-,O
CoV-2,O
sequence,O
(,O
isolate,O
SARS,O
-,O
CoV-2,O
/,O
human,O
/,O
USA,O
/,O
CA,O
-,O
CZB-1525/2020,O
;,O
Accession,O
:,O
MT628199.1,S-AccessionNumber
),O
confirming,O
the,O
positive,O
identification,O
of,O
human,O
SARS,O
-,O
CoV2,O
by,O
means,O
of,O
RT,O
-,O
qPCR,O
(,O
Supplementary,O
Fig,O
.,O
S1A,O
),O
",",O
no,O
match,O
to,O
SARS,O
-,O
CoV-2,O
was,O
detectable,O
for,O
C2,O
(,O
Supplementary,O
Fig,O
.,O
S1B,O
),O
.,O
In,O
addition,O
",",O
a,O
positive,O
BLAST,O
result,O
for,O
C4,O
with,O
SARS,O
-,O
CoV-2,O
synthetic,O
construct,O
(,O
accession,O
:,O
MT458696.1,S-AccessionNumber
),O
(,O
E,O
value,O
0.002,O
),O
(,O
Supplementary,O
Fig,O
.,O
S1C,O
),O
was,O
found,O
.,O
When,O
sequencing,O
the,O
different,O
PCR,O
amplicons,O
obtained,O
using,O
wastewater,O
samples,O
taken,O
during,O
the,O
SARS,O
-,O
CoV-2,O
pandemic,O
and,O
long,O
before,O
the,O
outbreak,O
(,O
retained,O
samples,O
),O
",",O
distinct,O
results,O
for,O
the,O
test,O
sample,O
(,O
P12,O
),O
which,O
fits,O
SARS,O
-,O
CoV-2,O
/,O
human,O
/,O
USA,O
/,O
CA,O
-,O
CZB-1525/2020,O
isolate,O
from,O
NCBI,S-Repository
 ,O
database,O
was,O
found,O
",",O
but,O
not,O
for,O
the,O
retained,O
samples,O
suggesting,O
an,O
unspecific,O
signal,O
in,O
RT,O
-,O
qPCR,O
",",O
respectively,O
.,O
On,O
the,O
day,O
of,O
our,O
sampling,O
campaign,O
",",O
we,O
estimate,O
the,O
nominal,O
acute,O
incidence,O
of,O
COVID-19,O
to,O
range,O
between,O
30,O
and,O
174,O
cases,O
per,O
"100,000",O
residents,O
in,O
the,O
nine,O
catchment,O
areas,O
studied,O
(,O
Table,O
4,O
),O
.,O
The,O
nine,O
catchment,O
areas,O
studied,O
differ,O
considerably,O
in,O
size,O
",",O
wastewater,O
flow,O
(,O
Table,O
2,O
),O
",",O
and,O
nominal,O
numbers,O
of,O
COVID-19,O
cases,O
at,O
the,O
day,O
of,O
sampling,O
ranging,O
from,O
36,O
to,O
1037,O
acute,O
cases,O
and,O
from,O
85,O
to,O
1924,O
cumulative,O
cases,O
(,O
Table,O
4,O
),O
.,O
Clearly,O
",",O
the,O
estimated,O
nominal,O
number,O
of,O
COVID-19,O
cases,O
increases,O
with,O
increasing,O
measured,O
SARS,O
-,O
CoV-2,O
load,O
",",O
resulting,O
in,O
correlations,O
both,O
for,O
cumulative,O
and,O
acute,O
prevalence,O
(,O
Fig,O
.,O
8A,O
and,O
B,O
),O
.,O
Concurrently,O
",",O
in,O
the,O
last,O
weeks,O
the,O
relevance,O
of,O
the,O
recent,O
COVID‐19,O
(,O
2019‐nCoV,O
),O
outbreak,O
and,O
its,O
effects,O
started,O
to,O
become,O
evident,O
as,O
everybody,O
was,O
monitoring,O
the,O
number,O
of,O
cases,O
registered,O
globally,O
2,O
.,O
On,O
26,O
January,O
2020,O
",",O
the,O
first,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
case,O
was,O
reported,O
in,O
Arizona,O
(,O
third,O
case,O
in,O
the,O
United,O
States,O
),O
(,O
1,O
),O
.,O
In,O
anticipation,O
of,O
COVID-19,O
spreading,O
in,O
Arizona,O
",",O
we,O
initiated,O
a,O
surveillance,O
effort,O
for,O
the,O
local,O
emergence,O
of,O
SARS,O
-,O
CoV-2,O
starting,O
24,O
January,O
2020,O
.,O
Given,O
the,O
estimated,O
1-,O
to,O
14,O
-,O
day,O
incubation,O
period,O
for,O
COVID-19,O
",",O
the,O
spike,O
in,O
cases,O
might,O
be,O
related,O
to,O
university,O
spring,O
break,O
holiday,O
travel,O
(,O
8,O
to,O
15,O
March,O
),O
",",O
as,O
previously,O
seen,O
in,O
other,O
outbreaks,O
(,O
4,O
",",O
5,O
),O
.,O
This,O
generated,O
an,O
NGS,O
data,O
set,O
of,O
20.7,O
to,O
22.7,O
million,O
paired,O
-,O
end,O
reads,O
per,O
sample,O
.,O
GenBank,S-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
accession,O
numbers,O
were,O
the,O
following,O
:,O
SARS,O
-,O
CoV-2,O
AZ,O
-,O
ASU2922,O
",",O
MT339039,S-AccessionNumber
 ,O
and,O
EPI_ISL_424668,S-AccessionNumber
;,O
SARS,O
-,O
CoV-2,O
AZ,O
-,O
ASU2923,O
",",O
MT339040,S-AccessionNumber
 ,O
and,O
EPI_ISL_424669,S-AccessionNumber
;,O
SARS,O
-,O
CoV-2,O
AZ,O
-,O
ASU2936,O
",",O
MT339041,S-AccessionNumber
 ,O
and,O
EPI_ISL_424671,S-AccessionNumber
;,O
SARS,O
-,O
CoV-2,O
Wuhan1,O
",",O
MN908947.3,S-AccessionNumber
;,O
Pangolin,O
",",O
EPI_ISL_410721,S-AccessionNumber
;,O
Bat,O
-,O
RaTG13,O
",",O
MN996532.1,S-AccessionNumber
;,O
and,O
SARS,O
-,O
CoV,O
",",O
AY278741.1,S-AccessionNumber
.,O
The,O
81,O
-,O
nt,O
(,O
27,O
-,O
amino,O
-,O
acid,O
),O
deletion,O
observed,O
in,O
SARS,O
-,O
CoV-2,O
AZ_ASU2923,O
ORF7a,O
was,O
not,O
present,O
in,O
the,O
"6,290",O
SARS,O
-,O
CoV-2,O
sequences,O
available,O
from,O
GISAID,S-Dataset
 ,O
as,O
of,O
12,O
April,O
2020,O
.,O
The,O
Chinese,O
Centre,O
for,O
Disease,O
Control,O
and,O
Prevention,O
identified,O
this,O
infection,O
as,O
a,O
novel,O
coronavirus,O
infection,O
on,O
Jan,O
7,O
",",O
2020,O
and,O
on,O
Feb,O
11,O
",",O
2020,O
",",O
the,O
WHO,O
announced,O
a,O
new,O
name,O
for,O
the,O
pandemic,O
disease,O
as,O
2019,O
-,O
new,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
.,O
Studies,O
from,O
Europe,O
",",O
China,O
",",O
and,O
USA,O
on,O
COVID‐19,O
have,O
consistently,O
shown,O
that,O
older,O
age,O
and,O
comorbidity,O
are,O
major,O
risk,O
factors,O
for,O
adverse,O
outcomes,O
and,O
mortality,O
.,O
Although,O
most,O
reported,O
COVID-19,O
cases,O
in,O
China,O
were,O
mild,O
(,O
81,O
%,O
),O
",",O
approximately,O
80,O
%,O
of,O
deaths,O
had,O
occurred,O
among,O
adults,O
population,O
older,O
than,O
60,O
years,O
of,O
age,O
;,O
only,O
one,O
(,O
0.1,O
%,O
),O
death,O
had,O
occurred,O
in,O
a,O
person,O
under,O
19,O
years,O
of,O
age,O
[,O
[,O
3,O
],O
",",O
[,O
4,O
],O
",",O
[,O
5,O
],O
],O
.,O
Data,O
from,O
the,O
UK,O
[,O
10,O
],O
of,O
more,O
than,O
400,O
pregnant,O
patients,O
hospitalised,O
with,O
COVID-19,O
suggest,O
an,O
increased,O
potential,O
for,O
adverse,O
maternal,O
outcomes,O
in,O
pregnant,O
patients,O
hospitalised,O
with,O
confirmed,O
COVID-19,O
infection,O
;,O
while,O
the,O
risk,O
of,O
an,O
intrauterine,O
vertical,O
transmission,O
is,O
inconclusive,O
.,O
Royal,O
college,O
of,O
Obstetrics,O
and,O
Gynaecology,O
recommends,O
that,O
delivery,O
in,O
COVID-19,O
patients,O
should,O
be,O
determined,O
primarily,O
by,O
obstetric,O
indication,O
and,O
recommends,O
against,O
routine,O
separation,O
of,O
affected,O
mothers,O
and,O
their,O
babies,O
[,O
11,O
],O
.,O
Our,O
study,O
aims,O
to,O
provide,O
additional,O
emerging,O
information,O
for,O
maternity,O
and,O
neonatal,O
services,O
planning,O
their,O
response,O
to,O
COVID-19,O
.,O
RT,O
-,O
PCR,O
for,O
SARS,O
-,O
CoV-2,O
nucleic,O
acid,O
was,O
used,O
to,O
determine,O
COVID-19,O
in,O
suspected,O
infection,O
from,O
both,O
maternal,O
and,O
neonatal,O
nasopharyngeal,O
samples,O
.,O
A,O
total,O
of,O
6779,O
pregnant,O
patients,O
attended,O
our,O
Maternity,O
unscheduled,O
triaging,O
system,O
(,O
Fig,O
.,O
1,O
),O
",",O
of,O
which,O
79,O
had,O
suspected,O
COVID-19,O
symptoms,O
for,O
which,O
nasopharyngeal,O
samples,O
for,O
RT,O
-,O
PCR,O
for,O
SARS,O
-,O
CoV-2,O
nucleic,O
acid,O
were,O
taken,O
.,O
23/79,O
(,O
29,O
%,O
),O
of,O
patients,O
had,O
confirmed,O
COVID-19,O
infection,O
based,O
on,O
the,O
RT,O
-,O
PCT,O
test,O
.,O
For,O
all,O
the,O
23,O
patients,O
",",O
chest,O
radiography,O
also,O
showed,O
scattered,O
multiple,O
patchy,O
infiltrates,O
alongside,O
ground,O
glass,O
appearances,O
in,O
both,O
lungs,O
consistent,O
with,O
COVID-19,O
.,O
In,O
our,O
cohort,O
of,O
23,O
women,O
",",O
we,O
had,O
19,O
pregnant,O
women,O
with,O
confirmed,O
COVID-19,O
in,O
their,O
3rd,O
trimester,O
delivering,O
20,O
neonates,O
(,O
18,O
singleton,O
",",O
and,O
1,O
set,O
of,O
twins,O
),O
",",O
and,O
4,O
women,O
with,O
confirmed,O
COVID-19,O
in,O
their,O
second,O
trimester,O
.,O
One,O
new,O
-,O
born,O
",",O
who,O
was,O
delivered,O
at,O
35,O
weeks,O
by,O
emergency,O
C,O
-,O
section,O
to,O
black,O
African,O
patient,O
due,O
to,O
severe,O
COVID-19,O
respiratory,O
symptoms,O
requiring,O
ventilation,O
",",O
had,O
low,O
Apgar,O
score,O
of,O
3,O
and,O
5,O
",",O
at,O
1,O
and,O
5,O
min,O
respectively,O
following,O
delivery,O
(,O
Table,O
1,O
),O
.,O
Recently,O
",",O
Chen,O
et,O
al,O
.,O
[,O
5,O
],O
",",O
and,O
Zhu,O
et,O
al,O
.,O
[,O
17,O
],O
reported,O
that,O
the,O
perinatal,O
infection,O
COVID-19,O
may,O
have,O
adverse,O
effects,O
on,O
new,O
-,O
borns,O
",",O
but,O
compared,O
with,O
SARS,O
-,O
CoV,O
",",O
the,O
adverse,O
mother,O
-,O
to,O
-,O
child,O
outcomes,O
are,O
fewer,O
.,O
One,O
pregnancy,O
with,O
confirmed,O
COVID-19,O
infection,O
in,O
the,O
third,O
trimester,O
had,O
a,O
neonate,O
with,O
intrauterine,O
growth,O
restriction,O
.,O
To,O
study,O
the,O
effect,O
of,O
COVID-19,O
on,O
pregnancy,O
and,O
neonatal,O
outcomes,O
.,O
We,O
prospectively,O
collected,O
and,O
analysed,O
data,O
for,O
a,O
cohort,O
of,O
23,O
pregnant,O
patients,O
including,O
singleton,O
and,O
multiple,O
pregnancies,O
tested,O
positive,O
for,O
COVID-19,O
between,O
February,O
2020,O
and,O
April,O
2020,O
inclusive,O
to,O
assess,O
the,O
effect,O
of,O
COVID-19,O
on,O
pregnancy,O
",",O
and,O
neonatal,O
outcomes,O
.,O
Twenty,O
-,O
three,O
pregnant,O
patients,O
tested,O
positive,O
for,O
COVID-19,O
",",O
delivering,O
20,O
babies,O
including,O
a,O
set,O
of,O
twins,O
",",O
with,O
four,O
ongoing,O
pregnancies,O
at,O
the,O
time,O
of,O
manuscript,O
submission,O
.,O
Four,O
out,O
of,O
total,O
23,O
COVID-19,O
pregnant,O
patients,O
(,O
17.4,O
%,O
),O
developed,O
severe,O
adult,O
respiratory,O
distress,O
syndrome,O
complications,O
requiring,O
ICU,O
support,O
",",O
one,O
of,O
whom,O
led,O
to,O
maternal,O
death,O
1/23,O
(,O
4.3,O
%,O
),O
.,O
Conclusion,O
 ,O
COVID-19,O
is,O
associated,O
with,O
high,O
prevalence,O
of,O
preterm,O
birth,O
",",O
preeclampsia,O
",",O
and,O
caesarean,O
section,O
compared,O
to,O
non−COVID,O
pregnancies,O
.,O
COVID-19,O
infection,O
was,O
not,O
found,O
in,O
the,O
newborns,O
and,O
none,O
developed,O
severe,O
neonatal,O
complications,O
.,O
Abstract,O
  ,O
Background,O
 ,O
Detection,O
of,O
SARS,O
-,O
CoV-2,O
viral,O
RNA,O
is,O
important,O
for,O
the,O
diagnosis,O
and,O
management,O
of,O
COVID-19,O
.,O
The,O
antitumor,O
capacity,O
of,O
these,O
therapeutic,O
NK,O
cells,O
can,O
be,O
further,O
enhanced,O
via,O
incorporation,O
of,O
chimeric,O
antigen,O
receptors,O
(,O
CARs,O
),O
or,O
other,O
engineered,O
components,O
.,O
At,O
the,O
time,O
of,O
this,O
writing,O
",",O
three,O
global,O
trials,O
incorporating,O
NK,O
-,O
cell,O
based,O
cellular,O
therapies,O
have,O
been,O
initiated,O
.,O
The,O
sampling,O
dates,O
were,O
incorporated,O
into,O
TMRCA,O
estimation,O
.,O
We,O
downloaded,O
137,O
SARS,O
-,O
CoV-2,O
genomes,O
available,O
from,O
GISAID,S-Dataset
 ,O
as,O
of,O
2/23/2019,O
.,O
All,O
genome,O
sequences,O
were,O
downloaded,O
from,O
Global,B-Dataset
Initiative,I-Dataset
on,I-Dataset
Sharing,I-Dataset
Avian,I-Dataset
Influenza,I-Dataset
Data,I-Dataset
(GISAID,E-Dataset
",",O
https://www.gisaid.org/,S-URL
),O
and,O
GenBank,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/nucleotide/,S-URL
),O
.,O
Italy,O
is,O
one,O
of,O
the,O
countries,O
most-,O
and,O
earliest,O
-,O
affected,O
in,O
Europe,O
by,O
the,O
COVID-19,O
pandemic,O
(,O
https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6,S-URL
),O
.,O
The,O
first,O
autochthonous,O
cases,O
of,O
Coronavirus,O
2019,O
Disease,O
(,O
COVID-19,O
),O
were,O
observed,O
starting,O
from,O
21,O
February,O
2020,O
in,O
Codogno,O
(,O
Lodi,O
province,O
),O
",",O
determining,O
on,O
22,O
February,O
2020,O
the,O
establishment,O
of,O
a,O
“,O
red,O
zone,O
”,O
to,O
contain,O
the,O
epidemic,O
",",O
encompassing,O
11,O
municipalities,O
.,O
A,O
total,O
of,O
59,O
SARS,O
-,O
CoV-2,O
whole,O
genomes,O
were,O
newly,O
-,O
characterized,O
from,O
an,O
equal,O
number,O
of,O
patients,O
affected,O
by,O
COVID-19,O
",",O
attending,O
different,O
clinical,O
centres,O
in,O
Northern,O
and,O
Central,O
Italy,O
",",O
from,O
the,O
beginning,O
of,O
the,O
epidemic,O
(,O
22,O
February,O
2020,O
),O
until,O
27,O
April,O
2020,O
(,O
Table,O
S1,O
),O
.,O
The,O
results,O
were,O
mapped,O
and,O
aligned,O
to,O
the,O
reference,O
genome,O
obtained,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
",",O
accession,O
ID,O
:,O
EPI_ISL_412973,S-AccessionNumber
),O
using,O
Geneious,O
software,O
",",O
v.,O
9.1.5,O
(,O
Biomatters,O
",",O
Auckland,O
",",O
New,O
Zealand,O
),O
(,O
http://www.geneious.com,O
),O
[,O
6,O
],O
or,O
Torrent,O
Suite,O
v.,O
5.10.1,O
(,O
Euformatics,O
Oy,O
",",O
Espoo,O
",",O
Finland,O
),O
or,O
BWA,O
-,O
mem,O
and,O
rescued,O
using,O
Samtools,O
alignment,O
/,O
Map,O
(,O
Hinxton,O
",",O
UK,O
),O
(,O
v,O
1.9,O
),O
.,O
The,O
newly,O
-,O
characterized,O
59,O
genomes,O
plus,O
three,O
previously,O
characterized,O
isolates,O
by,O
us,O
(,O
EPI_ISL_417445,S-AccessionNumber
-417447,O
),O
[,O
1,O
],O
were,O
aligned,O
with,O
a,O
total,O
of,O
77,O
Italian,O
sequences,O
available,O
in,O
public,O
databases,O
(,O
GISAID,S-Dataset
",",O
https://www.gisaid.org/,S-URL
),O
on,O
13,O
May,O
2020,O
and,O
452,O
genomes,O
sampled,O
in,O
different,O
European,O
and,O
Asian,O
countries,O
(,O
513,O
and,O
16,O
",",O
respectively,O
),O
representing,O
all,O
the,O
different,O
viral,O
clades,O
described,O
in,O
the,O
Nextstrain,S-Repository
 ,O
platform,O
(,O
https://nextstrain.org/,S-URL
),O
.,O
The,O
final,O
data,O
set,O
thus,O
included,O
588,O
sequences,O
.,O
The,O
sampling,O
dates,O
of,O
the,O
entire,O
dataset,O
ranged,O
from,O
30,O
December,O
2019,O
to,O
27,O
April,O
2020,O
.,O
Table,O
S2,O
shows,O
the,O
accession,O
IDs,O
",",O
sampling,O
dates,O
and,O
locations,O
of,O
the,O
sequences,O
included,O
in,O
the,O
dataset,O
.,O
The,O
phylogenetic,O
analysis,O
for,O
clade,O
assignment,O
was,O
performed,O
by,O
RaxML,O
[,O
11,O
],O
on,O
the,O
entire,O
dataset,O
of,O
588,O
genomes,O
.,O
A,O
root,O
-,O
to,O
-,O
tip,O
regression,O
analysis,O
was,O
made,O
using,O
TempEst,O
in,O
order,O
to,O
investigate,O
the,O
temporal,O
signal,O
of,O
the,O
dataset,O
[,O
15,O
],O
.,O
Two,O
from,O
Chinese,O
patients,O
visiting,O
Italy,O
at,O
the,O
end,O
of,O
January,O
2020,O
after,O
being,O
infected,O
in,O
Wuhan,O
and,O
one,O
characterized,O
by,O
us,O
from,O
an,O
Italian,O
subject,O
",",O
living,O
in,O
Padua,O
",",O
sampled,O
in,O
March,O
2020,O
",",O
not,O
reporting,O
any,O
recent,O
trip,O
outside,O
Italy,O
or,O
contacts,O
with,O
subjects,O
affected,O
by,O
COVID-19,O
(,O
pp,O
=,O
0.99,O
),O
(,O
Figure,O
1,O
",",O
clade,O
19A,O
),O
.,O
In,O
Italy,O
",",O
values,O
between,O
2.4,O
and,O
3.6,O
have,O
been,O
estimated,O
in,O
the,O
early,O
phase,O
of,O
COVID-19,O
epidemic,O
before,O
the,O
control,O
measures,O
were,O
taken,O
[,O
"23,24,25",O
],O
.,O
We,O
observed,O
that,O
the,O
Re,O
was,O
>,O
1,O
since,O
the,O
first,O
decade,O
of,O
February,O
",",O
suggesting,O
that,O
the,O
infection,O
was,O
circulating,O
within,O
the,O
population,O
before,O
the,O
first,O
notified,O
(,O
hospitalized,O
),O
COVID-19,O
cases,O
.,O
Since,O
early,O
February,O
",",O
an,O
effective,O
reproduction,O
number,O
(,O
R,O
e,O
),O
greater,O
than,O
1,O
was,O
estimated,O
",",O
which,O
then,O
increased,O
reaching,O
the,O
peak,O
of,O
2.3,O
in,O
early,O
March,O
",",O
confirming,O
the,O
circulation,O
of,O
the,O
virus,O
before,O
the,O
first,O
COVID-19,O
cases,O
were,O
documented,O
.,O
A,O
new,O
virus,O
-,O
associated,O
disease,O
",",O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
was,O
initially,O
reported,O
in,O
China,O
on,O
30th,O
December,O
2019,O
(,O
Wu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
The,O
causative,O
agent,O
of,O
COVID-19,O
is,O
the,O
novel,O
human,O
coronavirus,O
SARS,O
-,O
CoV-2,O
(,O
Wu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
",",O
and,O
",",O
as,O
of,O
24th,O
March,O
2020,O
",",O
there,O
have,O
been,O
"372,757",O
confirmed,O
infections,O
and,O
"16,231",O
deaths,O
reported,O
worldwide,O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
.,O
In,O
China,O
",",O
the,O
COVID-19,O
epidemic,O
grew,O
exponentially,O
during,O
January,O
2020,O
",",O
peaking,O
on,O
12th,O
February,O
2020,O
with,O
"15,153",O
newly,O
confirmed,O
cases,O
per,O
day,O
.,O
One,O
month,O
later,O
",",O
reported,O
COVID-19,O
cases,O
in,O
China,O
dropped,O
to,O
~20,O
per,O
day,O
",",O
indicating,O
the,O
epidemic,O
there,O
was,O
contained,O
.,O
By,O
11th,O
March,O
2020,O
",",O
the,O
day,O
that,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
announced,O
COVID-19,O
to,O
be,O
a,O
new,O
pandemic,O
",",O
"37,371",O
cases,O
had,O
been,O
reported,O
outside,O
of,O
China,O
(,O
World,O
Health,O
Organization,O
",",O
2020,O
),O
.,O
Our,O
results,O
may,O
provide,O
valuable,O
information,O
for,O
implementing,O
and,O
interpreting,O
genomic,O
surveillance,O
of,O
COVID-19,O
in,O
other,O
regions,O
.,O
COVID-19,O
cases,O
in,O
Guangdong,O
grew,O
until,O
early,O
February,O
2020,O
(,O
peaking,O
at,O
>,O
100,O
cases,O
per,O
day,O
),O
and,O
declined,O
thereafter,O
(,O
Figure,O
 ,O
1,O
A,O
),O
.,O
However,O
",",O
since,O
the,O
beginning,O
of,O
March,O
2020,O
COVID-19,O
cases,O
imported,O
into,O
Guangdong,O
from,O
abroad,O
have,O
been,O
detected,O
with,O
increasing,O
frequency,O
.,O
As,O
of,O
26th,O
March,O
2020,O
",",O
a,O
total,O
of,O
102,O
imported,O
cases,O
were,O
reported,O
from,O
19,O
different,O
countries,O
(,O
Figure,O
 ,O
1A,O
),O
",",O
highlighting,O
the,O
risk,O
that,O
local,O
COVID-19,O
transmission,O
could,O
reignite,O
in,O
China,O
.,O
More,O
intensive,O
surveillance,O
was,O
initiated,O
on,O
30th,O
January,O
2020,O
in,O
response,O
to,O
the,O
Spring,O
Festival,O
period,O
",",O
which,O
results,O
in,O
greater,O
mobility,O
among,O
regions,O
and,O
provinces,O
in,O
China,O
(,O
Kraemer,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Tian,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
and,O
because,O
asymptomatic,O
COVID-19,O
cases,O
had,O
been,O
reported,O
(,O
Guan,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Surveillance,O
commenced,O
at,O
Guangdong,O
airports,O
in,O
early,O
March,O
",",O
following,O
the,O
growth,O
of,O
COVID-19,O
outbreaks,O
outside,O
of,O
China,O
.,O
To,O
understand,O
the,O
genetic,O
structure,O
of,O
the,O
COVID-19,O
outbreak,O
in,O
Guangdong,O
",",O
we,O
generated,O
near,O
-,O
complete,O
and,O
partial,O
genomes,O
from,O
53,O
COVID-19,O
patients,O
in,O
Guangdong,O
Province,O
.,O
The,O
median,O
tMRCA,O
estimate,O
of,O
the,O
COVID-19,O
pandemic,O
was,O
1st,O
December,O
2019,O
(,O
95,O
%,O
HPD,O
15th,O
November,O
to,O
13th,O
December,O
2019,O
;,O
Figure,O
 ,O
4,O
),O
",",O
consistent,O
with,O
previous,O
analyses,O
(,O
Rambaut,O
",",O
2020,O
),O
.,O
Our,O
analyses,O
of,O
the,O
genomic,O
epidemiology,O
of,O
SARS,O
-,O
CoV-2,O
in,O
Guangdong,O
province,O
indicate,O
that,O
",",O
following,O
the,O
first,O
COVID-19,O
case,O
detected,O
in,O
early,O
January,O
",",O
most,O
infections,O
were,O
the,O
result,O
of,O
virus,O
importation,O
from,O
elsewhere,O
",",O
and,O
that,O
chains,O
of,O
local,O
transmission,O
were,O
limited,O
in,O
size,O
and,O
duration,O
.,O
However,O
",",O
vigilance,O
is,O
still,O
required,O
as,O
there,O
remains,O
a,O
risk,O
that,O
SARS,O
-,O
CoV-2,O
transmission,O
could,O
reignite,O
in,O
Guangdong,O
following,O
the,O
recent,O
increase,O
in,O
the,O
number,O
of,O
COVID-19,O
cases,O
imported,O
to,O
China,O
from,O
other,O
countries,O
.,O
Further,O
",",O
the,O
low,O
and,O
variable,O
sampling,O
of,O
COVID-19,O
cases,O
among,O
different,O
regions,O
makes,O
it,O
challenging,O
to,O
evaluate,O
phylogenetic,O
clusters,O
that,O
comprise,O
cases,O
from,O
a,O
single,O
region,O
;,O
although,O
such,O
clusters,O
could,O
indeed,O
represent,O
local,O
transmission,O
",",O
our,O
results,O
show,O
they,O
can,O
also,O
include,O
multiple,O
introductions,O
from,O
a,O
genomically,O
undersampled,O
location,O
.,O
The,O
accession,O
numbers,O
for,O
the,O
sequences,O
reported,O
in,O
this,O
paper,O
are,O
GISAID,S-Dataset
:,O
EPI_ISL_413850–413902,S-AccessionNumber
.,O
Suspected,O
COVID-19,O
cases,O
were,O
screened,O
by,O
31,O
designated,O
hospitals,O
",",O
local,O
CDCs,O
in,O
21,O
prefecture,O
cities,O
",",O
and,O
6,O
third,O
-,O
party,O
detection,O
institutions,O
with,O
commercial,O
real,O
-,O
time,O
reverse,O
transcription,O
PCR,O
(,O
RT,O
-,O
PCR,O
),O
kits,O
(,O
see,O
below,O
for,O
further,O
details,O
),O
.,O
These,O
cities,O
recorded,O
the,O
highest,O
number,O
of,O
COVID-19,O
cases,O
(,O
Figure,O
 ,O
1B,O
),O
.,O
We,O
collected,O
a,O
further,O
21,O
samples,O
from,O
18,O
patients,O
from,O
a,O
screening,O
project,O
of,O
hospitalized,O
COVID-19,O
cases,O
in,O
Guangdong,O
",",O
which,O
was,O
launched,O
on,O
28th,O
February,O
.,O
Virus,O
genomes,O
were,O
generated,O
by,O
two,O
different,O
approaches,O
",",O
(,O
i,O
),O
untargeted,O
metagenomic,O
sequencing,O
on,O
the,O
BGI,O
MGISEQ-2000,O
(,O
n,O
 ,O
=,O
63,O
),O
and,O
Illumina,O
NextSeq,O
(,O
n,O
 ,O
=,O
4,O
),O
sequencing,O
platforms,O
",",O
and,O
(,O
ii,O
),O
using,O
version,O
1,O
of,O
the,O
ARTIC,O
COVID-19,O
multiplex,O
PCR,O
primers,O
(,O
https://artic.network/ncov-2019,O
),O
",",O
followed,O
by,O
nanopore,O
sequencing,O
on,O
an,O
ONT,O
MinION,O
(,O
n,O
 ,O
=,O
45,O
),O
.,O
The,O
ARTIC,O
bioinformatics,O
pipeline,O
for,O
COVID,O
(,O
https://artic.network/ncov-2019,O
),O
was,O
used,O
to,O
generate,O
consensus,O
sequences,O
and,O
call,O
single,O
nucleotide,O
changes,O
relative,O
to,O
the,O
reference,O
sequence,O
.,O
Assembly,O
of,O
the,O
nanopore,O
raw,O
data,O
was,O
performed,O
using,O
the,O
ARTIC,O
bioinformatic,O
pipeline,O
for,O
COVID-19,O
with,O
minimap2,O
(,O
Li,O
",",O
2018,O
),O
and,O
medaka,O
(,O
https://github.com/nanoporetech/medaka,O
),O
for,O
consensus,O
sequence,O
generation,O
.,O
All,O
available,O
SARS,O
-,O
CoV-2,O
sequences,O
(,O
n,O
 ,O
=,O
323,O
),O
on,O
GISAID,S-Dataset
 ,O
(,O
gisaid.org,S-URL
),O
on,O
13th,O
March,O
2020,O
were,O
downloaded,O
.,O
Sequences,O
from,O
GISAID,S-Dataset
 ,O
that,O
were,O
error,O
-,O
rich,O
",",O
those,O
which,O
represented,O
multiple,O
sequences,O
from,O
the,O
same,O
patient,O
",",O
and,O
those,O
without,O
a,O
date,O
of,O
sampling,O
were,O
removed,O
.,O
Finally,O
",",O
the,O
dataset,O
was,O
reduced,O
by,O
only,O
retaining,O
the,O
earliest,O
and,O
most,O
recently,O
sampled,O
sequences,O
from,O
epidemiologically,O
linked,O
outbreaks,O
(,O
e.g.,O
",",O
the,O
Diamond,O
Princess,O
cruise,O
ship,O
),O
.,O
The,O
resulting,O
dataset,O
of,O
250,O
sequences,O
therefore,O
represents,O
the,O
global,O
diversity,O
of,O
the,O
virus,O
while,O
minimizing,O
the,O
impact,O
of,O
sampling,O
bias,O
.,O
Root,O
-,O
to,O
-,O
Tip,O
Genetic,O
Distance,O
for,O
250,O
Sequences,O
in,O
the,O
Maximum,O
Likelihood,O
Tree,O
Plotted,O
against,O
Collection,O
Date,O
",",O
Related,O
to,O
Figure,O
 ,O
3,O
Details,O
of,O
the,O
Clusters,O
(,O
A,O
–,O
E,O
),O
of,O
Guangdong,O
Genome,O
Sequences,O
",",O
Related,O
to,O
Figure,O
 ,O
3,O
Screenshots,O
of,O
the,O
Online,O
Tree,O
Visualization,O
Tool,O
",",O
Related,O
to,O
Figure,O
 ,O
3,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
was,O
first,O
reported,O
in,O
central,O
China,O
in,O
December,O
2019,O
.,O
Despite,O
these,O
successes,O
",",O
COVID-19,O
surveillance,O
in,O
Guangdong,O
is,O
still,O
required,O
",",O
because,O
the,O
number,O
of,O
cases,O
imported,O
from,O
other,O
countries,O
has,O
increased,O
.,O
Effective,O
control,O
measures,O
helped,O
reduce,O
and,O
eliminate,O
chains,O
of,O
viral,O
transmission,O
     ,O
Genomic,O
and,O
epidemiological,O
analyses,O
provide,O
insights,O
into,O
how,O
COVID-19,O
was,O
contained,O
in,O
China,O
’s,O
most,O
populous,O
province,O
using,O
a,O
combination,O
of,O
surveillance,O
and,O
travel,O
restriction,O
measures,O
.,O
Among,O
the,O
problems,O
raised,O
by,O
the,O
COVID-19,O
pandemic,O
",",O
there,O
is,O
the,O
increased,O
risk,O
of,O
exposure,O
of,O
healthcare,O
workers,O
to,O
the,O
virus,O
.,O
Forster,O
et,O
al,O
.,O
(,O
1,O
),O
use,O
a,O
median,O
-,O
joining,O
(,O
MJ,O
),O
network,O
(,O
MJN,O
),O
and,O
its,O
Steinerization,O
process,O
to,O
investigate,O
the,O
evolution,O
of,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
causes,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
within,O
humans,O
.,O
Because,O
their,O
work,O
may,O
have,O
profound,O
implications,O
for,O
understanding,O
and,O
managing,O
the,O
COVID-19,O
global,O
pandemic,O
",",O
scrutiny,O
is,O
necessary,O
.,O
In,O
fact,O
",",O
the,O
implication,O
that,O
MJNs,O
reflect,O
phylogenetic,O
signal,O
in,O
the,O
traditional,O
sense,O
has,O
previously,O
been,O
challenged,O
by,O
Kong,O
(,O
3,O
),O
",",O
who,O
compared,O
inference,O
based,O
on,O
MJNs,O
with,O
Bayesian,O
model,O
-,O
based,O
phylogenetic,O
inference,O
for,O
85,O
published,O
datasets,O
and,O
found,O
substantial,O
disagreement,O
between,O
inferred,O
MJNs,O
and,O
posterior,O
distributions,O
on,O
phylogenies,O
",",O
indicating,O
that,O
the,O
two,O
methods,O
provide,O
different,O
measures,O
of,O
relatedness,O
in,O
a,O
phylogenetic,O
sense,O
.,O
The,O
pandemic,O
caused,O
by,O
the,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
(,O
COVID-19,O
),O
has,O
resulted,O
in,O
significant,O
pulmonary,O
morbidity,O
and,O
mortality,O
",",O
but,O
has,O
also,O
raised,O
many,O
questions,O
regarding,O
involvement,O
of,O
other,O
organ,O
systems,O
such,O
as,O
the,O
liver,O
.,O
Hepatologists,O
and,O
liver,O
pathologists,O
were,O
therefore,O
interested,O
to,O
find,O
that,O
researchers,O
from,O
China,O
demonstrated,O
liver,O
function,O
test,O
(,O
LFT,O
),O
abnormalities,O
in,O
~44,O
%,O
of,O
COVID-19,O
patients,O
and,O
that,O
these,O
abnormalities,O
seemed,O
to,O
correlate,O
with,O
the,O
severity,O
of,O
pulmonary,O
disease,O
[,O
1,O
",",O
2,O
],O
.,O
Nonetheless,O
",",O
the,O
spectrum,O
of,O
histological,O
liver,O
injury,O
in,O
COVID-19,O
remains,O
unknown,O
.,O
Early,O
in,O
the,O
course,O
of,O
the,O
pandemic,O
",",O
New,O
York,O
City,O
was,O
the,O
global,O
epicenter,O
for,O
cases,O
of,O
",",O
and,O
deaths,O
from,O
",",O
COVID-19,O
.,O
Our,O
volume,O
of,O
autopsies,O
increased,O
sharply,O
",",O
and,O
most,O
of,O
the,O
cases,O
were,O
due,O
to,O
sequelae,O
of,O
COVID-19,O
.,O
The,O
lung,O
findings,O
predominated,O
",",O
as,O
expected,O
;,O
however,O
",",O
~2/3,O
of,O
COVID-19,O
patients,O
in,O
our,O
healthcare,O
system,O
had,O
abnormal,O
LFTs,O
[,O
10,O
],O
.,O
Following,O
approval,O
from,O
the,O
Columbia,O
University,O
Irving,O
Medical,O
Center,O
Institutional,O
Review,O
Board,O
",",O
we,O
reviewed,O
lung,O
and,O
liver,O
sections,O
from,O
40,O
consecutive,O
autopsies,O
from,O
patients,O
who,O
died,O
of,O
illness,O
related,O
to,O
COVID-19,O
.,O
Quantitative,O
RT,O
-,O
PCR,O
was,O
performed,O
on,O
extracted,O
RNA,O
using,O
Taqman,O
4X,O
master,O
mix,O
and,O
SARS,O
-,O
COV-2,O
primer,O
/,O
probe,O
sets,O
(,O
IDT,O
),O
to,O
detect,O
presence,O
of,O
virus,O
per,O
the,O
CDC,O
recommendations,O
[,O
11,O
],O
.,O
We,O
sequentially,O
examined,O
the,O
liver,O
sections,O
of,O
the,O
first,O
44,O
COVID-19,O
autopsies,O
at,O
our,O
institution,O
;,O
however,O
",",O
four,O
were,O
excluded,O
for,O
severe,O
autolysis,O
resulting,O
in,O
a,O
cohort,O
of,O
40,O
patients,O
.,O
This,O
patient,O
had,O
been,O
treated,O
with,O
a,O
number,O
of,O
potentially,O
hepatotoxic,O
medications,O
throughout,O
the,O
hospital,O
course,O
including,O
hydroxychloroquine,O
and,O
tocilizumab,O
for,O
severe,O
COVID-19,O
",",O
as,O
well,O
as,O
amiodarone,O
for,O
atrial,O
fibrillation,O
and,O
ceftriaxone,O
and,O
piperacillin,O
/,O
tazobactam,O
for,O
infection,O
.,O
Therefore,O
",",O
it,O
would,O
seem,O
likely,O
that,O
the,O
steatosis,O
in,O
some,O
of,O
these,O
cases,O
developed,O
during,O
the,O
course,O
of,O
their,O
COVID-19,O
illness,O
.,O
A,O
series,O
of,O
over,O
300,O
COVID-19,O
cases,O
in,O
China,O
investigated,O
the,O
relationship,O
between,O
steatosis,O
and,O
neutrophil,O
to,O
lymphocyte,O
ratio,O
(,O
NLR,O
),O
.,O
The,O
exact,O
mechanism,O
/,O
pathobiology,O
of,O
hepatic,O
steatosis,O
in,O
COVID-19,O
is,O
worthy,O
of,O
further,O
investigation,O
.,O
The,O
role,O
of,O
immunosuppression,O
and,O
allograft,O
recipient,O
status,O
on,O
liver,O
injury,O
associated,O
with,O
COVID-19,O
will,O
need,O
further,O
study,O
.,O
The,O
potential,O
role,O
of,O
endothelial,O
injury,O
in,O
COVID-19,O
continues,O
to,O
evolve,O
.,O
While,O
we,O
can,O
not,O
exclude,O
these,O
findings,O
being,O
meaningful,O
(,O
if,O
they,O
are,O
present,O
throughout,O
the,O
entire,O
liver,O
),O
",",O
we,O
do,O
not,O
believe,O
that,O
vascular,O
injury,O
is,O
the,O
major,O
mechanism,O
of,O
injury,O
in,O
the,O
liver,O
in,O
COVID-19,O
patients,O
.,O
As,O
the,O
epidemic,O
evolves,O
",",O
it,O
will,O
be,O
important,O
to,O
gather,O
data,O
on,O
liver,O
injury,O
in,O
patients,O
with,O
non,O
-,O
lethal,O
COVID-19,O
.,O
We,O
attempted,O
to,O
validate,O
in,O
-,O
situ,O
hybridization,O
(,O
ISH,O
),O
protocols,O
and,O
IHC,O
for,O
SARS,O
-,O
CoV-2,O
",",O
but,O
nonspecific,O
marking,O
of,O
lipofuscin,O
",",O
and,O
reaction,O
with,O
endogenous,O
alkaline,O
phosphatase,O
in,O
liver,O
tissue,O
from,O
non,O
-,O
COVID-19,O
patients,O
who,O
died,O
years,O
ago,O
was,O
nearly,O
ubiquitous,O
(,O
sometimes,O
strong,O
and,O
diffuse,O
),O
.,O
It,O
will,O
be,O
important,O
and,O
interesting,O
to,O
attempt,O
to,O
identify,O
virus,O
in,O
specific,O
cells,O
in,O
the,O
liver,O
 ,O
and,O
to,O
determine,O
whether,O
the,O
ACE2,O
receptor,O
is,O
upregulated,O
in,O
hepatocytes,O
in,O
patients,O
with,O
severe,O
COVID-19,O
.,O
The,O
novel,O
coronavirus,O
SARS,O
-,O
CoV-2,O
(,O
coronavirus,O
disease,O
19,O
",",O
or,O
COVID-19,O
),O
primarily,O
causes,O
pulmonary,O
injury,O
",",O
but,O
has,O
been,O
implicated,O
to,O
cause,O
hepatic,O
injury,O
",",O
both,O
by,O
serum,O
markers,O
and,O
histologic,O
evaluation,O
.,O
Here,O
we,O
report,O
the,O
clinical,O
and,O
histologic,O
findings,O
related,O
to,O
the,O
liver,O
in,O
40,O
patients,O
who,O
died,O
of,O
complications,O
of,O
COVID-19,O
.,O
In,O
conclusion,O
",",O
we,O
found,O
patients,O
dying,O
of,O
COVID-19,O
had,O
biochemical,O
evidence,O
of,O
hepatitis,O
(,O
of,O
variable,O
severity,O
),O
and,O
demonstrated,O
histologic,O
findings,O
of,O
macrovesicular,O
steatosis,O
and,O
mild,O
acute,O
hepatitis,O
(,O
lobular,O
necroinflammation,O
),O
and,O
mild,O
portal,O
inflammation,O
.,O
Since,O
December,O
2019,O
",",O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
outbreak,O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
has,O
produced,O
a,O
worldwide,O
panic,O
.,O
Recent,O
clinical,O
studies,O
have,O
observed,O
digestive,O
symptoms,O
in,O
patients,O
with,O
"COVID-19,1",O
possibly,O
because,O
of,O
the,O
enrichment,O
and,O
infection,O
of,O
SARS,O
-,O
CoV-2,O
in,O
the,O
gastrointestinal,O
tract,O
",",O
mediated,O
by,O
virus,O
receptor,O
of,O
angiotensin,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
",",O
which,O
suggests,O
the,O
potential,O
for,O
a,O
fecal,O
-,O
oral,O
route,O
of,O
SARS,O
-,O
CoV-2,O
transmission,O
.,O
",",O
However,O
",",O
there,O
is,O
still,O
a,O
large,O
gap,O
in,O
the,O
biological,O
knowledge,O
of,O
COVID-19,O
.,O
Clinical,O
and,O
epidemiologic,O
data,O
of,O
patients,O
with,O
COVID-19,O
were,O
collected,O
from,O
a,O
continually,O
updated,O
resource,O
.,O
The,O
transcriptome,O
and,O
proteome,O
derived,O
from,O
bulk,O
tissues,O
and,O
cells,O
were,O
accessed,O
from,O
multiple,O
databases,O
.,O
A,O
phenome,O
-,O
wide,O
association,O
study,O
data,O
set,O
was,O
supplied,O
for,O
genetic,O
analysis,O
on,O
the,O
ACE2,O
pathway,O
.,O
We,O
constructed,O
a,O
user,O
-,O
friendly,O
interface,O
for,O
the,O
visualization,O
of,O
clinical,O
symptoms,O
of,O
COVID-19,O
(,O
https://mulongdu.shinyapps.io/map_covid/,O
;,O
A,O
similar,O
expression,O
pattern,O
could,O
be,O
found,O
in,O
extra,O
data,O
sets,O
(,O
Figure,O
 ,O
1,O
B,O
–,O
D,O
),O
.,O
ACC,O
",",O
adrenocortical,O
carcinoma,O
;,O
BLCA,O
",",O
bladder,O
urothelial,O
carcinoma,O
;,O
BRCA,O
",",O
breast,O
invasive,O
carcinoma,O
;,O
CESC,O
",",O
cervical,O
squamous,O
cell,O
carcinoma,O
and,O
endocervical,O
adenocarcinoma,O
;,O
CHOL,O
",",O
cholangiocarcinoma,O
;,O
COAD,O
",",O
colon,O
adenocarcinoma,O
;,O
DLBC,O
",",O
Lymphoid,O
neoplasm,O
diffuse,O
large,O
B,O
-,O
cell,O
lymphoma,O
;,O
ESCA,O
",",O
esophageal,O
carcinoma,O
;,O
GBM,O
",",O
glioblastoma,O
multiforme,O
;,O
HNSC,O
",",O
head,O
and,O
Neck,O
squamous,O
cell,O
carcinoma,O
;,O
KICH,O
",",O
kidney,O
chromophobe,O
;,O
KIRC,O
",",O
kidney,O
renal,O
clear,O
cell,O
carcinoma,O
;,O
KIRP,O
",",O
kidney,O
renal,O
papillary,O
cell,O
carcinoma,O
;,O
LAML,O
",",O
acute,O
myeloid,O
leukemia,O
;,O
LGG,O
",",O
brain,O
lower,O
-,O
grade,O
glioma,O
;,O
LIHC,O
",",O
liver,O
hepatocellular,O
carcinoma,O
;,O
LUAD,O
",",O
lung,O
adenocarcinoma,O
;,O
LUSC,O
",",O
lung,O
squamous,O
cell,O
carcinoma,O
;,O
MESO,O
",",O
mesothelioma,O
;,O
ns,O
",",O
no,O
significance,O
;,O
OV,O
",",O
ovarian,O
serous,O
cystadenocarcinoma,O
;,O
PAAD,O
",",O
pancreatic,O
adenocarcinoma,O
;,O
PCPG,O
",",O
pheochromocytoma,O
and,O
paraganglioma,O
;,O
PRAD,O
",",O
prostate,O
adenocarcinoma,O
;,O
READ,O
",",O
rectum,O
adenocarcinoma,O
;,O
SARC,O
",",O
sarcoma,O
;,O
SKCM,O
",",O
skin,O
cutaneous,O
melanoma,O
;,O
STAD,O
",",O
stomach,O
adenocarcinoma,O
;,O
TGCT,O
",",O
testicular,O
germ,O
cell,O
tumors,O
;,O
THCA,O
",",O
thyroid,O
carcinoma,O
;,O
THY,O
",",O
thymoma,O
;,O
TPM,O
",",O
transcripts,O
per,O
million,O
;,O
UCEC,O
",",O
uterine,O
corpus,O
endometrial,O
carcinoma,O
;,O
UCS,O
",",O
uterine,O
carcinosarcoma,O
;,O
UHR,O
",",O
Universal,O
Human,O
Reference,O
RNA,O
;,O
UVM,O
",",O
uveal,O
melanoma,O
.,O
We,O
obtained,O
7,O
phenotypes,O
related,O
to,O
the,O
intestinal,O
tract,O
and,O
kidney,O
deposited,O
in,O
the,O
phenome,O
-,O
wide,O
association,O
study,O
data,O
set,O
and,O
extracted,O
genome,O
-,O
wide,O
association,O
study,O
summary,O
statistics,O
with,O
more,O
than,O
3000,O
single,O
-,O
nucleotide,O
polymorphisms,O
assigned,O
to,O
33,O
genes,O
of,O
the,O
ACE2,O
pathway,O
for,O
the,O
gene,O
set,O
analysis,O
(,O
Supplementary,O
Table,O
 ,O
2,O
and,O
Supplementary,O
Figure,O
 ,O
3,O
),O
.,O
This,O
was,O
corroborated,O
by,O
the,O
clinical,O
observation,O
that,O
the,O
patients,O
with,O
severe,O
cases,O
of,O
COVID-19,O
were,O
more,O
likely,O
to,O
have,O
a,O
smoking,O
history,O
(,O
22.1,O
%,O
),O
than,O
those,O
with,O
nonsevere,O
COVID-19,O
(,O
13.1,O
%,O
),O
.,O
Nevertheless,O
",",O
renal,O
impairment,O
was,O
common,O
in,O
patients,O
with,O
severe,O
COVID-19,O
",",O
which,O
could,O
be,O
supported,O
by,O
the,O
potential,O
that,O
SARS,O
-,O
CoV-2,O
damaged,O
renal,O
tubular,O
cells,O
and,O
induced,O
the,O
disruption,O
of,O
the,O
ACE2,O
pathway,O
referring,O
to,O
ACE2,O
",",O
ACE,O
",",O
ENPEP,O
",",O
TGFB1,O
",",O
THOP1,O
",",O
MAS1,O
",",O
and,O
NLN,O
involved,O
in,O
kidney,O
dysfunction,O
.,O
It,O
is,O
reasonable,O
to,O
emphasize,O
the,O
monitoring,O
of,O
digestive,O
and,O
excretory,O
system,O
complications,O
in,O
patients,O
with,O
COVID-19,O
and,O
the,O
possibility,O
of,O
SARS,O
-,O
CoV-2,O
transmission,O
via,O
the,O
fecal,O
-,O
oral,O
route,O
by,O
individuals,O
with,O
suspected,O
infection,O
and,O
asymptomatic,O
carriers,O
(,O
Supplementary,O
Figure,O
 ,O
4,O
),O
.,O
Their,O
positions,O
on,O
the,O
3D,O
structure,O
of,O
the,O
MERS,O
-,O
CoV,O
spike,O
protein,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
5X5F,S-AccessionNumber
),O
are,O
illustrated,O
in,O
Figure,O
3,O
.,O
For,O
the,O
sake,O
of,O
comparison,O
",",O
we,O
also,O
retrieved,O
21,O
complete,O
genomes,O
of,O
betacoronavirus,O
strains,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
database,O
(,O
http://www.ncbi.nlm.nih.gov/genomes/VirusVariation/Database/nph-select2.cgi,S-URL
),O
",",O
along,O
with,O
those,O
of,O
two,O
2019,O
-,O
nCoV,O
strains,O
isolated,O
in,O
Saudi,O
Arabia,O
(,O
https://www.gisaid.org,S-URL
),O
.,O
Primers,O
were,O
designed,O
and,O
checked,O
using,O
Primer,O
Express,O
software,O
(,O
v3.0,O
),O
(,O
Applied,O
Biosystems,O
",",O
Foster,O
City,O
",",O
CA,O
",",O
USA,O
),O
and,O
NetPrimer,O
(,O
Premier,O
Biosoft,O
",",O
Palo,O
Alto,O
",",O
CA,O
",",O
USA,O
),O
",",O
with,O
gap,O
flanking,O
regions,O
incorporated,O
into,O
the,O
primers,O
.,O
For,O
the,O
spike,O
protein,O
dataset,O
",",O
we,O
used,O
the,O
Blosum62+Gamma,O
substitution,O
model,O
",",O
a,O
strict,O
clock,O
model,O
",",O
and,O
a,O
constant,O
-,O
size,O
tree,O
prior,O
.,O
The,O
BEAST,O
package,O
TreeAnnotator,O
was,O
utilized,O
to,O
summarize,O
a,O
maximum,O
clade,O
credibility,O
(,O
MCC,O
),O
tree,O
for,O
every,O
dataset,O
using,O
MCMC,O
tree,O
samples,O
.,O
The,O
novel,O
coronavirus,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
which,O
is,O
responsible,O
for,O
the,O
currently,O
ongoing,O
COVID-19,O
pandemic,O
that,O
has,O
caused,O
over,O
15,O
million,O
reported,O
cases,O
worldwide,O
and,O
over,O
"600,000",O
deaths,O
as,O
of,O
July,O
2020,O
",",O
also,O
contains,O
the,O
heavily,O
glycosylated,O
surface,O
glycoprotein,O
spike,O
(,O
S,O
),O
protein,O
.,O
Because,O
no,O
vaccines,O
or,O
therapeutics,O
are,O
currently,O
available,O
for,O
COVID-19,O
",",O
studies,O
of,O
SARS,O
-,O
CoV-2,O
as,O
a,O
prime,O
target,O
for,O
anti,O
-,O
viral,O
lectins,O
",",O
especially,O
those,O
that,O
bind,O
to,O
complex,O
-,O
type,O
N,O
-,O
glycans,O
",",O
are,O
of,O
special,O
interest,O
and,O
substantial,O
importance,O
.,O
The,O
50,O
%,O
infective,O
dose,O
(,O
TCID50,O
),O
and,O
immunoplaque,O
assay,O
(,O
PFU,O
/,O
ml,O
),O
of,O
viruses,O
in,O
MDCK,O
or,O
Vero,O
E6,O
cells,O
were,O
determined,O
beforehand,O
.,O
These,O
findings,O
suggest,O
a,O
potential,O
application,O
of,O
FRIL,O
for,O
the,O
prevention,O
and/or,O
treatment,O
of,O
influenza,O
and,O
COVID-19,O
.,O
For,O
a,O
coordinated,O
long,O
-,O
term,O
response,O
to,O
epidemic,O
threats,O
",",O
including,O
COVID-19,O
",",O
Canadian,O
researchers,O
should,O
coordinate,O
their,O
data,O
collection,O
and,O
data,O
governance,O
practices,O
with,O
those,O
of,O
established,O
international,O
consortia,O
to,O
facilitate,O
efficient,O
data,O
deposit,O
(,O
Council,O
of,O
Canadian,O
Academies,O
2015,O
),O
.,O
The,O
COVID-19,O
pandemic,O
has,O
lain,O
bare,O
the,O
fault,O
lines,O
in,O
Canada,O
’s,O
health,O
data,O
regulation,O
.,O
Challenges,O
faced,O
in,O
sharing,O
health,O
data,O
to,O
respond,O
to,O
the,O
COVID-19,O
epidemic,O
demonstrate,O
how,O
Canada,O
’s,O
duplicative,O
privacy,O
legislation,O
can,O
create,O
considerable,O
barriers,O
for,O
health,O
data,O
sharing,O
in,O
Canada,O
with,O
minimal,O
gains,O
in,O
personal,O
privacy,O
.,O
Consequently,O
",",O
we,O
suggest,O
inhibition,O
of,O
E,O
protein,O
can,O
be,O
a,O
good,O
target,O
to,O
alleviate,O
ARDS,O
complication,O
of,O
COVID-19,O
.,O
These,O
GenBank,S-Repository
 ,O
annotations,O
contain,O
heterogeneous,O
identifiers,O
for,O
genes,O
so,O
we,O
included,O
unique,O
locus,O
tags,O
containing,O
the,O
strain,O
accession,O
number,O
and,O
gene,O
index,O
number,O
for,O
computational,O
processing,O
.,O
Other,O
databases,O
showing,O
greater,O
detail,O
about,O
many,O
viruses,O
",",O
such,O
as,O
Virus,B-Repository
Pathogen,I-Repository
Resource,I-Repository
(VIPR,E-Repository
",",O
https://www.viprbrc.org,S-URL
),O
and,O
GSAID,S-Dataset
 ,O
(,O
https://www.gisaid.org,S-URL
),O
are,O
very,O
useful,O
but,O
these,O
resources,O
do,O
not,O
provide,O
gene,O
clustering,O
or,O
pan,O
-,O
genome,O
analysis,O
.,O
We,O
used,O
all,O
genes,O
from,O
Betacoronavirus,O
dataset,O
in,O
order,O
to,O
explore,O
Gene,O
Ontology,O
predictions,O
through,O
our,O
in,O
-,O
house,O
DeepGOPlus,O
(,O
Kulmanov,O
and,O
Hoehndorf,O
",",O
2020,O
),O
tool,O
that,O
combines,O
deep,O
convolutional,O
neural,O
network,O
(,O
CNN,O
),O
model,O
with,O
sequence,O
similarity,O
-,O
based,O
predictions,O
to,O
derive,O
relevant,O
functional,O
classes,O
from,O
Gene,O
Ontology,O
alongside,O
a,O
confidence,O
score,O
.,O
To,O
validate,O
the,O
conservation,O
and,O
specificity,O
of,O
the,O
SARS,O
E,O
cluster,O
",",O
we,O
compared,O
the,O
SARS,O
-,O
CoV-2,O
E,O
sequence,O
with,O
all,O
known,O
sequences,O
in,O
NCBI's,B-Repository
non-redundant,I-Repository
(NR),I-Repository
protein,E-Repository
 ,O
database,O
.,O
However,O
",",O
a,O
blast,O
-,O
based,O
search,O
against,O
the,O
DNA,O
of,O
all,O
sequences,O
in,O
NCBI's,B-Repository
NT,E-Repository
 ,O
database,O
showed,O
that,O
the,O
ORF10,O
sequence,O
matches,O
with,O
100,O
%,O
coverage,O
in,O
DNA,O
of,O
other,O
SARS,O
-,O
like,O
genomes,O
",",O
but,O
there,O
is,O
no,O
open,O
-,O
reading,O
frame,O
predicted,O
for,O
those,O
genomes,O
in,O
the,O
matching,O
region,O
(,O
Figure,O
1A,O
),O
.,O
Moreover,O
",",O
our,O
analysis,O
is,O
in,O
agreement,O
with,O
ORFs,O
3a,O
",",O
6,O
",",O
7a,O
",",O
8,O
",",O
and,O
being,O
accessory,O
non,O
-,O
essential,O
proteins,O
",",O
that,O
would,O
be,O
inefficient,O
targets,O
for,O
COVID-2019,O
therapy,O
.,O
A,O
number,O
of,O
isolates,O
from,O
COVID-19,O
patients,O
are,O
now,O
being,O
made,O
available,O
from,O
several,O
countries,O
",",O
thanks,O
to,O
resources,O
such,O
as,O
gisaid.org,O
.,O
Given,O
the,O
conservation,O
of,O
the,O
key,O
features,O
of,O
E,O
proteins,O
from,O
SARS,O
anSARS,O
-,O
CoV-2,O
",",O
these,O
compounds,O
would,O
be,O
promising,O
candidates,O
for,O
inhibiting,O
ARDS,O
in,O
COVID-19,O
.,O
Such,O
more,O
indirect,O
targeting,O
of,O
the,O
protein,O
E,O
function,O
might,O
also,O
be,O
considered,O
for,O
COVID-19,O
therapy,O
.,O
Therapies,O
to,O
combat,O
the,O
spread,O
of,O
SARS,O
-,O
CoV-2,O
and,O
the,O
lethality,O
caused,O
by,O
the,O
resulting,O
COVID-2019,O
are,O
currently,O
focusing,O
primarily,O
on,O
S,O
",",O
the,O
viral,O
spike,O
protein,O
(,O
Kruse,O
",",O
2020,O
;,O
Liu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Wrapp,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Our,O
pangenomic,O
analysis,O
suggests,O
that,O
the,O
protein,O
E,O
of,O
all,O
SARS,O
viruses,O
preserves,O
its,O
critical,O
motifs,O
used,O
for,O
pathogenesis,O
",",O
and,O
should,O
be,O
considered,O
as,O
an,O
alternative,O
target,O
to,O
be,O
tested,O
for,O
therapies,O
to,O
mitigate,O
COVID-2019,O
.,O
All,O
datasets,O
presented,O
in,O
this,O
study,O
are,O
included,O
in,O
the,O
article,O
/,O
Supplementary,O
Material,O
and,O
https://pangenomedb.cbrc.kaust.edu.sa,S-URL
.,O
Together,O
with,O
functional,O
pangenomic,O
analysis,O
",",O
mutation,O
tracking,O
",",O
and,O
previous,O
evidence,O
",",O
on,O
E,O
protein,O
as,O
a,O
determinant,O
of,O
pathogenicity,O
in,O
SARS,O
",",O
we,O
suggest,O
E,O
protein,O
as,O
an,O
alternative,O
therapeutic,O
target,O
to,O
be,O
considered,O
for,O
further,O
studies,O
to,O
reduce,O
complications,O
of,O
SARS,O
-,O
CoV-2,O
infections,O
in,O
COVID-19,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
is,O
a,O
CoV,O
identified,O
as,O
the,O
causal,O
agent,O
of,O
the,O
respiratory,O
epidemic,O
first,O
detected,O
in,O
China,O
(,O
Wuhan,O
),O
and,O
subsequently,O
declared,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
as,O
the,O
COVID-19,O
pandemics,O
due,O
to,O
the,O
spread,O
of,O
the,O
outbreak,O
to,O
other,O
countries,O
worldwide,O
(,O
Lai,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zheng,O
",",O
2020,O
),O
.,O
COVID-19,O
has,O
caused,O
a,O
significant,O
loss,O
in,O
human,O
lives,O
and,O
has,O
resulted,O
in,O
a,O
tremendous,O
economic,O
damage,O
across,O
the,O
five,O
continents,O
(,O
Ahn,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
At,O
present,O
",",O
there,O
is,O
no,O
accurate,O
therapy,O
for,O
COVID-19,O
though,O
some,O
medications,O
such,O
as,O
chloroquine,O
/,O
hydroxychloroquine,O
(,O
Wright,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
combinations,O
of,O
antiviral,O
and,O
anti,O
-,O
inflammatory,O
treatments,O
(,O
Stebbing,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
traditional,O
Chinese,O
medicine,O
(,O
Ren,O
et,O
al,O
.,O
",",O
2020,O
),O
and,O
other,O
therapeutics,O
(,O
Ahn,O
et,O
al,O
.,O
",",O
2020,O
;,O
Elfiky,O
",",O
2020,O
),O
have,O
been,O
proposed,O
.,O
The,O
development,O
of,O
vaccines,O
against,O
COVID-9,O
is,O
also,O
at,O
its,O
infancy,O
(,O
Ahmed,O
et,O
al,O
.,O
",",O
2020,O
;,O
Prompetchara,O
et,O
al,O
.,O
",",O
2020,O
;,O
Robson,O
",",O
2020,O
),O
.,O
Due,O
to,O
the,O
extent,O
of,O
the,O
pandemic,O
",",O
experimental,O
research,O
on,O
COVID-19,O
vaccine,O
candidates,O
and,O
therapeutics,O
as,O
well,O
as,O
the,O
identification,O
of,O
suitable,O
experimental,O
models,O
are,O
needed,O
to,O
limit,O
the,O
impact,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
With,O
the,O
outbreak,O
of,O
COVID-19,O
",",O
scientists,O
have,O
put,O
forward,O
effort,O
to,O
analyze,O
the,O
codon,O
usage,O
bias,O
of,O
CoVs,O
in,O
order,O
to,O
improve,O
our,O
understanding,O
on,O
the,O
emergence,O
",",O
adaptation,O
",",O
spread,O
and,O
evolution,O
of,O
SARS,O
-,O
CoV-2,O
(,O
Tort,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
As,O
a,O
systems,O
biology,O
approach,O
",",O
network,O
-,O
pharmacology,O
has,O
been,O
also,O
used,O
for,O
evaluating,O
the,O
potential,O
of,O
traditional,O
Chinese,O
medicines,O
against,O
COVID-19,O
(,O
Yu,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
In,O
silico,O
prediction,O
of,O
drug,O
candidates,O
against,O
COVID-19,O
has,O
been,O
also,O
proposed,O
on,O
the,O
basis,O
of,O
Angiotensin,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
regulatory,O
network,O
(,O
Cava,O
et,O
al,O
.,O
",",O
2020,O
),O
;,O
however,O
",",O
this,O
prediction,O
had,O
no,O
direct,O
connection,O
with,O
viral,O
infection,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
systems,O
biology,O
approaches,O
based,O
on,O
codon,O
usage,O
co,O
-,O
adaptation,O
between,O
SARS,O
-,O
CoV-2,O
and,O
its,O
human,O
host,O
as,O
well,O
as,O
SARS,O
-,O
CoV-2,O
-,O
induced,O
differential,O
gene,O
expression,O
have,O
not,O
been,O
applied,O
for,O
discovering,O
potential,O
therapeutics,O
for,O
COVID-19,O
and,O
other,O
respiratory,O
CoVs,O
.,O
Hence,O
",",O
the,O
primary,O
purpose,O
of,O
the,O
present,O
study,O
was,O
to,O
use,O
systems,O
biology,O
approaches,O
for,O
analyzing,O
the,O
codon,O
usage,O
profile,O
of,O
SARS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV-2,O
and,O
MERS,O
-,O
CoV,O
in,O
order,O
to,O
provide,O
useful,O
molecular,O
data,O
for,O
the,O
development,O
of,O
attenuated,O
SARS,O
-,O
CoV-2,O
vaccine,O
strains,O
that,O
may,O
have,O
vaccine,O
potential,O
against,O
COVID-19,O
and,O
a,O
broader,O
applicability,O
for,O
CoVs,O
.,O
Finally,O
",",O
based,O
on,O
our,O
knowledge,O
of,O
these,O
genes,O
",",O
we,O
also,O
aimed,O
to,O
predict,O
",",O
in,O
silico,O
",",O
the,O
potential,O
drugs,O
for,O
the,O
treatment,O
of,O
the,O
ongoing,O
COVID-19,O
in,O
particular,O
",",O
and,O
CoV,O
infection,O
in,O
general,O
.,O
Based,O
on,O
the,O
model,O
of,O
CAI,O
",",O
ENc,O
-,O
GC3,O
and,O
RSCU,O
of,O
the,O
three,O
CoVs,O
",",O
we,O
uncovered,O
the,O
functional,O
role,O
of,O
CoV,O
-,O
responsive,O
human,O
genes,O
and,O
how,O
respiratory,O
CoVs,O
affect,O
human,O
genes,O
",",O
and,O
revealed,O
a,O
useful,O
set,O
of,O
drugs,O
that,O
could,O
guide,O
practitioners,O
in,O
strategical,O
monitoring,O
of,O
COVID-19,O
.,O
The,O
full,O
-,O
length,O
CDS,O
sequences,O
of,O
SARS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV-2,O
and,O
MERS,O
-,O
CoV,O
were,O
downloaded,O
from,O
the,O
NCBI,S-Repository
 ,O
virus,O
(,O
https://www.ncbi.nlm.nih.gov/labs/virus/vssi/,S-URL
),O
database,O
.,O
The,O
gene,O
expression,O
dataset,O
GSE147507,S-AccessionNumber
 ,O
(,O
Blanco-Melo,B-Creator
et,I-Creator
"al.,",I-Creator
2020,E-Creator
),O
containing,O
the,O
gene,O
expression,O
of,O
human,O
cells,O
transfected,O
or,O
untransfected,O
with,O
SARS,O
-,O
CoV-2,O
was,O
downloaded,O
from,O
the,O
GEO,S-Repository
 ,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/geo/,S-URL
),O
.,O
The,O
viruSITE,S-Repository
 ,O
(,O
http://www.virusite.org/,S-URL
),O
",",O
a,O
database,O
of,O
viral,O
genomes,O
and,O
genes,O
(,O
Stano,B-Creator
et,I-Creator
"al.,",I-Creator
2016,E-Creator
),O
",",O
was,O
used,O
for,O
analyzing,O
the,O
sequences,O
of,O
SARS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV-2,O
and,O
MERS,O
-,O
CoV,O
based,O
on,O
the,O
reference,O
sequences,O
deposited,O
in,O
this,O
database,O
.,O
PCA,O
is,O
a,O
multivariate,O
analysis,O
approach,O
that,O
is,O
used,O
for,O
geometrical,O
plotting,O
of,O
sets,O
of,O
columns,O
and,O
rows,O
in,O
a,O
given,O
dataset,O
(,O
Wold,O
et,O
al,O
.,O
",",O
1987,O
),O
.,O
In,O
order,O
to,O
examine,O
the,O
genomic,O
similarity,O
of,O
SARS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV-2,O
and,O
MERS,O
-,O
CoV,O
",",O
similarity,O
analysis,O
was,O
performed,O
using,O
the,O
viruSITE,S-Repository
 ,O
database,O
.,O
Using,O
the,O
Drug-Gene,B-Repository
Interaction,I-Repository
database,I-Repository
(DGIdb),E-Repository
",",O
we,O
identified,O
drug,O
candidates,O
targeting,O
the,O
potential,O
human,O
genes,O
affected,O
by,O
viral,O
infection,O
.,O
Among,O
the,O
remaining,O
genes,O
we,O
found,O
hydroxychloroquine,O
(,O
3,O
target,O
genes,O
),O
and,O
chloroquine,O
(,O
2,O
target,O
genes,O
),O
which,O
have,O
been,O
recently,O
proposed,O
as,O
therapeutics,O
for,O
COVID-19,O
.,O
We,O
inferred,O
that,O
the,O
list,O
of,O
drugs,O
found,O
in,O
this,O
study,O
could,O
be,O
useful,O
for,O
the,O
treatment,O
of,O
COVID-19,O
.,O
This,O
approach,O
could,O
be,O
adopted,O
in,O
the,O
search,O
for,O
vaccines,O
against,O
respiratory,O
viruses,O
such,O
as,O
the,O
SARS,O
-,O
CoV2,O
responsible,O
for,O
COVID-19,O
.,O
Currently,O
",",O
the,O
mechanism,O
underlying,O
the,O
pathogenesis,O
of,O
COVID-19,O
is,O
unknown,O
.,O
In,O
addition,O
",",O
recent,O
studies,O
have,O
reported,O
that,O
segmental,O
pulmonary,O
emboli,O
(,O
hemoptysis,O
),O
occurs,O
in,O
COVID-19,O
infection,O
(,O
Casey,O
et,O
al,O
.,O
",",O
2020,O
),O
",",O
which,O
corroborated,O
with,O
our,O
finding,O
that,O
the,O
pathway,O
of,O
hematopoietic,O
cell,O
lineage,O
is,O
potentially,O
dysregulated,O
in,O
CoV,O
infections,O
.,O
Currently,O
",",O
there,O
is,O
no,O
precise,O
therapy,O
for,O
treating,O
the,O
ongoing,O
COVID-19,O
.,O
Here,O
",",O
we,O
predicted,O
a,O
set,O
of,O
drugs,O
that,O
could,O
be,O
efficient,O
in,O
the,O
treatment,O
of,O
COVID-19,O
and,O
other,O
CoV,O
infections,O
.,O
In,O
the,O
early,O
search,O
of,O
treatment,O
for,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
researchers,O
have,O
proposed,O
hydroxycholoroquine,O
and,O
chloroquine,O
as,O
treatment,O
for,O
COVID-19,O
(,O
Singh,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Our,O
study,O
also,O
predicted,O
these,O
drugs,O
as,O
a,O
treatment,O
for,O
COVID-19,O
and,O
other,O
CoV,O
infections,O
.,O
Thus,O
",",O
we,O
believe,O
that,O
its,O
administration,O
to,O
CoV,O
-,O
infected,O
patients,O
will,O
probably,O
be,O
salutary,O
for,O
patients,O
especially,O
due,O
to,O
the,O
fact,O
that,O
studies,O
have,O
demonstrated,O
that,O
the,O
neuroinvasive,O
ability,O
of,O
SARS,O
-,O
CoV2,O
is,O
partially,O
associated,O
with,O
the,O
respiratory,O
failure,O
of,O
COVID-19,O
patients,O
(,O
Li,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
has,O
caused,O
thousands,O
of,O
deaths,O
worldwide,O
and,O
has,O
become,O
an,O
urgent,O
public,O
health,O
concern,O
.,O
Herein,O
",",O
based,O
on,O
publicly,O
available,O
genomic,O
data,O
",",O
we,O
analyzed,O
the,O
codon,O
usage,O
co,O
-,O
adaptation,O
profiles,O
of,O
SARS,O
-,O
CoV-2,O
and,O
other,O
respiratory,O
coronaviruses,O
(,O
CoVs,O
),O
with,O
their,O
human,O
host,O
",",O
identified,O
CoV,O
-,O
responsive,O
human,O
genes,O
and,O
their,O
functional,O
roles,O
on,O
the,O
basis,O
of,O
both,O
the,O
relative,O
synonymous,O
codon,O
usage,O
(,O
RSCU)-based,O
correlation,O
of,O
viral,O
genes,O
with,O
human,O
genes,O
and,O
differential,O
gene,O
expression,O
analysis,O
",",O
and,O
predicted,O
potential,O
drugs,O
for,O
COVID-19,O
treatment,O
based,O
on,O
these,O
genes,O
.,O
Using,O
the,O
drug,O
-,O
gene,O
interaction,O
database,O
",",O
we,O
screened,O
a,O
list,O
of,O
drugs,O
that,O
could,O
target,O
these,O
genes,O
as,O
potential,O
COVID-19,O
therapeutics,O
.,O
Our,O
findings,O
not,O
only,O
will,O
contribute,O
in,O
vaccine,O
development,O
but,O
also,O
provide,O
a,O
useful,O
set,O
of,O
drugs,O
that,O
could,O
guide,O
practitioners,O
in,O
strategical,O
monitoring,O
of,O
COVID-19,O
.,O
We,O
recommend,O
practitioners,O
to,O
scrupulously,O
screen,O
this,O
list,O
of,O
predicted,O
drugs,O
in,O
order,O
to,O
authenticate,O
those,O
qualified,O
for,O
treating,O
COVID-19,O
symptoms,O
.,O
A,O
novel,O
coronavirus,O
disease,O
",",O
named,O
COVID-19,O
",",O
responsible,O
for,O
SARS,O
",",O
appeared,O
in,O
late,O
2019,O
",",O
originating,O
most,O
likely,O
from,O
a,O
seafood,O
market,O
in,O
Wuhan,O
",",O
in,O
the,O
Hubei,O
province,O
of,O
China,O
.,O
3,O
COVID-19,O
infection,O
has,O
rapidly,O
spread,O
and,O
was,O
declared,O
a,O
pandemic,O
by,O
the,O
WHO,O
on,O
11,O
March,O
2020,O
.,O
An,O
analysis,O
of,O
1524,O
patients,O
admitted,O
to,O
a,O
radiation,O
and,O
medical,O
oncology,O
unit,O
in,O
Wuhan,O
from,O
December,O
2019,O
to,O
February,O
2020,O
found,O
a,O
twofold,O
increase,O
of,O
the,O
risk,O
of,O
COVID-19,O
infection,O
rate,O
in,O
patients,O
with,O
cancer,O
compared,O
with,O
the,O
general,O
population,O
(,O
0.79,O
%,O
vs,O
0.37,O
%,O
),O
over,O
the,O
same,O
period,O
of,O
time,O
.,O
5,O
Data,O
derived,O
from,O
a,O
nationwide,O
analysis,O
in,O
China,O
reported,O
that,O
COVID-19,O
-,O
positive,O
patients,O
with,O
cancer,O
(,O
N=18,O
),O
had,O
a,O
higher,O
risk,O
of,O
severe,O
events,O
compared,O
with,O
patients,O
without,O
cancer,O
(,O
39,O
%,O
vs,O
8,O
%,O
",",O
p=0.0003,O
),O
",",O
especially,O
patients,O
in,O
active,O
treatment,O
compared,O
with,O
cancer,O
survivors,O
.,O
Facing,O
this,O
exceptional,O
and,O
rapidly,O
developing,O
situation,O
",",O
no,O
standard,O
operating,O
procedures,O
for,O
care,O
organisations,O
existed,O
in,O
oncologiocal,O
institutions,O
",",O
although,O
general,O
recommendations,O
for,O
healthcare,O
in,O
hospital,O
units,O
",",O
for,O
COVID-19,O
and,O
suspected,O
case,O
management,O
were,O
rapidly,O
drafted,O
.,O
We,O
aimed,O
to,O
assess,O
how,O
oncology,O
centres,O
and,O
departments,O
reacted,O
to,O
the,O
health,O
crisis,O
related,O
to,O
the,O
COVID-19,O
pandemic,O
",",O
in,O
order,O
to,O
improve,O
oncological,O
care,O
and,O
to,O
implement,O
preventive,O
measures,O
.,O
A,O
survey,O
(,O
online,O
supplementary,O
material,O
),O
was,O
sent,O
by,O
email,O
to,O
30,O
representatives,O
of,O
oncological,O
departments,O
in,O
12,O
of,O
the,O
most,O
affected,O
countries,O
by,O
COVID-19,O
in,O
Europe,O
and,O
the,O
USA,O
in,O
order,O
to,O
provide,O
quality,O
assessment,O
.,O
The,O
burden,O
on,O
the,O
health,O
system,O
for,O
each,O
country,O
at,O
the,O
moment,O
of,O
the,O
survey,O
completion,O
was,O
reported,O
as,O
the,O
number,O
of,O
affected,O
cases,O
per,O
100,O
 ,O
000,O
inhabitants,O
",",O
with,O
data,O
extracted,O
from,O
the,O
Johns,B-Repository
Hopkins,I-Repository
University,I-Repository
COVID-19,I-Repository
Data,I-Repository
Repository,E-Repository
.,O
The,O
burden,O
of,O
COVID-19,O
cases,O
on,O
the,O
health,O
system,O
is,O
calculated,O
as,O
the,O
number,O
of,O
total,O
infections,O
per,O
100,O
 ,O
000,O
inhabitants,O
in,O
each,O
country,O
(,O
figure,O
1,O
),O
.,O
For,O
Italy,O
",",O
Belgium,O
",",O
Switzerland,O
",",O
Spain,O
and,O
the,O
other,O
centre,O
from,O
USA,O
",",O
200–400,O
patients,O
were,O
affected,O
by,O
COVID-19,O
per,O
100,O
 ,O
000,O
inhabitants,O
.,O
In,O
10/21,O
(,O
47.6,O
%,O
),O
centres,O
",",O
physicians,O
discussed,O
the,O
option,O
to,O
avoid,O
intensive,O
care,O
in,O
case,O
of,O
worsening,O
of,O
clinical,O
conditions,O
in,O
those,O
with,O
terminal,O
illness,O
",",O
regardless,O
of,O
COVID-19,O
infection,O
",",O
accepting,O
the,O
risk,O
of,O
early,O
death,O
.,O
In,O
13/20,O
(,O
65,O
%,O
),O
centres,O
",",O
swab,O
tests,O
were,O
performed,O
before,O
hospitalisation,O
",",O
and,O
in,O
10/20,O
(,O
50,O
%,O
),O
centres,O
",",O
admissions,O
were,O
limited,O
to,O
COVID-19,O
-,O
negative,O
patients,O
.,O
Although,O
some,O
legal,O
and,O
reimbursement,O
issues,O
remain,O
",",O
COVID-19,O
crisis,O
has,O
led,O
to,O
a,O
rapid,O
expansion,O
of,O
telemedicine,O
",",O
which,O
could,O
remain,O
a,O
good,O
option,O
also,O
outside,O
the,O
pandemic,O
crisis,O
",",O
especially,O
when,O
a,O
clinical,O
examination,O
is,O
not,O
necessary,O
and,O
in,O
areas,O
of,O
the,O
world,O
where,O
reaching,O
the,O
hospital,O
raises,O
practical,O
difficulties,O
for,O
patients,O
.,O
Chest,O
CT,O
scan,O
seems,O
to,O
be,O
more,O
sensitive,O
than,O
RT,O
-,O
PCR,O
for,O
COVID-19,O
diagnosis,O
and,O
in,O
60%–93,O
%,O
of,O
the,O
cases,O
becomes,O
positive,O
before,O
the,O
RT,O
-,O
PCR.25,O
27,O
However,O
",",O
the,O
disadvantage,O
of,O
CT,O
is,O
the,O
limited,O
availability,O
in,O
terms,O
of,O
number,O
of,O
exams,O
per,O
day,O
in,O
each,O
institution,O
compared,O
with,O
the,O
swab,O
",",O
which,O
can,O
be,O
easily,O
made,O
on,O
a,O
large,O
scale,O
and,O
is,O
less,O
cost,O
-,O
effective,O
.,O
32,O
33,O
Finally,O
",",O
predisposed,O
dedicated,O
facilities,O
to,O
manage,O
cancer,O
care,O
during,O
COVID-19,O
pandemic,O
could,O
be,O
advisable,O
.,O
34,O
Although,O
COVID-19,O
wards,O
have,O
been,O
organised,O
in,O
most,O
centres,O
",",O
in,O
only,O
57.1,O
%,O
of,O
the,O
centres,O
healthcare,O
professionals,O
caring,O
for,O
oncohaematological,O
patients,O
did,O
not,O
take,O
part,O
in,O
the,O
care,O
of,O
COVID-19,O
-,O
positive,O
patients,O
.,O
Although,O
some,O
recommendations,O
for,O
hospital,O
management,O
during,O
the,O
COVID-19,O
pandemic,O
are,O
actually,O
available,O
",",O
such,O
as,O
those,O
of,O
the,O
European,O
Centre,O
for,O
Disease,O
Prevention,O
and,O
Control,O
",",O
our,O
study,O
allows,O
assessment,O
of,O
adherence,O
to,O
this,O
recommendation,O
",",O
in,O
addition,O
to,O
providing,O
an,O
insight,O
into,O
the,O
management,O
of,O
oncological,O
care,O
during,O
the,O
pandemic,O
in,O
a,O
real,O
-,O
world,O
context,O
.,O
Background,O
 ,O
COVID-19,O
appeared,O
in,O
late,O
2019,O
",",O
causing,O
a,O
pandemic,O
spread,O
.,O
Separated,O
pathways,O
for,O
COVID-19,O
-,O
positive,O
and,O
COVID-19,O
-,O
negative,O
patients,O
were,O
organised,O
",",O
with,O
separate,O
inpatient,O
units,O
and,O
day,O
care,O
areas,O
.,O
Self,O
-,O
isolation,O
was,O
required,O
for,O
COVID-19,O
-,O
positive,O
or,O
symptomatic,O
staff,O
",",O
while,O
return,O
to,O
work,O
policies,O
required,O
a,O
negative,O
swab,O
test,O
in,O
76.2,O
%,O
of,O
the,O
centres,O
.,O
Conclusion,O
 ,O
Many,O
pragmatic,O
measures,O
have,O
been,O
quickly,O
implemented,O
to,O
deal,O
with,O
the,O
health,O
emergency,O
linked,O
to,O
COVID-19,O
",",O
although,O
the,O
relative,O
efficacy,O
of,O
each,O
intervention,O
should,O
be,O
further,O
analysed,O
in,O
large,O
observational,O
studies,O
.,O
The,O
pathophysiology,O
of,O
severe,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
similar,O
to,O
that,O
of,O
severe,O
disease,O
caused,O
by,O
SARS,O
-,O
CoV,O
and,O
is,O
characterized,O
by,O
acute,O
respiratory,O
distress,O
and,O
excessive,O
inflammation,O
capable,O
of,O
inducing,O
respiratory,O
failure,O
",",O
multi,O
-,O
organ,O
failure,O
",",O
and,O
death,O
(,O
Wong,O
et,O
 ,O
al,O
.,O
",",O
2004,O
;,O
Zhang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
These,O
characteristics,O
contribute,O
to,O
the,O
difficulty,O
of,O
containing,O
SARS,O
-,O
CoV-2,O
spread,O
through,O
public,O
health,O
strategies,O
and,O
amplify,O
the,O
need,O
to,O
develop,O
vaccines,O
and,O
therapies,O
to,O
protect,O
against,O
and,O
treat,O
COVID-19,O
.,O
Clinical,O
management,O
of,O
COVID-19,O
is,O
largely,O
limited,O
to,O
infection,O
prevention,O
and,O
supportive,O
care,O
.,O
So,O
far,O
",",O
remdesivir,O
",",O
a,O
broad,O
-,O
spectrum,O
antiviral,O
agent,O
",",O
is,O
the,O
only,O
medication,O
approved,O
for,O
emergency,O
use,O
to,O
treat,O
COVID-19,O
by,O
the,O
US,O
Food,O
and,O
Drug,O
Administration,O
(,O
FDA,O
),O
(,O
Grein,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Although,O
the,O
evidence,O
supporting,O
remdesivir,O
use,O
in,O
patients,O
with,O
advanced,O
COVID-19,O
is,O
promising,O
",",O
there,O
remains,O
an,O
urgent,O
need,O
for,O
potent,O
SARS,O
-,O
CoV-2,O
therapeutic,O
agents,O
",",O
especially,O
those,O
that,O
could,O
be,O
given,O
in,O
an,O
outpatient,O
setting,O
",",O
to,O
effectively,O
combat,O
the,O
COVID-19,O
pandemic,O
.,O
Quality,O
control,O
filtering,O
of,O
the,O
data,O
was,O
performed,O
",",O
and,O
two,O
samples,O
from,O
each,O
of,O
the,O
phosphorylation,O
and,O
protein,O
abundance,O
datasets,O
were,O
removed,O
because,O
of,O
poor,O
correlation,O
with,O
their,O
respective,O
replicates,O
(,O
Figures,O
S1,O
A,O
and,O
S1B,O
),O
.,O
The,O
downregulation,O
of,O
these,O
proteins,O
suggests,O
that,O
they,O
may,O
mechanistically,O
contribute,O
to,O
symptoms,O
of,O
blood,O
coagulation,O
and,O
stroke,O
in,O
COVID-19,O
patients,O
(,O
Han,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
We,O
detected,O
25,O
phosphorylation,O
sites,O
in,O
SARS,O
-,O
CoV-2,O
viral,O
proteins,O
that,O
we,O
combined,O
with,O
another,O
proteomics,O
dataset,O
(,O
Davidson,B-Creator
"et al.,",I-Creator
2020,E-Creator
),O
to,O
amass,O
a,O
total,O
of,O
49,O
sites,O
detected,O
across,O
seven,O
viral,O
proteins,O
(,O
Table,O
S2,O
),O
.,O
Dot,O
color,O
indicates,O
whether,O
the,O
residue,O
is,O
(,O
true,O
),O
or,O
is,O
not,O
(,O
false,O
),O
predicted,O
to,O
form,O
part,O
of,O
an,O
interaction,O
interface,O
based,O
on,O
SPPIDER,O
analysis,O
.,O
To,O
identify,O
phosphorylation,O
sites,O
that,O
may,O
regulate,O
protein,O
-,O
protein,O
interactions,O
",",O
all,O
sites,O
were,O
mapped,O
to,O
3D,O
structures,O
",",O
and,O
solvent,O
accessibility,O
based,O
protein,O
-,O
protein,O
interface,O
identification,O
and,O
recognition,O
(,O
SPPIDER,O
),O
was,O
used,O
to,O
assess,O
whether,O
sites,O
resided,O
within,O
interface,O
regions,O
(,O
Porollo,O
and,O
Meller,O
2007,O
;,O
Figure,O
 ,O
2A,O
;,O
Table,O
S2,O
),O
.,O
Kinase,O
activities,O
were,O
estimated,O
for,O
a,O
wide,O
-,O
range,O
of,O
biological,O
conditions,O
obtained,O
from,O
previously,O
published,O
phosphoproteomics,O
datasets,O
(,O
Ochoa,B-Creator
"et al.,",I-Creator
2016,E-Creator
),O
.,O
To,O
better,O
understand,O
the,O
signaling,O
states,O
of,O
cells,O
over,O
the,O
course,O
of,O
infection,O
",",O
we,O
compared,O
our,O
data,O
with,O
a,O
compilation,O
of,O
public,O
phosphoproteomics,O
datasets,O
of,O
other,O
conditions,O
(,O
Ochoa,B-Creator
"et al.,",I-Creator
2016,E-Creator
;,O
Figures,O
4D,O
and,O
S2B,O
),O
.,O
Comparing,O
phosphoproteomics,O
profiles,O
of,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
cells,O
with,O
a,O
database,O
of,O
phosphorylation,O
profiles,O
collected,O
at,O
specific,O
cell,O
cycle,O
stages,O
",",O
viral,O
infection,O
was,O
most,O
highly,O
correlated,O
with,O
cells,O
arrested,O
at,O
the,O
S,O
/,O
G2,O
transition,O
and,O
was,O
negatively,O
correlated,O
with,O
profiles,O
of,O
cells,O
in,O
mitosis,O
(,O
Figure,O
 ,O
6,O
G,O
),O
.,O
Here,O
",",O
68,O
total,O
drugs,O
and,O
compounds,O
were,O
tested,O
for,O
antiviral,O
efficacy,O
(,O
via,O
qRT,O
-,O
PCR,O
",",O
anti,O
-,O
NP,O
antibody,O
",",O
plaque,O
assay,O
",",O
and/or,O
TCID50,O
),O
and,O
cellular,O
toxicity,O
at,O
two,O
different,O
institutions,O
(,O
in,O
New,O
York,O
[,O
Mount,O
Sinai,O
",",O
25,O
drugs,O
/,O
compounds,O
],O
and,O
Paris,O
[,O
Institut,O
Pasteur,O
",",O
62,O
],O
),O
and,O
in,O
two,O
cell,O
lines,O
(,O
Vero,O
E6,O
[,O
68,O
],O
and,O
A549,O
-,O
ACE2,O
[,O
61,O
],O
),O
.,O
Furthermore,O
",",O
silmitasertib,O
is,O
currently,O
being,O
considered,O
for,O
human,O
testing,O
as,O
a,O
potential,O
treatment,O
for,O
COVID-19,O
.,O
Recent,O
immunological,O
studies,O
have,O
indicated,O
that,O
increased,O
IL-6,O
",",O
IL-10,O
",",O
and,O
TNF,O
-,O
α,O
and,O
lymphopenia,O
are,O
associated,O
with,O
severe,O
COVID-19,O
cases,O
(,O
Pedersen,O
and,O
Ho,O
2020,O
),O
.,O
In,O
contrast,O
",",O
during,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
p38,O
/,O
MAPK,O
inhibition,O
suppressed,O
cytokine,O
production,O
and,O
impaired,O
viral,O
replication,O
by,O
a,O
still,O
unknown,O
mechanism,O
",",O
suggesting,O
that,O
p38,O
/,O
MAPK,O
inhibition,O
may,O
target,O
multiple,O
mechanisms,O
related,O
to,O
COVID-19,O
pathogenesis,O
.,O
Silmitasertib,O
",",O
a,O
small,O
molecule,O
undergoing,O
clinical,O
trials,O
for,O
various,O
cancers,O
",",O
is,O
now,O
being,O
considered,O
for,O
testing,O
in,O
humans,O
to,O
combat,O
COVID-19,O
.,O
The,O
antiviral,O
activity,O
observed,O
for,O
gilteritinib,O
",",O
an,O
FDA,O
-,O
approved,O
drug,O
for,O
treatment,O
of,O
acute,O
myeloid,O
leukemia,O
",",O
is,O
supported,O
by,O
involvement,O
of,O
another,O
AXL,O
inhibitor,O
",",O
bencentinib,O
",",O
in,O
the,O
RECOVERY,O
COVID-19,O
clinical,O
trial,O
in,O
the,O
United,O
Kingdom,O
.,O
The,O
mass,O
spectrometry,O
proteomics,O
data,O
have,O
been,O
deposited,O
to,O
the,O
ProteomeXchange,B-Repository
Consortium,E-Repository
 ,O
via,O
the,O
PRIDE,S-Repository
 ,O
partner,O
repository,O
with,O
the,O
dataset,O
identifier,O
PXD019113,S-AccessionNumber
 ,O
(,O
Perez-Riverol,B-Creator
et al.,E-Creator
",",O
2019,O
),O
.,O
For,O
infection,O
experiments,O
in,O
ACE2,O
-,O
A549,O
cells,O
",",O
SARS,O
-,O
CoV-2,O
",",O
isolate,O
USA,O
-,O
WA1/2020,O
(,O
NR-52281,O
),O
",",O
which,O
shares,O
99.983,O
%,O
sequence,O
identity,O
with,O
the,O
BetaCoV,O
/,O
France,O
/,O
IDF0372/2020,O
isolate,O
",",O
was,O
deposited,O
by,O
the,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
and,O
obtained,O
through,O
BEI,O
Resources,O
",",O
NIAID,O
",",O
NIH,O
.,O
Raw,O
mass,O
spectrometry,O
data,O
from,O
each,O
DDA,O
dataset,O
were,O
used,O
to,O
build,O
separate,O
libraries,O
for,O
DIA,O
searches,O
using,O
the,O
Pulsar,O
search,O
engine,O
integrated,O
into,O
Spectronaut,O
version,O
13.12.200217.43655,O
(,O
Bruderer,O
et,O
 ,O
al,O
.,O
",",O
2015,O
),O
by,O
searching,O
against,O
a,O
database,O
of,O
Uniprot,S-Repository
 ,O
Chlorocebus,O
sequences,O
(,O
"19,136",O
proteins,O
",",O
downloaded,O
April,O
3,O
",",O
2020,O
),O
and,O
29,O
SARS,O
-,O
CoV-2,O
protein,O
sequences,O
translated,O
from,O
genomic,O
sequence,O
downloaded,O
from,O
GISAID,S-Dataset
 ,O
(,O
accession,O
EPI_ISL_406596,S-AccessionNumber
",",O
downloaded,O
April,O
7,O
",",O
2020,O
),O
with,O
two,O
mutations,O
(,O
G22661,O
T,O
Spike,O
V367F,O
and,O
G26144,O
T,O
ORF3a,O
G251V,O
),O
detected,O
by,O
RNASeq,O
analysis,O
of,O
virus,O
stocks,O
.,O
This,O
complex,O
dataset,O
was,O
reduced,O
to,O
a,O
single,O
fold,O
change,O
per,O
site,O
and,O
time,O
point,O
by,O
choosing,O
(,O
per,O
time,O
point,O
),O
the,O
fold,O
change,O
with,O
the,O
lowest,O
p,O
value,O
",",O
favoring,O
those,O
detected,O
in,O
both,O
treatment,O
and,O
control,O
",",O
i.e.,O
",",O
non,O
-,O
infinite,O
log2,O
fold,O
change,O
values,O
.,O
This,O
single,O
-,O
site,O
dataset,O
",",O
further,O
reduced,O
to,O
those,O
with,O
human,O
orthology,O
(,O
Table,O
S1,O
),O
",",O
was,O
used,O
as,O
the,O
input,O
for,O
kinase,O
activity,O
analysis,O
.,O
Significance,O
filters,O
of,O
adjusted,O
p,O
value,O
 ,O
<,O
0.05,O
and,O
absolute,O
log2,O
fold,O
change,O
(,O
infected,O
/,O
mock,O
),O
>,O
1,O
were,O
applied,O
to,O
both,O
phosphorylation,O
and,O
abundance,O
datasets,O
.,O
The,O
resource,O
comprises,O
of,O
a,O
comprehensive,O
collection,O
of,O
phosphosite,O
annotations,O
of,O
direct,O
substrates,O
of,O
kinases,O
obtained,O
from,O
six,O
databases,O
",",O
PhosphoSitePlus,O
",",O
SIGNOR,O
",",O
HPRD,O
",",O
NCI,O
-,O
PID,O
",",O
Reactome,O
",",O
and,O
the,O
BEL,O
Large,O
Corpus,O
",",O
and,O
using,O
three,O
text,O
-,O
mining,O
tools,O
",",O
REACH,O
",",O
Sparser,O
",",O
and,O
RLIMS,O
-,O
P.,O
Kinase,O
activities,O
were,O
inferred,O
as,O
a,O
-log10(p,O
value,O
),O
of,O
Z,O
-,O
test,O
from,O
the,O
comparison,O
of,O
fold,O
changes,O
in,O
phosphosite,O
measurements,O
of,O
the,O
known,O
substrates,O
against,O
the,O
overall,O
distribution,O
of,O
fold,O
changes,O
across,O
the,O
sample,O
.,O
In,O
addition,O
to,O
the,O
time,O
-,O
course,O
experiment,O
",",O
we,O
also,O
estimated,O
kinase,O
activities,O
of,O
cell,O
line,O
perturbation,O
in,O
a,O
range,O
of,O
biological,O
conditions,O
using,O
the,O
K,O
-,O
test,O
based,O
approach,O
",",O
from,O
a,O
large,O
resource,O
of,O
previously,O
published,O
phosphoproteomics,O
datasets,O
comprising,O
of,O
435,O
biological,O
conditions,O
which,O
include,O
several,O
drug,O
treatments,O
(,O
chlorzoxazone,O
",",O
paclitaxel,O
),O
",",O
inhibitors,O
(,O
EGFRi,O
",",O
AKTi,O
),O
and,O
cell,O
cycle,O
states,O
(,O
Ochoa,B-Creator
"et al.,",I-Creator
2016,E-Creator
),O
.,O
Annotations,O
for,O
protein,O
complexes,O
were,O
obtained,O
from,O
CORUM,O
v3.0,O
database,O
(,O
Giurgiu,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
.,O
To,O
evaluate,O
the,O
effect,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
at,O
the,O
Transcription,O
Factor,O
(,O
TF,O
),O
level,O
",",O
we,O
applied,O
DoRothEA,O
(,O
Garcia,O
-,O
Alonso,O
et,O
 ,O
al,O
.,O
",",O
2019,O
),O
to,O
RNA,O
-,O
seq,O
datasets,O
of,O
different,O
human,O
lung,O
cell,O
lines,O
from,O
a,O
recent,O
study,O
(,O
GSE147507,S-AccessionNumber
),O
(,O
Blanco-Melo,B-Creator
"et al.,",I-Creator
2020,E-Creator
),O
.,O
For,O
TCID50,O
and,O
plaque,O
assay,O
results,O
",",O
which,O
are,O
not,O
depicted,O
in,O
a,O
percent,O
scale,O
",",O
the,O
IC50,O
values,O
were,O
extracted,O
directly,O
from,O
the,O
parameterized,O
hill,O
equation,O
(,O
see,O
Figure,O
 ,O
S5,O
and,O
Table,O
S8,O
),O
.,O
The,O
causative,O
agent,O
of,O
the,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
pandemic,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
has,O
infected,O
millions,O
and,O
killed,O
hundreds,O
of,O
thousands,O
of,O
people,O
worldwide,O
",",O
highlighting,O
an,O
urgent,O
need,O
to,O
develop,O
antiviral,O
therapies,O
.,O
We,O
found,O
pharmacologic,O
inhibition,O
of,O
the,O
p38,O
",",O
CK2,O
",",O
CDK,O
",",O
AXL,O
",",O
and,O
PIKFYVE,O
kinases,O
to,O
possess,O
antiviral,O
efficacy,O
",",O
representing,O
potential,O
COVID-19,O
therapies,O
.,O
],O
both,O
of,O
which,O
are,O
clinical,O
manifestations,O
observed,O
in,O
hospitalized,O
patients,O
infected,O
by,O
SARS‐CoV‐2,O
and,O
suffering,O
from,O
COVID‐19,O
.,O
[,O
As,O
new,O
CoVID,O
policies,O
and,O
responses,O
are,O
implemented,O
to,O
lessen,O
the,O
impact,O
of,O
the,O
virus,O
",",O
it,O
is,O
imperative,O
(,O
1,O
),O
to,O
consider,O
additional,O
mitigation,O
strategies,O
critical,O
for,O
the,O
development,O
of,O
effective,O
countermeasures,O
",",O
(,O
2,O
),O
to,O
promote,O
long,O
-,O
term,O
policies,O
and,O
strict,O
regulations,O
of,O
the,O
trade,O
of,O
wildlife,O
and,O
live,O
animal,O
markets,O
",",O
and,O
(,O
3,O
),O
to,O
advocate,O
for,O
necessary,O
funding,O
and,O
investments,O
in,O
global,O
health,O
",",O
specifically,O
for,O
the,O
prevention,O
of,O
and,O
response,O
to,O
natural,O
and,O
manmade,O
pandemics,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
is,O
caused,O
by,O
a,O
novel,O
coronavirus,O
",",O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
[,O
1,O
],O
",",O
which,O
shares,O
high,O
genetic,O
similarity,O
with,O
the,O
most,O
closely,O
-,O
related,O
bat,O
origin,O
SARS,O
-,O
like,O
virus,O
(,O
RaTG13,O
),O
[,O
2,O
],O
.,O
The,O
design,O
of,O
risk,O
assessments,O
and,O
successful,O
interventions,O
for,O
COVID-19,O
now,O
depend,O
on,O
how,O
well,O
we,O
understand,O
the,O
course,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
The,O
COVID-19,O
pandemic,O
is,O
underway,O
[,O
5,O
],O
.,O
Social,O
measures,O
for,O
monitoring,O
",",O
controlling,O
and,O
treating,O
COVID-19,O
vary,O
among,O
and,O
within,O
countries,O
.,O
It,O
has,O
been,O
suggested,O
that,O
the,O
detection,O
of,O
antibodies,O
to,O
SARS,O
-,O
CoV-2,O
could,O
serve,O
as,O
the,O
basis,O
for,O
an,O
“,O
immunity,O
passport,O
”,O
",",O
however,O
it,O
is,O
currently,O
unclear,O
whether,O
recovered,O
COVID-19,O
cases,O
have,O
neutralizing,O
antibodies,O
that,O
protect,O
them,O
from,O
a,O
second,O
infection,O
.,O
There,O
have,O
been,O
reports,O
that,O
some,O
recovered,O
COVID-19,O
cases,O
have,O
re,O
-,O
tested,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
some,O
time,O
after,O
discharge,O
[,O
"6,7",O
],O
.,O
Guangdong,O
Province,O
reported,O
the,O
highest,O
number,O
of,O
COVID-19,O
cases,O
in,O
China,O
except,O
Hubei,O
.,O
Guangdong,O
launched,O
an,O
enhanced,O
surveillance,O
network,O
and,O
a,O
series,O
of,O
intervention,O
measures,O
in,O
response,O
to,O
the,O
outbreak,O
soon,O
after,O
the,O
first,O
COVID-19,O
case,O
was,O
reported,O
in,O
December,O
2019,O
[,O
8,O
],O
.,O
Since,O
23,O
January,O
",",O
all,O
discharged,O
COVID-19,O
cases,O
were,O
isolated,O
in,O
designated,O
hotels,O
under,O
medical,O
observation,O
for,O
another,O
14,O
days,O
.,O
In,O
this,O
study,O
",",O
we,O
screened,O
619,O
recovered,O
COVID-19,O
cases,O
in,O
Guangdong,O
discharged,O
between,O
23,O
January,O
and,O
19,O
February,O
.,O
The,O
Discharge,O
criteria,O
for,O
COVID-19,O
cases,O
in,O
Guangdong,O
include,O
:,O
1,O
),O
body,O
temperature,O
is,O
normal,O
for,O
more,O
than,O
three,O
days,O
",",O
2,O
),O
respiratory,O
symptoms,O
including,O
fever,O
",",O
dry,O
cough,O
and,O
tiredness,O
noticeably,O
improve,O
",",O
3,O
),O
pulmonary,O
imaging,O
shows,O
obvious,O
absorption,O
of,O
inflammation,O
",",O
and,O
4,O
),O
nucleic,O
acid,O
tests,O
are,O
negative,O
twice,O
consecutively,O
",",O
on,O
both,O
respiratory,O
tract,O
samples,O
(,O
such,O
as,O
sputum,O
and,O
nasopharyngeal,O
swabs,O
),O
and,O
digestive,O
tract,O
samples,O
(,O
such,O
as,O
stool,O
and,O
anal,O
swabs,O
),O
",",O
with,O
a,O
sampling,O
interval,O
of,O
at,O
least,O
24,O
 ,O
h.,O
The,O
intervention,O
measures,O
for,O
discharged,O
COVID-19,O
cases,O
are,O
as,O
follows,O
:,O
1,O
),O
all,O
discharged,O
COVID-19,O
cases,O
are,O
isolated,O
in,O
designated,O
hotels,O
for,O
another,O
14,O
days,O
;,O
2,O
),O
during,O
isolation,O
",",O
discharged,O
cases,O
live,O
in,O
a,O
well,O
-,O
ventilated,O
single,O
room,O
",",O
dine,O
separately,O
",",O
practice,O
hand,O
hygiene,O
",",O
and,O
minimize,O
close,O
contact,O
with,O
others,O
",",O
3,O
),O
health,O
status,O
is,O
monitored,O
during,O
isolation,O
and,O
SARS,O
-,O
CoV-2,O
RT,O
-,O
PCR,O
tests,O
are,O
performed,O
on,O
7th,O
and,O
14th,O
days,O
after,O
discharge,O
or,O
more,O
frequently,O
",",O
4,O
),O
cases,O
return,O
home,O
only,O
when,O
nucleic,O
acid,O
tests,O
are,O
negative,O
on,O
both,O
respiratory,O
tract,O
samples,O
and,O
digestive,O
tract,O
samples,O
during,O
isolation,O
.,O
The,O
ARTIC,O
bioinformatics,O
pipeline,O
for,O
COVID,O
(,O
https://artic.network/ncov-2019,O
),O
was,O
used,O
to,O
generate,O
consensus,O
sequences,O
and,O
call,O
single,O
nucleotide,O
changes,O
relative,O
to,O
the,O
reference,O
sequence,O
(,O
MN908947,O
),O
.,O
Assembly,O
of,O
the,O
nanopore,O
raw,O
data,O
was,O
performed,O
using,O
the,O
ARTIC,O
bioinformatic,O
pipeline,O
for,O
COVID-19,O
with,O
minimap2,O
[,O
11,O
],O
and,O
medaka,O
(,O
https://github.com/nanoporetech/medaka,O
),O
for,O
consensus,O
sequence,O
generation,O
.,O
Sequencing,O
data,O
after,O
mapping,O
to,O
SARS,O
-,O
COV-2,O
reference,O
genome,O
(,O
MN908947.3,S-AccessionNumber
),O
have,O
been,O
deposited,O
in,O
the,O
Genome,B-Repository
Sequence,I-Repository
Archive,E-Repository
 ,O
[,O
12,O
],O
in,O
BIG,B-Repository
Data,I-Repository
Center,E-Repository
 ,O
[,O
13,O
],O
",",O
Beijing,B-Repository
Institute,I-Repository
of,I-Repository
Genomics,I-Repository
(BIG),E-Repository
",",O
Chinese,B-Repository
Academy,I-Repository
of,I-Repository
Sciences,E-Repository
",",O
under,O
project,O
accession,O
numbers,O
CRA002500,S-AccessionNumber
",",O
publicly,O
accessible,O
at,O
https://bigd.big.ac.cn/gsa,S-URL
.,O
A,O
total,O
of,O
619,O
COVID-19,O
cases,O
were,O
discharged,O
from,O
designated,O
hospitals,O
between,O
23,O
January,O
and,O
19,O
February,O
2020,O
.,O
The,O
demographic,O
characteristics,O
of,O
the,O
87,O
re,O
-,O
positive,O
cases,O
are,O
as,O
follows,O
:,O
(,O
i,O
),O
gender,O
distribution,O
was,O
equal,O
",",O
with,O
45,O
males,O
and,O
42,O
females,O
;,O
(,O
ii,O
),O
re,O
-,O
positive,O
detection,O
of,O
virus,O
RNA,O
was,O
observed,O
in,O
all,O
age,O
groups,O
",",O
ranging,O
from,O
3,O
months,O
to,O
69,O
years,O
",",O
with,O
a,O
median,O
age,O
of,O
28,O
years,O
",",O
which,O
is,O
significantly,O
younger,O
than,O
that,O
of,O
discharged,O
COVID-19,O
patients,O
in,O
Guangdong,O
in,O
general,O
(,O
median,O
age,O
of,O
47,O
years,O
",",O
Table,O
 ,O
1,O
),O
.,O
The,O
median,O
time,O
for,O
discharged,O
COVID-19,O
cases,O
re,O
-,O
tested,O
as,O
viral,O
RNA,O
positive,O
was,O
7,O
days,O
(,O
range,O
2,O
to,O
19,O
days,O
),O
post,O
-,O
discharge,O
.,O
Possibly,O
due,O
to,O
their,O
moderate,O
clinical,O
symptoms,O
",",O
re,O
-,O
positive,O
cases,O
had,O
shorter,O
hospital,O
stays,O
(,O
median,O
",",O
14,O
days,O
),O
than,O
general,O
discharged,O
COVID-19,O
cases,O
(,O
median,O
",",O
28,O
days,O
),O
(,O
Table,O
 ,O
1,O
),O
.,O
An,O
impaired,O
immune,O
response,O
has,O
been,O
associated,O
with,O
fatal,O
COVID-19,O
infections,O
that,O
exhibit,O
prolonged,O
persistence,O
of,O
viral,O
RNA,O
[,O
14,O
],O
.,O
One,O
possible,O
explanation,O
for,O
the,O
re,O
-,O
positive,O
detection,O
of,O
SARS,O
-,O
CoV-2,O
RNA,O
is,O
that,O
some,O
COVID-19,O
patients,O
may,O
have,O
insufficient,O
immune,O
responses,O
and,O
neutralization,O
antibodies,O
(,O
NAbs,O
),O
to,O
clear,O
infection,O
completely,O
.,O
To,O
investigate,O
the,O
immunological,O
and,O
virological,O
characteristics,O
of,O
re,O
-,O
positive,O
COVID-19,O
cases,O
",",O
70,O
of,O
87,O
re,O
-,O
positive,O
cases,O
were,O
sampled,O
by,O
the,O
Guangdong,O
Provincial,O
Center,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
GDCDC,O
),O
between,O
22,O
February,O
and,O
1,O
March,O
2020,O
",",O
including,O
59,O
serum,O
and,O
137,O
swab,O
samples,O
(,O
Fig,O
.,O
 ,O
1a,O
),O
.,O
Our,O
results,O
demonstrated,O
competent,O
immune,O
activation,O
in,O
re,O
-,O
positive,O
cases,O
",",O
which,O
exhibit,O
a,O
distribution,O
of,O
NAbs,O
titres,O
similar,O
to,O
that,O
of,O
cases,O
who,O
detected,O
as,O
negative,O
in,O
14,O
days,O
after,O
discharge,O
and,O
COVID-19,O
cases,O
in,O
hospitalization,O
(,O
Kruskal,O
-,O
Wallis,O
H,O
test,O
",",O
p,O
 ,O
=,O
 ,O
0.2663,O
",",O
Fig,O
.,O
 ,O
1b,O
),O
.,O
Millions,O
of,O
people,O
have,O
recovered,O
from,O
COVID-19,O
infection,O
",",O
and,O
there,O
have,O
been,O
preliminary,O
reports,O
of,O
people,O
testing,O
re,O
-,O
positive,O
for,O
SARS,O
-,O
CoV-2,O
viral,O
RNA,O
after,O
recovery,O
[,O
7,O
",",O
8,O
],O
.,O
Here,O
",",O
we,O
use,O
data,O
from,O
the,O
Guangdong,O
COVID-19,O
surveillance,O
system,O
to,O
analyze,O
the,O
characteristics,O
of,O
re,O
-,O
positive,O
cases,O
between,O
23,O
January,O
and,O
26,O
February,O
2020,O
.,O
The,O
first,O
question,O
we,O
addressed,O
is,O
the,O
re,O
-,O
positive,O
rate,O
in,O
COVID-19,O
discharged,O
cases,O
.,O
All,O
re,O
-,O
re,O
-,O
positive,O
cases,O
in,O
our,O
study,O
developed,O
only,O
mild,O
or,O
moderate,O
symptoms,O
in,O
the,O
initial,O
diagnosis,O
",",O
with,O
the,O
median,O
age,O
being,O
significantly,O
lower,O
than,O
that,O
of,O
the,O
general,O
COVID-19,O
cases,O
(,O
Table,O
 ,O
1,O
),O
.,O
The,O
relatively,O
mild,O
symptoms,O
may,O
explain,O
why,O
the,O
median,O
time,O
from,O
onset,O
to,O
discharge,O
in,O
re,O
-,O
positive,O
cases,O
(,O
median,O
17,O
days,O
),O
is,O
slightly,O
lower,O
than,O
that,O
of,O
the,O
other,O
discharged,O
COVID-19,O
cases,O
(,O
median,O
33,O
days,O
),O
.,O
The,O
time,O
from,O
symptom,O
onset,O
to,O
discharge,O
(,O
the,O
time,O
when,O
COVID-19,O
cases,O
have,O
twice,O
tested,O
negative,O
by,O
PCR,O
),O
for,O
re,O
-,O
positive,O
cases,O
(,O
median,O
17,O
",",O
Table,O
 ,O
1,O
),O
is,O
consistent,O
with,O
the,O
time,O
that,O
detectable,O
SARS,O
-,O
CoV-2,O
RNA,O
is,O
reported,O
on,O
other,O
studies,O
to,O
persist,O
(,O
median,O
20,O
),O
in,O
respiratory,O
sites,O
[,O
"14,15",O
],O
.,O
These,O
data,O
indicate,O
that,O
the,O
course,O
in,O
re,O
-,O
positive,O
cases,O
is,O
similar,O
to,O
other,O
COVID-19,O
cases,O
.,O
Our,O
microneutralization,O
result,O
shows,O
that,O
58,O
of,O
59,O
(,O
98,O
%,O
),O
re,O
-,O
positive,O
cases,O
generated,O
specific,O
NAbs,O
to,O
SARS,O
-,O
CoV-2,O
",",O
and,O
their,O
titre,O
distribution,O
is,O
similar,O
to,O
cured,O
COVID-19,O
cases,O
that,O
were,O
SARS,O
-,O
CoV-2,O
negative,O
after,O
discharge,O
and,O
to,O
hospitalized,O
COVID-19,O
cases,O
(,O
Fig,O
.,O
 ,O
1b,O
),O
.,O
Background,O
 ,O
Some,O
COVID-19,O
cases,O
test,O
positive,O
again,O
for,O
SARS,O
-,O
CoV-2,O
RNA,O
following,O
negative,O
test,O
results,O
and,O
discharge,O
",",O
raising,O
questions,O
about,O
the,O
meaning,O
of,O
virus,O
detection,O
.,O
Methods,O
 ,O
Clinical,O
data,O
were,O
obtained,O
through,O
Guangdong,O
's,O
COVID-19,O
surveillance,O
network,O
.,O
Findings,O
 ,O
Among,O
619,O
discharged,O
COVID-19,O
cases,O
",",O
87,O
re,O
-,O
tested,O
as,O
SARS,O
-,O
CoV-2,O
positive,O
in,O
circumstances,O
of,O
social,O
isolation,O
.,O
Re,O
-positive,O
cases,O
(,O
n,O
=,O
 ,O
59,O
),O
exhibited,O
similar,O
neutralization,O
antibodies,O
(,O
NAbs,O
),O
titre,O
distributions,O
to,O
other,O
COVID-19,O
cases,O
(,O
n,O
=,O
 ,O
218,O
),O
tested,O
here,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
continues,O
to,O
spread,O
globally,O
and,O
cause,O
massive,O
societal,O
disruption,O
and,O
death,O
.,O
As,O
of,O
August,O
3,O
",",O
2020,O
",",O
COVID-19,O
has,O
been,O
responsible,O
for,O
>,O
18,O
million,O
cases,O
and,O
approximately,O
"690,000",O
deaths,O
worldwide,O
(,O
Johns,O
Hopkins,O
University,O
&,O
Medicine,O
",",O
",",O
last,O
accessed,O
August,O
3,O
",",O
2020,O
),O
.,O
The,O
United,O
States,O
is,O
in,O
the,O
midst,O
of,O
a,O
substantial,O
surge,O
of,O
new,O
cases,O
",",O
and,O
despite,O
months,O
of,O
effort,O
",",O
few,O
treatment,O
options,O
with,O
proven,O
efficacy,O
for,O
COVID-19,O
are,O
available,O
.,O
Currently,O
",",O
hundreds,O
of,O
registered,O
clinical,O
trials,O
are,O
underway,O
",",O
most,O
of,O
which,O
are,O
assessing,O
antiretroviral,O
agents,O
",",O
anti,O
-,O
inflammatory,O
or,O
immunosuppressant,O
therapies,O
",",O
and,O
passive,O
antibody,O
treatments.1,O
",",O
2,O
",",O
3,O
The,O
antiretroviral,O
remdesivir,O
",",O
an,O
RNA,O
polymerase,O
inhibitor,O
with,O
activity,O
against,O
SARS,O
-,O
associated,O
coronavirus,O
and,O
Middle,O
East,O
respiratory,O
syndrome,O
coronavirus,O
",",O
has,O
shown,O
promise,O
in,O
a,O
recent,O
randomized,O
controlled,O
trial,O
",",O
reducing,O
recovery,O
time,O
in,O
certain,O
COVID-19,O
patients,O
.,O
Many,O
vaccines,O
are,O
in,O
various,O
stages,O
of,O
development,O
",",O
and,O
one,O
is,O
being,O
studied,O
in,O
a,O
phase,O
3,O
trial,O
",",O
but,O
it,O
will,O
be,O
at,O
least,O
many,O
months,O
before,O
an,O
efficacious,O
vaccine,O
is,O
available,O
.,O
",",O
 ,O
Thus,O
",",O
although,O
many,O
prophylactic,O
and,O
therapeutic,O
strategies,O
are,O
under,O
investigation,O
",",O
the,O
primary,O
management,O
of,O
COVID-19,O
remains,O
supportive,O
care,O
.,O
The,O
Food,O
and,O
Drug,O
Administration,O
rapidly,O
made,O
pathways,O
available,O
for,O
the,O
administration,O
or,O
study,O
of,O
COVID-19,O
convalescent,O
plasma,O
",",O
and,O
convalescent,O
plasma,O
remains,O
the,O
only,O
widely,O
available,O
passive,O
antibody,O
therapy,O
.,O
Similar,O
safety,O
findings,O
have,O
been,O
shown,O
in,O
other,O
studies.18,O
",",O
19,O
",",O
20,O
",",O
21,O
",",O
22,O
",",O
23,O
We,O
recently,O
published,O
our,O
early,O
experience,O
with,O
convalescent,O
plasma,O
treatment,O
in,O
25,O
patients,O
with,O
severe,O
COVID-19,O
.,O
COVID-19,O
patients,O
admitted,O
to,O
any,O
of,O
the,O
eight,O
Houston,O
Methodist,O
hospitals,O
were,O
considered,O
for,O
enrollment,O
in,O
this,O
trial,O
.,O
",",O
 ,O
Patients,O
were,O
eligible,O
for,O
this,O
study,O
if,O
they,O
had,O
severe,O
and/or,O
life,O
-,O
threatening,O
COVID-19,O
(,O
US,O
Food,O
and,O
Drug,O
Administration,O
",",O
",",O
last,O
accessed,O
July,O
11,O
",",O
2020,O
),O
.,O
US,O
Food,O
and,O
Drug,O
Administration,O
recommendations,O
for,O
COVID-19,O
convalescent,O
plasma,O
donor,O
collection,O
were,O
followed,O
(,O
",",O
last,O
accessed,O
July,O
11,O
",",O
2020,O
),O
.,O
All,O
plasma,O
was,O
donated,O
by,O
recovered,O
and,O
healthy,O
COVID-19,O
patients,O
who,O
had,O
been,O
asymptomatic,O
for,O
>,O
14,O
days,O
.,O
Convalescent,O
plasma,O
titer,O
assessment,O
was,O
performed,O
as,O
recently,O
described,O
.,O
",",O
 ,O
Briefly,O
",",O
purified,O
recombinant,O
ectodomain,O
",",O
composed,O
of,O
amino,O
acid,O
residues,O
1,O
to,O
1208,O
",",O
and/or,O
RBD,O
",",O
composed,O
of,O
amino,O
acids,O
319,O
to,O
591,O
",",O
of,O
the,O
SARS,O
-,O
CoV-2,O
spike,O
protein,O
(;,O
GenBank,S-Repository
 ,O
accession,O
number,O
MN908947,S-AccessionNumber
),O
were,O
coated,O
onto,O
microtiter,O
plates,O
.,O
Baseline,O
patient,O
characteristics,O
for,O
all,O
COVID-19,O
patients,O
and,O
for,O
patients,O
who,O
met,O
a,O
28,O
-,O
day,O
outcome,O
are,O
shown,O
in,O
Supplemental,O
Table,O
S1,O
.,O
A,O
titer,O
of,O
≥1:1350,O
was,O
chosen,O
on,O
the,O
basis,O
of,O
previous,O
work,O
that,O
demonstrated,O
that,O
an,O
anti,O
-,O
RBD,O
IgG,O
1:1350,O
indicated,O
an,O
80,O
%,O
probability,O
of,O
viral,O
neutralization,O
titer,O
≥1:160,O
",",O
the,O
recommended,O
viral,O
neutralization,O
cutoff,O
for,O
COVID-19,O
convalescent,O
plasma,O
for,O
therapeutic,O
purposes,O
.,O
In,O
this,O
study,O
",",O
data,O
from,O
2724,O
admitted,O
COVID-19,O
patients,O
were,O
available,O
for,O
analysis,O
",",O
316,O
of,O
whom,O
were,O
transfused,O
with,O
COVID-19,O
convalescent,O
plasma,O
(,O
Figure,O
 ,O
1,O
),O
.,O
Baseline,O
characteristics,O
of,O
all,O
admitted,O
COVID-19,O
patients,O
are,O
shown,O
(,O
Supplemental,O
Table,O
S1,O
),O
.,O
Most,O
transfused,O
patients,O
(,O
242/316,O
;,O
76,O
%,O
),O
received,O
only,O
one,O
unit,O
of,O
COVID-19,O
convalescent,O
plasma,O
.,O
In,O
a,O
smaller,O
study,O
by,O
Hegerova,O
et,O
 ,O
al,O
",",O
20,O
COVID-19,O
patients,O
who,O
received,O
convalescent,O
plasma,O
had,O
improved,O
laboratory,O
and,O
respiratory,O
parameters,O
compared,O
with,O
matched,O
controls,O
",",O
and,O
in,O
both,O
matched,O
control,O
studies,O
",",O
nonintubated,O
patients,O
benefited,O
more,O
from,O
transfusion,O
than,O
intubated,O
patients,O
.,O
Data,O
from,O
"20,000",O
transfused,O
COVID-19,O
patients,O
support,O
the,O
notion,O
that,O
transfusion,O
earlier,O
in,O
the,O
clinical,O
course,O
is,O
more,O
beneficial,O
.,O
A,O
recent,O
study,O
from,O
the,O
Netherlands,O
showed,O
that,O
at,O
the,O
time,O
of,O
transfusion,O
(,O
median,O
",",O
10,O
days,O
post,O
-,O
symptom,O
onset,O
),O
",",O
many,O
(,O
80,O
%,O
),O
of,O
the,O
COVID-19,O
patients,O
already,O
had,O
detectable,O
neutralizing,O
antibody,O
titers,O
",",O
although,O
the,O
titer,O
of,O
transfused,O
plasma,O
units,O
was,O
higher,O
than,O
that,O
found,O
in,O
recipients,O
;,O
the,O
study,O
was,O
discontinued,O
as,O
a,O
result,O
of,O
this,O
finding,O
.,O
This,O
analysis,O
has,O
implications,O
for,O
collection,O
",",O
use,O
",",O
and,O
study,O
of,O
COVID-19,O
convalescent,O
plasma,O
.,O
Substantial,O
efforts,O
are,O
underway,O
in,O
the,O
United,O
States,O
to,O
collect,O
COVID-19,O
convalescent,O
plasma,O
.,O
Clinical,O
trials,O
are,O
ongoing,O
in,O
many,O
centers,O
",",O
and,O
the,O
data,O
presented,O
herein,O
may,O
inform,O
the,O
assessment,O
of,O
equipoise,O
in,O
their,O
design,O
and,O
conduct.39,O
",",O
40,O
",",O
41,O
",",O
42,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
",",O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
",",O
has,O
spread,O
globally,O
",",O
and,O
proven,O
treatments,O
are,O
limited,O
.,O
Transfusion,O
of,O
convalescent,O
plasma,O
collected,O
from,O
donors,O
who,O
have,O
recovered,O
from,O
COVID-19,O
is,O
among,O
many,O
approaches,O
being,O
studied,O
as,O
potentially,O
efficacious,O
therapy,O
.,O
We,O
are,O
conducting,O
a,O
prospective,O
",",O
propensity,O
score,O
–,O
matched,O
study,O
assessing,O
the,O
efficacy,O
of,O
COVID-19,O
convalescent,O
plasma,O
transfusion,O
versus,O
standard,O
of,O
care,O
as,O
treatment,O
for,O
severe,O
and/or,O
critical,O
COVID-19,O
.,O
Of,O
the,O
316,O
transfused,O
patients,O
",",O
136,O
met,O
a,O
28,O
-,O
day,O
outcome,O
and,O
were,O
matched,O
to,O
251,O
non,O
-,O
transfused,O
control,O
COVID-19,O
patients,O
.,O
These,O
data,O
suggest,O
that,O
treatment,O
of,O
COVID-19,O
with,O
high,O
anti,O
–,O
receptor,O
binding,O
domain,O
IgG,O
titer,O
convalescent,O
plasma,O
is,O
efficacious,O
in,O
early,O
-,O
disease,O
patients,O
.,O
Staff,O
shortages,O
in,O
health,O
care,O
are,O
significant,O
amidst,O
the,O
global,O
effort,O
against,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
The,O
number,O
of,O
asymptomatic,O
cases,O
of,O
COVID-19,O
is,O
significant,O
.,O
In,O
a,O
study,O
of,O
COVID-19,O
symptomatic,O
and,O
asymptomatic,O
infection,O
on,O
the,O
Diamond,O
Princess,O
cruise,O
ship,O
",",O
328,O
of,O
the,O
634,O
positive,O
cases,O
(,O
51·7,O
%,O
),O
were,O
asymptomatic,O
at,O
the,O
time,O
of,O
testing,O
.,O
Furthermore,O
",",O
evidence,O
from,O
modelled,O
COVID-19,O
infectiousness,O
profiles,O
suggests,O
that,O
44,O
%,O
of,O
secondary,O
cases,O
were,O
infected,O
during,O
the,O
presymptomatic,O
phase,O
of,O
illnesses,O
from,O
index,O
cases,O
",",O
whereas,O
a,O
study,O
of,O
COVID-19,O
cases,O
in,O
a,O
homeless,O
shelter,O
in,O
Boston,O
",",O
MA,O
",",O
USA,O
",",O
implies,O
that,O
individual,O
COVID-19,O
symptoms,O
might,O
be,O
uncommon,O
and,O
proposed,O
universal,O
testing,O
irrespective,O
of,O
symptomatic,O
burden,O
.,O
Substantial,O
asymptomatic,O
transmission,O
might,O
also,O
mean,O
that,O
current,O
estimates,O
of,O
the,O
basic,O
reproduction,O
number,O
",",O
R0,O
",",O
for,O
COVID-19,O
are,O
inaccurate,O
.,O
This,O
disease,O
spread,O
could,O
",",O
in,O
turn,O
",",O
propagate,O
out,O
of,O
hospitals,O
:,O
during,O
a,O
period,O
of,O
lockdown,O
asymptomatic,O
COVID-19,O
carriage,O
among,O
hospital,O
staff,O
could,O
conceivably,O
act,O
as,O
a,O
potent,O
source,O
of,O
ongoing,O
transmission,O
.,O
The,O
scale,O
of,O
this,O
problem,O
is,O
not,O
yet,O
fully,O
understood,O
",",O
nor,O
is,O
the,O
full,O
potential,O
for,O
asymptomatic,O
and,O
presymptomatic,O
HCWs,O
to,O
transmit,O
infection,O
to,O
patients,O
who,O
do,O
not,O
have,O
COVID-19,O
",",O
other,O
HCWs,O
",",O
or,O
the,O
public,O
.,O
In,O
partnership,O
with,O
the,O
Francis,O
Crick,O
Institute,O
in,O
London,O
",",O
UK,O
",",O
where,O
COVID-19,O
testing,O
will,O
be,O
performed,O
",",O
this,O
initiative,O
is,O
an,O
attempt,O
to,O
further,O
limit,O
nosocomial,O
transmission,O
.,O
A,O
healthy,O
",",O
COVID-19,O
-,O
free,O
workforce,O
that,O
is,O
not,O
burned,O
out,O
will,O
be,O
an,O
asset,O
to,O
the,O
prolonged,O
response,O
to,O
the,O
COVID-19,O
crisis,O
.,O
This,O
approach,O
could,O
mean,O
that,O
presymptomatic,O
HCWs,O
who,O
are,O
capable,O
of,O
transmitting,O
the,O
virus,O
are,O
not,O
being,O
tested,O
;,O
if,O
they,O
were,O
tested,O
and,O
found,O
to,O
be,O
COVID-19,O
positive,O
",",O
they,O
could,O
be,O
advised,O
to,O
isolate,O
and,O
await,O
the,O
onset,O
of,O
symptoms,O
or,O
",",O
if,O
no,O
symptoms,O
develop,O
",",O
undergo,O
repeat,O
testing,O
.,O
The,O
Diamond,O
Princess,O
cruise,O
ship,O
was,O
the,O
site,O
of,O
a,O
large,O
outbreak,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Afterwards,O
",",O
the,O
disease,O
was,O
named,O
“,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
”,O
by,O
the,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
[,O
4,O
],O
.,O
GnomAD,S-Repository
 ,O
database,O
analysis,O
revealed,O
that,O
these,O
identified,O
ACE2,O
variants,O
are,O
reported,O
with,O
a,O
cumulative,O
frequency,O
of,O
0.2289,O
in,O
ethnically,O
matched,O
populations,O
(,O
EUR,O
),O
.,O
However,O
",",O
this,O
variant,O
deserves,O
further,O
investigation,O
in,O
a,O
larger,O
COVID-19,O
cohorts,O
as,O
well,O
as,O
functional,O
studies,O
.,O
The,O
missense,O
variant,O
c.2158A,O
>,O
G,O
p.(Asn720Asp,O
),O
was,O
found,O
in,O
two,O
patients,O
",",O
one,O
female,O
in,O
heterozygous,O
state,O
and,O
one,O
male,O
",",O
with,O
a,O
frequency,O
in,O
line,O
with,O
our,O
Italian,O
control,O
population,O
and,O
with,O
the,O
frequency,O
reported,O
for,O
the,O
European,O
non,O
-,O
Finnish,O
population,O
in,O
the,O
GnomAD,S-Repository
 ,O
database,O
.,O
We,O
tested,O
the,O
hypothesis,O
if,O
these,O
variants,O
were,O
associated,O
with,O
COVID-19,O
severity,O
.,O
For,O
this,O
reason,O
",",O
we,O
wanted,O
to,O
analyze,O
in,O
detail,O
the,O
genetic,O
variability,O
of,O
ACE2,O
in,O
our,O
population,O
",",O
among,O
the,O
most,O
affected,O
by,O
the,O
COVID-19,O
pandemic,O
.,O
Until,O
now,O
",",O
most,O
available,O
published,O
studies,O
were,O
carried,O
out,O
on,O
an,O
epidemiological,O
basis,O
of,O
population,O
allele,O
frequencies,O
deposited,O
in,O
the,O
various,O
available,O
databases,O
.,O
We,O
identified,O
in,O
a,O
single,O
COVID-19,O
patient,O
a,O
variant,O
(,O
p.,O
Asp630His,O
),O
",",O
very,O
rare,O
in,O
European,O
population,O
and,O
not,O
detected,O
in,O
our,O
Italian,O
control,O
population,O
.,O
Interestingly,O
very,O
recently,O
",",O
Bunyavanich,O
et,O
al,O
.,O
[,O
19,O
],O
showed,O
age,O
-,O
dependent,O
expression,O
of,O
ACE2,O
gene,O
in,O
nasal,O
epithelium,O
",",O
highlighting,O
that,O
the,O
different,O
levels,O
of,O
ACE2,O
expression,O
may,O
be,O
the,O
reason,O
for,O
a,O
lower,O
incidence,O
of,O
COVID-19,O
in,O
children,O
.,O
Animal,O
coronaviruses,O
rarely,O
infect,O
humans,O
with,O
the,O
exceptions,O
of,O
the,O
Middle,O
East,O
respiratory,O
syndrome,O
(,O
MERS,O
-,O
CoV,O
),O
",",O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
corona,O
virus,O
(,O
SARS,O
-,O
CoV,O
),O
",",O
and,O
now,O
SARS,O
-,O
CoV-2,O
",",O
which,O
is,O
the,O
cause,O
of,O
the,O
ongoing,O
pandemic,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
We,O
therefore,O
investigated,O
the,O
occurrence,O
of,O
ACE2,O
variants,O
in,O
a,O
cohort,O
of,O
131,O
Italian,O
unrelated,O
individuals,O
clinically,O
diagnosed,O
with,O
COVID-19,O
and,O
in,O
an,O
Italian,O
control,O
population,O
",",O
to,O
evaluate,O
a,O
possible,O
allelic,O
association,O
with,O
COVID-19,O
",",O
by,O
direct,O
DNA,O
analysis,O
.,O
As,O
a,O
pilot,O
study,O
",",O
we,O
analyzed,O
",",O
by,O
whole,O
-,O
exome,O
sequencing,O
",",O
genetic,O
variants,O
of,O
ACE2,O
gene,O
in,O
131,O
DNA,O
samples,O
of,O
COVID-19,O
patients,O
hospitalized,O
at,O
Tor,O
Vergata,O
University,O
Hospital,O
and,O
at,O
Bambino,O
Gesù,O
Children,O
’s,O
Hospital,O
",",O
Rome,O
.,O
Therefore,O
",",O
further,O
studies,O
are,O
needed,O
in,O
larger,O
cohorts,O
",",O
since,O
it,O
was,O
found,O
only,O
in,O
one,O
heterozygous,O
COVID-19,O
patient,O
.,O
Our,O
results,O
suggest,O
that,O
there,O
is,O
no,O
strong,O
evidence,O
",",O
in,O
our,O
cohort,O
",",O
of,O
consistent,O
association,O
of,O
ACE2,O
variants,O
with,O
COVID-19,O
severity,O
.,O
According,O
to,O
Centers,O
for,O
Disease,O
Control,O
and,O
Prevention,O
(,O
CDC,O
),O
",",O
common,O
human,O
infecting,O
coronaviruses,O
include,O
229E,O
coronavirus,O
",",O
NL63,O
coronavirus,O
",",O
OC43,O
beta,O
coronavirus,O
",",O
HKU1,O
coronavirus,O
",",O
MERS,O
-,O
CoV,O
",",O
SARS,O
-,O
CoV,O
",",O
and,O
the,O
recently,O
emerged,O
deadly,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
.,O
In,O
December,O
2019,O
",",O
COVID-19,O
was,O
initially,O
encountered,O
in,O
Wuhan,O
",",O
China,O
",",O
and,O
has,O
now,O
rapidly,O
spread,O
to,O
multiple,O
countries,O
.,O
Outbreaks,O
of,O
infectious,O
disease,O
like,O
COVID-19,O
poses,O
a,O
serious,O
challenge,O
to,O
the,O
scientific,O
community,O
since,O
they,O
usually,O
arise,O
from,O
unrecognized,O
zoonotic,O
sources,O
or,O
due,O
to,O
scarcity,O
data,O
.,O
The,O
current,O
study,O
focuses,O
on,O
finding,O
promiscuous,O
CD4,O
+,O
and,O
CD8,O
T+,O
cell,O
epitopes,O
for,O
chimeric,O
COVID-19,O
vaccine,O
development,O
using,O
a,O
variety,O
of,O
web,O
-,O
based,O
tools,O
.,O
The,O
Immune,B-Repository
epitope,I-Repository
database,I-Repository
(IEDB),E-Repository
 ,O
tool,O
for,O
immunogenicity,O
score,O
calculation,O
was,O
used,O
to,O
predict,O
immunogenicity,O
scores,O
for,O
all,O
MHC,O
-,O
I,O
predicted,O
epitopes,O
(,O
27,O
),O
.,O
Immunogenic,O
epitopes,O
were,O
then,O
verified,O
for,O
their,O
presence,O
in,O
IEDB,S-Repository
 ,O
database,O
.,O
PDBsum,O
is,O
a,O
database,O
that,O
is,O
exclusively,O
designed,O
to,O
show,O
the,O
molecules,O
that,O
build,O
DNA,O
or,O
proteins,O
",",O
ligands,O
",",O
and,O
metal,O
ions,O
along,O
with,O
the,O
illustration,O
of,O
graphical,O
representation,O
of,O
their,O
interactions,O
with,O
each,O
other,O
.,O
Prioritized,O
vaccine,O
constructs,O
were,O
docked,O
to,O
ACE2,O
receptor,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
3sci,S-AccessionNumber
),O
",",O
TLR2,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
2Z7X,S-AccessionNumber
),O
",",O
and,O
TLR4,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
4G8A,S-AccessionNumber
),O
.,O
Vaccine,O
3,O
",",O
having,O
a,O
B,O
-,O
cell,O
epitope,O
",",O
was,O
also,O
checked,O
for,O
its,O
interaction,O
with,O
a,O
B,O
-,O
cell,O
receptor,O
(,O
BCR,O
),O
CD79,O
(,O
PDB,S-Repository
 ,O
ID,O
:,O
3KG5,S-AccessionNumber
),O
.,O
Hence,O
",",O
for,O
this,O
purpose,O
",",O
class,O
I,O
[,O
HLA,O
A*02,O
01,O
(,O
PDB,S-Repository
 ,O
ID,O
4U6Y,S-AccessionNumber
),O
",",O
HLA,O
B*51,O
01,O
(,O
PDB,S-Repository
 ,O
ID,O
4MJI,S-AccessionNumber
),O
],O
and,O
class,O
II,O
[,O
HLA,O
-,O
DRB1,O
*,O
1402,O
(,O
PDB,S-Repository
 ,O
ID,O
6ATF,S-AccessionNumber
),O
],O
were,O
used,O
;,O
they,O
represent,O
broad,O
-,O
spectrum,O
peptide,O
-,O
binding,O
repertoires,O
.,O
Initially,O
",",O
"15,181",O
HLA,O
class,O
I,O
epitopes,O
have,O
been,O
predicted,O
within,O
spike,O
glycoprotein,O
of,O
COVID-19,O
.,O
Two,O
epitopes,O
191EFVFKNIDGYFKIYS205,O
and,O
506QPYRVVVLSFELLHA520,O
were,O
selected,O
for,O
vaccine,O
1,O
construction,O
on,O
the,O
basis,O
of,O
their,O
high,O
antigenic,O
potential,O
.,O
To,O
the,O
best,O
of,O
our,O
knowledge,O
",",O
none,O
of,O
the,O
epitopes,O
reported,O
in,O
this,O
study,O
have,O
been,O
previously,O
added,O
to,O
the,O
IEDB,S-Repository
 ,O
database,O
.,O
However,O
",",O
there,O
is,O
currently,O
no,O
available,O
FDA,O
-,O
approved,O
vaccine,O
against,O
COVID-19,O
(,O
42,O
",",O
43,O
),O
.,O
A,O
vaccination,O
regime,O
",",O
if,O
successfully,O
developed,O
against,O
COVID-19,O
",",O
has,O
the,O
ability,O
to,O
improve,O
global,O
human,O
health,O
statistics,O
.,O
Nevertheless,O
",",O
it,O
might,O
take,O
months,O
to,O
years,O
to,O
actually,O
derive,O
a,O
vaccine,O
against,O
COVID-19,O
",",O
we,O
believe,O
that,O
our,O
contribution,O
in,O
this,O
case,O
might,O
be,O
a,O
useful,O
to,O
initiate,O
the,O
process,O
.,O
Recent,O
studies,O
have,O
strongly,O
suggested,O
that,O
COVID-19,O
uses,O
angiotensin,O
-,O
converting,O
enzyme,O
2,O
(,O
ACE2,O
),O
as,O
its,O
potential,O
receptor,O
.,O
Several,O
critical,O
residues,O
in,O
COVID-19,O
receptor,O
binding,O
motif,O
(,O
RBM,O
),O
of,O
S1,O
domain,O
particularly,O
Gln493,O
provide,O
favorable,O
interactions,O
with,O
human,O
ACE2,O
(,O
53,O
),O
.,O
Vaccines,O
designed,O
in,O
this,O
study,O
may,O
also,O
interact,O
with,O
ACE2,O
resulting,O
interrupted,O
interaction,O
of,O
the,O
receptor,O
with,O
the,O
viral,O
spike,O
protein,O
and,O
thus,O
can,O
be,O
a,O
potential,O
therapeutic,O
target,O
against,O
COVID-19,O
.,O
All,O
datasets,O
presented,O
in,O
this,O
study,O
are,O
included,O
in,O
the,O
article,O
/,O
Supplementary,O
Material,O
.,O
A,O
recent,O
pandemic,O
caused,O
by,O
a,O
single,O
-,O
stranded,O
RNA,O
virus,O
",",O
COVID-19,O
",",O
initially,O
discovered,O
in,O
China,O
",",O
is,O
now,O
spreading,O
globally,O
.,O
We,O
adapted,O
a,O
comprehensive,O
predictive,O
framework,O
to,O
provide,O
novel,O
insights,O
into,O
immunogenic,O
epitopes,O
of,O
spike,O
proteins,O
",",O
which,O
can,O
further,O
be,O
evaluated,O
as,O
potential,O
vaccine,O
candidates,O
against,O
COVID-19,O
.,O
In,O
late,O
2019,O
",",O
an,O
outbreak,O
of,O
the,O
novel,O
​Severe,O
acute,O
respiratory,O
syndrome,O
-,O
related,O
coronavirus,O
SARS,O
-,O
CoV-2,O
",",O
the,O
causative,O
agent,O
of,O
COVID-19,O
",",O
began,O
in,O
Wuhan,O
",",O
China,O
and,O
rapidly,O
spread,O
throughout,O
the,O
world,O
(,O
Zhou,O
et,O
al,O
.,O
",",O
2020,O
;,O
Zhu,O
et,O
al,O
.,O
",",O
2020,O
;,O
Huang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Based,O
on,O
the,O
data,O
shared,O
by,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
as,O
of,O
June,O
25th,O
",",O
over,O
nine,O
million,O
people,O
have,O
tested,O
positive,O
for,O
COVID-19,O
",",O
with,O
a,O
mortality,O
of,O
over,O
"480,000",O
people,O
worldwide,O
.,O
Therefore,O
",",O
early,O
virus,O
detection,O
and,O
isolation,O
of,O
COVID-19,O
‘,O
positive,O
’,O
individuals,O
are,O
crucial,O
to,O
limit,O
virus,O
transmission,O
and,O
implementation,O
of,O
effective,O
measures,O
to,O
control,O
the,O
spread,O
of,O
the,O
virus,O
and,O
relieve,O
the,O
burden,O
on,O
the,O
healthcare,O
system,O
(,O
Jones,O
et,O
al,O
.,O
",",O
2014,O
;,O
Isere,O
et,O
al,O
.,O
",",O
2015,O
),O
.,O
However,O
",",O
these,O
methods,O
have,O
some,O
drawbacks,O
",",O
including,O
low,O
specificity,O
",",O
a,O
high,O
rate,O
of,O
false,O
positives,O
",",O
and,O
difficulty,O
of,O
adapting,O
these,O
techniques,O
for,O
effective,O
POC,O
diagnostics,O
for,O
pandemics,O
such,O
as,O
COVID-19,O
(,O
Chou,O
et,O
al,O
.,O
",",O
2011,O
;,O
Nagai,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
The,O
positive,O
samples,O
had,O
different,O
Ct,O
values,O
ranging,O
from,O
15,O
to,O
40,O
with,O
the,O
CDC,O
qPCR,O
N,O
gene,O
primer,O
sets,O
(,O
IDT,O
",",O
Catalogue,O
#,O
"10,006,606",O
),O
.,O
Various,O
detection,O
modules,O
",",O
including,O
GeneXpert,O
",",O
Cephied,O
",",O
and,O
ID,O
NOW,O
by,O
Abbot,O
are,O
low,O
throughput,O
and,O
require,O
the,O
use,O
of,O
a,O
single,O
machine,O
for,O
each,O
sample,O
",",O
which,O
may,O
be,O
impractical,O
for,O
low,O
-,O
resource,O
environments,O
and,O
where,O
large,O
-,O
scale,O
testing,O
in,O
a,O
short,O
time,O
window,O
is,O
needed,O
.,O
Lateral,O
flow,O
cleavage,O
reporter,O
(,O
​5′-​/56,O
-,O
FAM,O
/,O
TTATTATT/3Bio/​-3′​,O
",",O
IDT,O
),O
was,O
added,O
to,O
the,O
reaction,O
at,O
a,O
final,O
concentration,O
of,O
500,O
nM,O
in,O
100,O
μL,O
reaction,O
volume,O
along,O
with,O
the,O
2,O
μL,O
RT,O
-,O
LAMP,O
product,O
",",O
and,O
the,O
reaction,O
was,O
incubated,O
at,O
37,O
°,O
C,O
(,O
62,O
°,O
C,O
for,O
Cas12b,O
),O
for,O
10–30,O
minutes,O
.,O
The,O
initial,O
50,O
μL,O
of,O
reaction,O
mix,O
contains,O
the,O
complete,O
RT,O
-,O
LAMP,O
reagents,O
such,O
as,O
5,O
μL,O
10X,O
isothermal,O
amplification,O
buffer,O
",",O
5,O
μL,O
10X,O
Primer,O
Mix,O
",",O
4,O
μL,O
of,O
100,O
mM,O
MgSO4,O
",",O
7,O
μL,O
of,O
10,O
mM,O
dNTP,O
mix,O
",",O
2,O
μL,O
of,O
Bst,O
LF,O
DNA,O
polymerase,O
(,O
50,O
ng,O
),O
",",O
and,O
2,O
μL,O
of,O
RTx,O
reverse,O
transciptase,O
4,O
ng,O
/,O
μl,O
",",O
together,O
with,O
2.5,O
μL,O
of,O
500,O
ng,O
/,O
μL,O
salmon,O
sperm,O
DNA,O
",",O
2,O
μL,O
of,O
viral,O
(,O
control,O
or,O
clinical,O
sample,O
),O
RNA,O
",",O
5,O
μL,O
of,O
5,O
μM,O
specific,O
(,O
or,O
non,O
-,O
specific,O
),O
AacCas21b,O
sgRNAs,O
and,O
5,O
μL,O
of,O
5,O
μM,O
lateral,O
flow,O
cleavage,O
reporter,O
(,O
​5′-​/56,O
-,O
FAM,O
/,O
TTATTATT/3Bio/​-3′​,O
",",O
IDT,O
),O
and,O
5.5,O
μL,O
nuclease,O
-,O
free,O
water,O
.,O
The,O
COVID-19,O
pandemic,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
affects,O
all,O
aspects,O
of,O
human,O
life,O
.,O
Our,O
iSCAN,O
SARS,O
-,O
CoV-2,O
detection,O
module,O
",",O
which,O
exhibits,O
the,O
critical,O
features,O
of,O
a,O
robust,O
molecular,O
diagnostic,O
device,O
",",O
should,O
facilitate,O
the,O
effective,O
management,O
and,O
control,O
of,O
COVID-19,O
.,O
We,O
read,O
with,O
great,O
interest,O
the,O
review,O
by,O
Khan,O
et,O
al,O
 ,O
who,O
discussed,O
the,O
emerging,O
role,O
of,O
cardiovascular,O
disease,O
and,O
the,O
progression,O
of,O
the,O
novel,O
coronavirus,O
disease,O
19,O
(,O
COVID‐19,O
),O
.,O
We,O
commend,O
their,O
conclusions,O
that,O
appropriate,O
triage,O
and,O
risk,O
stratification,O
is,O
essential,O
in,O
patients,O
with,O
cardiovascular,O
disease,O
(,O
CVD,O
),O
and,O
COVID‐19,O
.,O
RAAS,O
inhibitors,O
contributing,O
to,O
increased,O
severity,O
of,O
COVID‐19,O
",",O
most,O
commonly,O
in,O
hypertension,O
",",O
is,O
a,O
logical,O
hypothesis,O
due,O
to,O
their,O
mode,O
of,O
action,O
.,O
Early,O
observational,O
studies,O
concluded,O
that,O
the,O
use,O
of,O
RAAS,O
inhibitors,O
may,O
not,O
be,O
associated,O
with,O
SARS‐CoV‐2,O
infection,O
or,O
more,O
severe,O
COVID‐19,O
progression,O
.,O
One,O
retrospective,O
multicentre,O
study,O
with,O
1128,O
participants,O
(,O
188,O
on,O
a,O
RAAS,O
inhibitor,O
),O
suggested,O
that,O
in,O
hospitalized,O
COVID‐19,O
patients,O
with,O
pre‐existing,O
hypertension,O
",",O
RAAS,O
inhibitors,O
had,O
better,O
outcomes,O
compared,O
to,O
non‐RAAS,O
inhibitor,O
use,O
.,O
It,O
is,O
pivotal,O
further,O
preclinical,O
studies,O
are,O
carried,O
out,O
to,O
understand,O
the,O
cardiovascular,O
mechanisms,O
in,O
COVID‐19,O
.,O
It,O
is,O
already,O
clear,O
that,O
maintaining,O
services,O
as,O
usual,O
during,O
the,O
COVID‐19,O
pandemic,O
is,O
",",O
in,O
many,O
settings,O
",",O
no,O
longer,O
possible,O
.,O
Colleagues,O
in,O
charge,O
of,O
services,O
in,O
the,O
main,O
childhood,O
cancer,O
center,O
serving,O
the,O
Lombardy,O
region,O
",",O
Northern,O
Italy,O
",",O
have,O
provided,O
highly,O
practical,O
information,O
on,O
how,O
they,O
have,O
managed,O
to,O
deliver,O
usual,O
anticancer,O
care,O
while,O
minimizing,O
transmission,O
of,O
COVID‐19,O
(,O
Supplement,O
II,O
),O
.,O
The,O
crucial,O
factors,O
for,O
managing,O
the,O
overwhelming,O
service,O
demand,O
included,O
:,O
(,O
1,O
),O
clear,O
clinical,O
leadership,O
;,O
(,O
2,O
),O
a,O
dynamic,O
standard,O
operating,O
procedure,O
for,O
the,O
service,O
;,O
(,O
3,O
),O
SARS‐CoV‐2,O
viral,O
testing,O
of,O
all,O
staff,O
and,O
all,O
patients,O
prior,O
to,O
any,O
elective,O
procedures,O
or,O
admission,O
;,O
(,O
4,O
),O
professional,O
monitoring,O
of,O
handwashing,O
and,O
the,O
use,O
of,O
appropriate,O
personal,O
protective,O
equipment,O
(,O
PPE,O
),O
by,O
staff,O
and,O
families,O
on,O
entering,O
and,O
leaving,O
clinical,O
areas,O
;,O
(,O
5,O
),O
restricting,O
accompanying,O
persons,O
to,O
one,O
per,O
patient,O
;,O
(,O
6,O
),O
“,O
cohorting,O
”,O
of,O
staff,O
for,O
work,O
and,O
rest,O
periods,O
;,O
(,O
7,O
),O
physical,O
separation,O
of,O
oncology,O
staff,O
from,O
staff,O
working,O
in,O
COVID‐19,O
areas,O
;,O
and,O
(,O
8),O
elective,O
reduction,O
of,O
high‐risk,O
procedures,O
(,O
CAR‐T,O
and,O
stem,O
cell,O
therapies,O
),O
to,O
reduce,O
the,O
demand,O
for,O
intensive,O
care,O
services,O
.,O
The,O
emerging,O
experience,O
from,O
regions,O
with,O
high,O
community,O
transmission,O
SARS‐CoV‐2,O
suggests,O
that,O
an,O
age‐related,O
pattern,O
of,O
upper,O
and,O
lower,O
respiratory,O
tract,O
syndromes,O
of,O
mild,O
to,O
moderate,O
severity,O
is,O
the,O
most,O
common,O
presentation,O
of,O
COVID‐19,O
in,O
children,O
",",O
but,O
with,O
some,O
reports,O
of,O
a,O
very,O
severe,O
clinical,O
disease,O
with,O
life‐threatening,O
respiratory,O
failure,O
.,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
COVID‐19,O
may,O
also,O
rarely,O
manifest,O
as,O
a,O
true,O
systemic,O
disease,O
",",O
including,O
myocarditis,O
",",O
meningo‐encephalitis,O
",",O
macrophage,O
activation,O
syndrome,O
",",O
and,O
thromboembolic,O
phenomena,O
.,O
At,O
the,O
time,O
of,O
manuscript,O
preparation,O
",",O
data,O
on,O
the,O
clinical,O
spectrum,O
and,O
outcome,O
of,O
children,O
with,O
cancer,O
and,O
concurrent,O
COVID‐19,O
are,O
limited,O
",",O
and,O
further,O
data,O
are,O
awaited,O
.,O
However,O
",",O
other,O
coronaviruses,O
can,O
produce,O
more,O
severe,O
disease,O
in,O
immunocompromised,O
children,O
with,O
increased,O
risk,O
with,O
coexisting,O
pulmonary,O
disease,O
or,O
concurrent,O
lower,O
respiratory,O
tract,O
infection,O
.,O
",",O
  ,O
Although,O
this,O
is,O
not,O
yet,O
proven,O
for,O
SARS‐CoV‐2,O
/,O
COVID‐19,O
",",O
prolonged,O
viral,O
shedding,O
(,O
≥,O
 ,O
21,O
days,O
),O
has,O
been,O
documented,O
in,O
hematopoietic,O
stem,O
cell,O
transplant,O
(,O
HSCT,O
),O
recipients,O
for,O
other,O
human,O
coronaviruses,O
",",O
particularly,O
in,O
the,O
setting,O
of,O
steroid,O
use,O
",",O
and,O
myeloablative,O
conditioning,O
.,O
ALL,O
is,O
the,O
most,O
common,O
single,O
childhood,O
cancer,O
",",O
with,O
the,O
longest,O
duration,O
of,O
treatment,O
;,O
hence,O
",",O
many,O
cancer,O
services,O
will,O
experience,O
some,O
COVID‐19,O
–,O
related,O
disruption,O
to,O
the,O
care,O
of,O
children,O
with,O
ALL,O
during,O
the,O
pandemic,O
.,O
Few,O
COVID‐19,O
–,O
positive,O
ALL,O
cases,O
have,O
been,O
reported,O
so,O
far,O
",",O
and,O
the,O
clinical,O
course,O
of,O
those,O
that,O
have,O
been,O
described,O
is,O
of,O
a,O
mild,O
to,O
moderately,O
severe,O
respiratory,O
syndrome,O
",",O
although,O
anecdotal,O
reports,O
of,O
severe,O
infections,O
and,O
fatal,O
outcomes,O
are,O
emerging,O
.,O
",",O
Thus,O
",",O
the,O
major,O
threat,O
to,O
children,O
with,O
ALL,O
may,O
be,O
COVID‐19,O
–,O
related,O
interruption,O
of,O
treatment,O
",",O
or,O
in,O
some,O
settings,O
",",O
treatment,O
noncompletion,O
.,O
Children,O
with,O
concurrent,O
COVID‐19,O
and,O
hyperleukocytosis,O
should,O
commence,O
immediate,O
treatment,O
with,O
supportive,O
care,O
and,O
a,O
steroid,O
prophase,O
",",O
and,O
commence,O
disease‐directed,O
therapy,O
on,O
recovery,O
from,O
COVID‐19,O
.,O
We,O
do,O
not,O
recommend,O
any,O
elective,O
modification,O
of,O
maintenance,O
chemotherapy,O
",",O
but,O
in,O
high,O
COVID‐19,O
prevalence,O
regions,O
",",O
clinic,O
visits,O
should,O
be,O
minimized,O
by,O
extended,O
dispensing,O
of,O
maintenance,O
chemotherapy,O
supported,O
by,O
virtual,O
contact,O
for,O
clinical,O
review,O
.,O
In,O
Supplement,O
I,O
",",O
Table,O
 ,O
1,O
",",O
we,O
provide,O
guidance,O
for,O
adapting,O
patient,O
care,O
if,O
the,O
COVID‐19,O
pandemic,O
disrupts,O
access,O
to,O
diagnostic,O
investigations,O
and,O
the,O
supply,O
of,O
essential,O
cancer,O
chemotherapy,O
.,O
At,O
diagnosis,O
in,O
fully,O
resourced,O
and,O
HIC,O
settings,O
with,O
an,O
emergency,O
presentation,O
",",O
no,O
pandemic,O
modifications,O
are,O
recommended,O
for,O
the,O
initial,O
assessment,O
and,O
diagnosis,O
",",O
even,O
if,O
a,O
child,O
presents,O
with,O
concurrent,O
COVID‐19,O
.,O
The,O
COVID‐19,O
pandemic,O
may,O
compromise,O
the,O
availability,O
and,O
access,O
to,O
the,O
SOC,O
investigations,O
for,O
a,O
complete,O
diagnosis,O
",",O
staging,O
",",O
and,O
response,O
evaluation,O
for,O
risk‐based,O
therapy,O
.,O
During,O
this,O
COVID‐19,O
pandemic,O
",",O
elements,O
of,O
these,O
approaches,O
may,O
not,O
be,O
practical,O
or,O
possible,O
",",O
and,O
there,O
will,O
likely,O
be,O
disruption,O
to,O
the,O
timing,O
of,O
planned,O
surgery,O
and,O
radiotherapy,O
.,O
This,O
may,O
not,O
be,O
the,O
case,O
in,O
countries,O
with,O
limited,O
resources,O
or,O
in,O
areas,O
where,O
access,O
to,O
operating,O
theater,O
and,O
ICU,O
is,O
affected,O
by,O
the,O
COVID‐19,O
situation,O
.,O
The,O
COVID‐19,O
pandemic,O
will,O
have,O
a,O
direct,O
impact,O
on,O
radiotherapy,O
resources,O
",",O
and,O
all,O
radiotherapy,O
centers,O
should,O
have,O
a,O
contingency,O
plan,O
in,O
place,O
to,O
deal,O
with,O
revised,O
staffing,O
and,O
workflows,O
at,O
short,O
notice,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
 ,O
",",O
  ,O
and,O
Supplement,O
II,O
.,O
Exposed,O
team,O
members,O
are,O
required,O
to,O
adhere,O
to,O
consensus,O
guidelines,O
",",O
use,O
airborne,O
precaution,O
PPE,O
(,O
e.g.,O
",",O
N95,O
mask,O
with,O
face,O
shield,O
),O
",",O
and,O
care,O
for,O
patients,O
with,O
suspected,O
or,O
confirmed,O
COVID‐19,O
cases,O
in,O
designated,O
operative,O
and,O
perioperative,O
area,O
.,O
",",O
Children,O
with,O
high‐risk,O
cancers,O
represent,O
a,O
particularly,O
vulnerable,O
population,O
during,O
this,O
COVID‐19,O
pandemic,O
",",O
especially,O
when,O
it,O
comes,O
to,O
palliative,O
care,O
needs,O
.,O
These,O
children,O
are,O
at,O
increased,O
risk,O
for,O
symptom‐related,O
distress,O
as,O
well,O
as,O
psychological,O
and,O
emotional,O
trauma,O
as,O
a,O
result,O
of,O
the,O
COVID‐19,O
crisis,O
in,O
addition,O
to,O
their,O
already,O
incredibly,O
distress‐inducing,O
cancer,O
diagnosis,O
.,O
COVID‐19,O
is,O
leading,O
to,O
a,O
surge,O
in,O
demand,O
for,O
healthcare,O
services,O
",",O
including,O
shifting,O
resources,O
and,O
requiring,O
uncomfortable,O
conversations,O
about,O
resource,O
allocation,O
.,O
The,O
potential,O
role,O
and,O
response,O
of,O
palliative,O
care,O
and,O
hospice,O
services,O
in,O
this,O
COVID‐19,O
pandemic,O
are,O
demonstrated,O
in,O
Supplement,O
II,O
and,O
Supporting,O
Information,O
Table,O
S9,O
.,O
Nurses,O
are,O
on,O
the,O
frontlines,O
of,O
treating,O
and,O
preventing,O
the,O
spread,O
of,O
COVID‐19,O
.,O
Hospital,O
leaders,O
should,O
provide,O
written,O
",",O
evidence‐based,O
recommendations,O
for,O
infection,O
prevention,O
and,O
control,O
practices,O
during,O
the,O
COVID‐19,O
crisis,O
",",O
including,O
guidelines,O
for,O
hand,O
hygiene,O
",",O
use,O
of,O
PPE,O
",",O
staff,O
and,O
visitor,O
screening,O
",",O
isolation,O
of,O
symptomatic,O
patients,O
",",O
and,O
environmental,O
disinfection,O
protocols,O
.,O
Nursing,O
shortages,O
due,O
to,O
COVID‐19,O
or,O
other,O
illnesses,O
challenge,O
appropriate,O
care,O
even,O
in,O
HIC,O
",",O
 ,O
but,O
threaten,O
basic,O
oncology,O
care,O
in,O
LMICs,O
.,O
Hospitals,O
need,O
rigorous,O
policies,O
and,O
procedures,O
for,O
the,O
screening,O
",",O
isolation,O
",",O
and,O
care,O
of,O
patients,O
and,O
families,O
at,O
risk,O
of,O
or,O
infected,O
with,O
COVID‐19,O
.,O
Hospital,O
cleaners,O
must,O
be,O
trained,O
and,O
supervised,O
in,O
disinfecting,O
patient,O
care,O
areas,O
and,O
equipment,O
",",O
and,O
nursing,O
staff,O
must,O
take,O
particular,O
care,O
in,O
handling,O
patient,O
excreta,O
",",O
soiled,O
bedlinen,O
etc,O
.,O
from,O
patients,O
with,O
confirmed,O
or,O
suspected,O
COVID‐19,O
infection,O
.,O
Similar,O
stringent,O
precautions,O
are,O
required,O
to,O
protect,O
the,O
pediatric,O
oncology,O
clinical,O
area,O
and,O
reduce,O
transmission,O
risks,O
of,O
COVID‐19,O
among,O
its,O
patients,O
.,O
The,O
Lombardy,O
experience,O
recommends,O
the,O
use,O
of,O
masks,O
for,O
all,O
staff,O
in,O
pediatric,O
oncology,O
for,O
all,O
clinical,O
encounters,O
",",O
with,O
surgical,O
masks,O
for,O
non,O
COVID‐19,O
contact,O
",",O
reserving,O
N95,O
masks,O
for,O
high‐risk,O
clinical,O
encounters,O
such,O
as,O
aerosol‐generating,O
procedures,O
.,O
Advice,O
on,O
the,O
use,O
of,O
PPE,O
during,O
the,O
COVID‐19,O
pandemic,O
is,O
evolving,O
and,O
differs,O
between,O
countries,O
.,O
The,O
Food,O
and,O
Drug,O
Administration,O
",",O
 ,O
the,O
National,O
Cancer,O
Institute,O
's,O
Cancer,O
Therapy,O
Evaluation,O
Program,O
",",O
 ,O
and,O
the,O
European,O
Medicines,O
Agency,O
 ,O
have,O
provided,O
recommendations,O
on,O
conducting,O
research,O
during,O
the,O
COVID‐19,O
pandemic,O
.,O
The,O
principles,O
of,O
these,O
recommendations,O
are,O
captured,O
in,O
guidances,O
provided,O
by,O
the,O
COG,O
and,O
the,O
European,O
Society,O
of,O
Paediatric,O
Oncology,O
(,O
SIOP‐E,O
),O
including,O
provision,O
for,O
telemedicine,O
evaluations,O
in,O
place,O
of,O
clinical,O
visits,O
",",O
remote,O
dispensing,O
of,O
oral,O
investigational,O
agents,O
",",O
and,O
acknowledging,O
minor,O
protocol,O
deviations,O
to,O
reduce,O
the,O
risk,O
of,O
COVID‐19,O
spread,O
among,O
patients,O
and,O
medical,O
providers,O
.,O
There,O
is,O
a,O
paucity,O
of,O
data,O
on,O
the,O
clinical,O
manifestations,O
and,O
outcome,O
of,O
COVID‐19,O
in,O
children,O
being,O
treated,O
for,O
or,O
having,O
recently,O
completed,O
cancer,O
.,O
Given,O
the,O
rarity,O
and,O
spectrum,O
of,O
childhood,O
cancers,O
",",O
it,O
is,O
unlikely,O
that,O
any,O
single,O
center,O
will,O
see,O
more,O
than,O
a,O
few,O
sporadic,O
cases,O
of,O
COVID‐19,O
.,O
To,O
address,O
the,O
need,O
for,O
well‐curated,O
clinical,O
data,O
",",O
St,B-Creator
Jude,I-Creator
Global,E-Creator
 ,O
and,O
SIOP,S-Creator
 ,O
have,O
created,O
a,O
global,O
COVID‐19,B-Repository
childhood,I-Repository
cancer,I-Repository
registry,E-Repository
 ,O
to,O
learn,O
more,O
about,O
the,O
impact,O
of,O
the,O
virus,O
on,O
childhood,O
cancer,O
patients,O
worldwide,O
and,O
for,O
us,O
all,O
to,O
be,O
better,O
prepared,O
to,O
meet,O
future,O
similar,O
challenges,O
",",O
 ,O
St,B-Creator
Jude,I-Creator
Global,E-Creator
 ,O
and,O
SIOP,S-Creator
 ,O
have,O
put,O
out,O
a,O
call,O
for,O
clinicians,O
worldwide,O
to,O
voluntarily,O
report,O
any,O
patient,O
with,O
a,O
malignancy,O
or,O
prior,O
hematopoietic,O
stem,O
cell,O
transplant,O
who,O
is,O
under,O
the,O
age,O
of,O
19,O
at,O
the,O
time,O
of,O
a,O
laboratory,O
confirmed,O
SARS‐CoV‐2,O
infection,O
.,O
Also,O
",",O
to,O
work,O
with,O
their,O
public,O
health,O
colleagues,O
to,O
send,O
a,O
clear,O
message,O
to,O
parents,O
and,O
communities,O
",",O
fear,O
of,O
COVID‐19,O
infection,O
should,O
not,O
prevent,O
seeking,O
medical,O
assessment,O
if,O
they,O
have,O
serious,O
concerns,O
about,O
their,O
child,O
's,O
health,O
.,O
A,O
full,O
understanding,O
of,O
who,O
is,O
at,O
risk,O
of,O
developing,O
serious,O
COVID‐19,O
disease,O
and,O
how,O
to,O
prevent,O
and,O
treat,O
this,O
can,O
only,O
come,O
from,O
a,O
global,O
effort,O
to,O
capture,O
detailed,O
prospective,O
data,O
.,O
More,O
worrying,O
is,O
the,O
potential,O
for,O
children,O
with,O
cancer,O
to,O
become,O
indirect,O
victims,O
of,O
the,O
COVID‐19,O
pandemic,O
",",O
due,O
to,O
late,O
diagnosis,O
and,O
disrupted,O
therapies,O
.,O
The,O
COVID‐19,O
pandemic,O
is,O
one,O
of,O
the,O
most,O
serious,O
global,O
challenges,O
to,O
delivering,O
affordable,O
and,O
equitable,O
treatment,O
to,O
children,O
with,O
cancer,O
we,O
have,O
witnessed,O
in,O
the,O
last,O
few,O
decades,O
.,O
This,O
Special,O
Report,O
aims,O
to,O
summarize,O
general,O
principles,O
for,O
continuing,O
multidisciplinary,O
care,O
during,O
the,O
SARS‐CoV‐2,O
(,O
COVID‐19,O
),O
pandemic,O
.,O
Functional,O
annotation,O
of,O
human,O
genes,O
was,O
accomplished,O
on,O
the,O
DAVID,O
website,O
(,O
Jiao,O
et,O
al,O
.,O
2012,O
),O
.,O
The,O
overlapping,O
between,O
the,O
top,O
1000,O
genes,O
in,O
the,O
two,O
datasets,O
 ,O
>,O
 ,O
86,O
%,O
(,O
Fig,O
.,O
 ,O
3b,O
),O
",",O
so,O
in,O
the,O
following,O
analyses,O
we,O
combined,O
GSM1120308,S-AccessionNumber
 ,O
and,O
GSE93482,S-AccessionNumber
.,O
The,O
RNA,O
-,O
seq,O
data,O
used,O
in,O
this,O
study,O
were,O
downloaded,O
with,O
accession,O
numbers,O
GSM1120308,S-AccessionNumber
 ,O
(,O
polyA,O
RNA,O
sequencing,O
of,O
STL001,O
Lung,O
Cells,O
),O
and,O
GSE93482,S-AccessionNumber
 ,O
(,O
polyA,O
mRNA,O
RNA,O
-,O
seq,O
from,O
lung,O
),O
.,O
The,O
COVID-19,O
outbreak,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
(,O
Lu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Ren,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Zhou,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Zhu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
has,O
been,O
declared,O
as,O
a,O
global,O
pandemic,O
.,O
Typical,O
clinical,O
symptoms,O
of,O
COVID-19,O
are,O
fever,O
",",O
cough,O
",",O
myalgia,O
",",O
and,O
shortness,O
of,O
breath,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
",",O
Wang,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
To,O
date,O
",",O
no,O
specific,O
antiviral,O
treatment,O
is,O
available,O
for,O
COVID-19,O
.,O
Clinical,O
study,O
on,O
COVID-19,O
has,O
suggested,O
the,O
hypercytokinemia,O
in,O
severe,O
cases,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Here,O
",",O
we,O
collected,O
the,O
bronchoalveolar,O
lavage,O
fluid,O
(,O
BALF,O
),O
of,O
eight,O
COVID-19,O
patients,O
",",O
146,O
community,O
-,O
acquired,O
pneumonia,O
patients,O
",",O
and,O
20,O
healthy,O
controls,O
;,O
this,O
is,O
followed,O
by,O
metatranscriptome,O
sequencing,O
and,O
functional,O
analysis,O
.,O
BALFs,O
were,O
obtained,O
from,O
laboratory,O
-,O
confirmed,O
COVID-19,O
patients,O
(,O
SARS2,O
),O
(,O
n,O
 ,O
=,O
8),O
",",O
community,O
-,O
acquired,O
pneumonia,O
patients,O
(,O
CAP,O
),O
(,O
n,O
 ,O
=,O
146,O
),O
",",O
and,O
healthy,O
controls,O
without,O
known,O
respiratory,O
diseases,O
(,O
Healthy,O
),O
(,O
n,O
 ,O
=,O
20,O
),O
.,O
The,O
read,O
counts,O
for,O
SARS,O
-,O
CoV-2,O
in,O
each,O
COVID-19,O
case,O
were,O
listed,O
in,O
Table,O
S2,O
.,O
Overall,O
",",O
our,O
global,O
functional,O
analysis,O
revealed,O
a,O
highly,O
responsive,O
state,O
against,O
noxious,O
stimuli,O
in,O
COVID-19,O
cases,O
",",O
characterized,O
by,O
the,O
potent,O
defense,O
responses,O
and,O
hyperactive,O
ribosome,O
biogenesis,O
.,O
To,O
understand,O
the,O
cytokine,O
profile,O
in,O
BALF,O
from,O
the,O
COVID-19,O
patients,O
",",O
we,O
assigned,O
DEGs,O
into,O
seven,O
categories,O
of,O
cytokine,O
-,O
related,O
genes,O
(,O
Figure,O
 ,O
2,O
A,O
),O
.,O
These,O
observations,O
suggested,O
that,O
the,O
exuberant,O
inflammation,O
in,O
COVID-19,O
could,O
be,O
progressively,O
resolved,O
",",O
and,O
unquenched,O
inflammation,O
may,O
result,O
in,O
detrimental,O
outcomes,O
.,O
CXCL17,O
upregulation,O
is,O
specific,O
to,O
SARS2,O
and,O
was,O
observed,O
in,O
all,O
eight,O
cases,O
(,O
Figure,O
 ,O
2B,O
),O
",",O
suggesting,O
a,O
role,O
of,O
CXCL17,O
in,O
COVID-19,O
pathogenesis,O
.,O
IL1RN,O
and,O
ILB,O
are,O
interleukin,O
genes,O
significantly,O
upregulated,O
in,O
SARS2,O
(,O
Figure,O
 ,O
2B,O
),O
",",O
and,O
these,O
upregulations,O
are,O
mirrored,O
by,O
elevated,O
protein,O
levels,O
of,O
IL-1Ra,O
and,O
IL-1β,O
in,O
plasma,O
of,O
COVID-19,O
patients,O
(,O
Huang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Because,O
IL-1β,O
was,O
recognized,O
as,O
the,O
key,O
cytokine,O
driving,O
proinflammatory,O
response,O
in,O
BALF,O
from,O
patients,O
with,O
ARDS,O
(,O
Pugin,O
et,O
 ,O
al,O
.,O
",",O
1996,O
),O
",",O
it,O
is,O
possible,O
that,O
the,O
ratio,O
of,O
IL-1β,O
to,O
its,O
inhibitor,O
",",O
IL-1Ra,O
",",O
may,O
correlate,O
to,O
inflammation,O
intensity,O
in,O
COVID-19,O
patients,O
;,O
however,O
",",O
we,O
did,O
not,O
observe,O
clear,O
correlation,O
in,O
the,O
current,O
study,O
(,O
Figure,O
 ,O
2B,O
),O
.,O
We,O
then,O
examined,O
the,O
IFN,O
response,O
in,O
COVID-19,O
patients,O
.,O
These,O
results,O
pointed,O
to,O
the,O
immunopathological,O
role,O
of,O
IFN,O
response,O
in,O
COVID-19,O
patients,O
.,O
A,O
recent,O
study,O
suggested,O
that,O
the,O
neutrophil,O
-,O
to,O
-,O
lymphocyte,O
(,O
NLR,O
),O
ratio,O
was,O
associated,O
with,O
the,O
disease,O
severity,O
of,O
COVID-19,O
(,O
Liu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
Our,O
analysis,O
also,O
showed,O
a,O
significantly,O
higher,O
NLR,O
in,O
COVID-19,O
cases,O
(,O
Figure,O
 ,O
S3A,O
),O
.,O
In,O
the,O
current,O
study,O
",",O
we,O
sampled,O
COVID-19,O
patients,O
with,O
bronchoalveolar,O
lavage,O
(,O
BAL,O
),O
",",O
a,O
method,O
for,O
retrieving,O
cells,O
and,O
solutes,O
from,O
different,O
areas,O
of,O
the,O
lung,O
(,O
Meyer,O
et,O
 ,O
al,O
.,O
",",O
2012,O
),O
.,O
By,O
sequencing,O
and,O
analyzing,O
the,O
BAL,O
fluid,O
cells,O
from,O
eight,O
COVID-19,O
patients,O
and,O
control,O
cohorts,O
",",O
we,O
obtained,O
gene,O
expression,O
profiles,O
of,O
both,O
host,O
and,O
virus,O
",",O
which,O
directly,O
reflected,O
the,O
in,O
situ,O
host,O
response,O
against,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
We,O
thus,O
provided,O
a,O
valuable,O
opportunity,O
to,O
garner,O
insights,O
into,O
COVID-19,O
pathogenesis,O
.,O
In,O
COVID-19,O
patients,O
",",O
we,O
observed,O
the,O
upregulation,O
of,O
a,O
plethora,O
of,O
proinflammatory,O
cytokines,O
",",O
suggesting,O
the,O
pathogenic,O
role,O
of,O
hypercytokinemia,O
.,O
Thus,O
",",O
our,O
data,O
unraveled,O
a,O
possible,O
chemokine,O
-,O
dominant,O
hyperactive,O
cytokine,O
response,O
in,O
COVID-19,O
cases,O
.,O
This,O
protective,O
potential,O
of,O
ISGs,O
may,O
account,O
for,O
the,O
lower,O
proportion,O
of,O
severe,O
cases,O
and,O
the,O
case,O
-,O
fatality,O
rate,O
in,O
COVID-19,O
as,O
compared,O
to,O
SARS,O
(,O
Wu,O
and,O
McGoogan,O
",",O
2020,O
),O
.,O
In,O
the,O
ISGs,O
identified,O
in,O
COVID-19,O
cases,O
",",O
we,O
found,O
a,O
subset,O
of,O
genes,O
with,O
proinflammatory,O
activities,O
",",O
which,O
is,O
relatively,O
underrepresented,O
in,O
other,O
viral,O
infections,O
.,O
The,O
accession,O
number,O
for,O
the,O
reads,O
mapped,O
to,O
human,O
genome,O
GRCh38,O
extracted,O
from,O
the,O
raw,O
sequencing,O
data,O
reported,O
in,O
this,O
paper,O
is,O
[,O
Genome,B-Repository
Warehouse,I-Repository
in,I-Repository
National,I-Repository
Genomics,I-Repository
Data,I-Repository
Center,E-Repository
 ,O
(,O
National,O
Genomics,O
Data,O
Center,O
Members,O
and,O
Partners,O
",",O
2020,O
),O
],O
:,O
[,O
PRJCA002273,S-AccessionNumber
],O
that,O
is,O
publicly,O
accessible,O
at,O
https://bigd.big.ac.cn/gsa,S-URL
.,O
BALF,O
samples,O
from,O
eight,O
laboratory,O
-,O
confirmed,O
COVID-19,O
patients,O
(,O
SARS2,O
),O
were,O
collected,O
from,O
hospitals,O
in,O
Wuhan,O
in,O
January,O
2020,O
.,O
The,O
data,O
collection,O
for,O
the,O
COVID-19,O
patients,O
were,O
deemed,O
by,O
the,O
National,O
Health,O
Commission,O
of,O
the,O
People,O
’s,O
Republic,O
of,O
China,O
as,O
the,O
contents,O
of,O
the,O
public,O
health,O
outbreak,O
investigation,O
.,O
Of,O
the,O
COVID-19,O
cases,O
",",O
five,O
were,O
male,O
and,O
three,O
were,O
female,O
.,O
Eight,O
COVID-19,O
cases,O
had,O
an,O
average,O
age,O
of,O
49,O
years,O
(,O
range,O
40,O
-,O
61,O
),O
",",O
and,O
112,O
CAP,O
cases,O
had,O
an,O
average,O
of,O
56.4,O
years,O
(,O
range,O
22,O
-,O
91,O
),O
.,O
The,O
outbreaks,O
of,O
2019,O
novel,O
coronavirus,O
disease,O
(,O
COVID-19,O
),O
caused,O
by,O
SARS,O
-,O
CoV-2,O
infection,O
have,O
posed,O
a,O
severe,O
threat,O
to,O
global,O
public,O
health,O
.,O
Here,O
",",O
we,O
used,O
metatranscriptomic,O
sequencing,O
to,O
profile,O
immune,O
signatures,O
in,O
the,O
bronchoalveolar,O
lavage,O
fluid,O
of,O
eight,O
COVID-19,O
cases,O
.,O
The,O
expression,O
of,O
proinflammatory,O
genes,O
",",O
especially,O
chemokines,O
",",O
was,O
markedly,O
elevated,O
in,O
COVID-19,O
cases,O
compared,O
to,O
community,O
-,O
acquired,O
pneumonia,O
patients,O
and,O
healthy,O
controls,O
",",O
suggesting,O
that,O
SARS,O
-,O
CoV-2,O
infection,O
causes,O
hypercytokinemia,O
.,O
Graphical,O
Abstract,O
     ,O
Highlights,O
    ,O
•,O
 ,O
BALF,O
cell,O
transcriptome,O
indicates,O
robust,O
innate,O
immune,O
responses,O
in,O
COVID-19,O
patients,O
   ,O
•,O
 ,O
COVID-19,O
patients,O
exhibit,O
chemokine,O
-,O
dominant,O
hypercytokinemia,O
   ,O
•,O
 ,O
ISGs,O
are,O
highly,O
expressed,O
in,O
COVID-19,O
patients,O
and,O
exhibit,O
pathogenic,O
potential,O
     ,O
Zhou,O
et,O
 ,O
al,O
.,O
use,O
metatranscriptomic,O
sequencing,O
to,O
profile,O
immune,O
signatures,O
in,O
the,O
bronchoalveolar,O
lavage,O
fluid,O
of,O
COVID-19,O
patients,O
.,O
COVID-19,O
patients,O
exhibit,O
robust,O
innate,O
immune,O
responses,O
with,O
notable,O
hypercytokinemia,O
and,O
increased,O
expression,O
of,O
IFN,O
-,O
stimulated,O
genes,O
.,O
This,O
analysis,O
provides,O
timely,O
information,O
for,O
understanding,O
SARS,O
-,O
CoV-2,O
-,O
host,O
interactions,O
and,O
COVID-19,O
pathogenesis,O
.,O
On,O
these,O
grounds,O
",",O
there,O
is,O
an,O
aspiration,O
to,O
generate,O
new,O
diagnostic,O
tests,O
that,O
combine,O
speed,O
(,O
incorporating,O
the,O
potential,O
for,O
POCT,O
[,O
18,O
",",O
19,O
],O
),O
",",O
sensitivity,O
",",O
detection,O
of,O
coinfection,O
(,O
20,O
",",O
21,O
),O
",",O
and,O
generation,O
of,O
quantitative,O
or,O
semiquantitative,O
data,O
that,O
can,O
be,O
used,O
to,O
identify,O
drug,O
resistance,O
and,O
reconstruct,O
phylogeny,O
to,O
inform,O
surveillance,O
",",O
public,O
health,O
strategy,O
",",O
and,O
vaccine,O
design,O
.,O
The,O
reads,O
were,O
first,O
taxonomically,O
classified,O
against,O
the,O
RefSeq,S-Repository
 ,O
database,O
using,O
Centrifuge,O
v1.0.3,O
(,O
31,O
),O
.,O
The,O
resulting,O
draft,O
consensus,O
sequences,O
were,O
subjected,O
to,O
a,O
BLAST,O
search,O
against,O
an,O
influenza,O
virus,O
sequence,O
database,O
that,O
included,O
>,O
"2,000",O
H1N1,O
and,O
H3N2,O
seasonal,O
influenza,O
virus,O
sequences,O
between,O
2018,O
and,O
2019,O
and,O
were,O
downloaded,O
from,O
the,O
Influenza,B-Repository
Research,I-Repository
Database,E-Repository
 ,O
(,O
33,O
),O
.,O
Based,O
on,O
this,O
small,O
data,O
set,O
",",O
sensitivity,O
is,O
83,O
%,O
and,O
specificity,O
is,O
100,O
%,O
(,O
95,O
%,O
CI,O
",",O
67,O
to,O
93,O
%,O
and,O
69,O
to,O
100,O
%,O
",",O
respectively,O
),O
.,O
Infectious,O
Diseases,O
Society,O
of,O
America,O
(,O
IDSA,O
),O
guidelines,O
(,O
9,O
),O
recommend,O
nasal,O
/,O
nasopharyngeal,O
specimens,O
for,O
influenza,O
diagnosis,O
",",O
but,O
throat,O
swabs,O
are,O
easier,O
to,O
collect,O
in,O
clinical,O
practice,O
and,O
therefore,O
account,O
for,O
the,O
majority,O
of,O
diagnostic,O
samples,O
processed,O
by,O
our,O
clinical,O
microbiology,O
laboratory,O
.,O
In,O
our,O
test,O
set,O
",",O
8,O
%,O
of,O
samples,O
showed,O
insufficient,O
sensitivity,O
for,O
Hazara,O
virus,O
;,O
however,O
",",O
half,O
of,O
these,O
contained,O
a,O
high,O
titer,O
of,O
influenza,O
virus,O
",",O
so,O
only,O
4,O
%,O
were,O
true,O
sensitivity,O
failures,O
.,O
Assessment,O
of,O
diversity,O
within,O
deep,O
-,O
sequence,O
data,O
sets,O
provides,O
an,O
opportunity,O
to,O
investigate,O
the,O
relationship,O
between,O
within,O
-,O
host,O
polymorphisms,O
and,O
clinical,O
outcomes,O
.,O
Larger,O
and,O
more,O
diverse,O
data,O
sets,O
will,O
be,O
required,O
to,O
set,O
more,O
rigorous,O
thresholds,O
for,O
base,O
calling,O
.,O
The,O
virus,O
titers,O
in,O
culture,O
supernatants,O
of,O
the,O
five,O
cases,O
at,O
3,O
d,O
p.i,O
.,O
were,O
4.6,O
×,O
106,O
to,O
6.8,O
×,O
107,O
median,O
tissue,O
culture,O
infectious,O
dose,O
(,O
TCID50,O
),O
per,O
mL,O
(,O
Table,O
1,O
),O
.,O
Next,O
-,O
generation,O
sequencing,O
(,O
NGS,O
),O
of,O
case,O
Wk-521,O
detected,O
the,O
nearly,O
full,O
-,O
length,O
genome,O
sequence,O
from,O
SARS,O
-,O
CoV-2,O
with,O
>,O
99.9,O
%,O
homology,O
(,O
1,O
",",O
2,O
),O
(,O
GISAID,S-Dataset
 ,O
database,O
ID,O
EPI_ISL_408667,S-AccessionNumber
),O
.,O
All,O
sequences,O
are,O
amplified,O
",",O
followed,O
by,O
classification,O
of,O
sequences,O
based,O
on,O
a,O
reference,O
database,O
.,O
However,O
",",O
detection,O
and,O
identification,O
of,O
novel,O
",",O
previously,O
unknown,O
emerging,O
viruses,O
presents,O
a,O
challenge,O
due,O
to,O
the,O
absence,O
of,O
their,O
genome,O
sequences,O
in,O
reference,O
databases,O
.,O
Identification,O
of,O
coronaviruses,O
was,O
tested,O
using,O
modified,O
databases,O
lacking,O
SARS,O
-,O
CoV-2,O
",",O
SARS,O
-,O
CoV,O
",",O
and,O
MERS,O
-,O
CoV,O
",",O
mimicking,O
the,O
situation,O
at,O
the,O
time,O
of,O
virus,O
discovery,O
.,O
After,O
quality,O
pre,O
-,O
processing,O
using,O
an,O
in,O
-,O
house,O
QC,O
pipeline,O
",",O
Biopet,O
version,O
0.9.0,O
[,O
17,O
],O
and,O
removal,O
of,O
human,O
reads,O
after,O
mapping,O
them,O
to,O
human,O
reference,O
genome,O
GRCh38,O
[,O
18,O
],O
with,O
Bowtie2,O
version,O
2.3.4,O
[,O
19,O
],O
",",O
the,O
remaining,O
sequencing,O
reads,O
were,O
taxonomically,O
classified,O
using,O
Centrifuge,O
1.0.2,O
-,O
beta,O
[,O
20,O
],O
with,O
the,O
databases,O
prepared,O
by,O
taking,O
all,O
"12,302",O
Refseq,S-Dataset
 ,O
viral,O
genomes,O
(,O
as,O
of,O
Juny,O
16th,O
",",O
2020,O
),O
and,O
extracting,O
the,O
GenBank,S-Repository
 ,O
records,O
annotated,O
before,O
the,O
dates,O
of,O
the,O
existence,O
of,O
the,O
MERS,O
-,O
CoV,O
and,O
SARS,O
-,O
CoV,O
index,O
patients,O
in,O
2012,O
and,O
2002,O
",",O
respectively,O
.,O
All,O
contigs,O
were,O
analyzed,O
using,O
the,O
NCBI,S-Repository
 ,O
Basic,O
Local,O
Alignment,O
Search,O
Tool,O
(,O
BLAST,O
2.8.1,O
),O
[,O
23,O
],O
using,O
the,O
BLAST,O
NCBI’s,B-Repository
nucleotide,I-Repository
(nt),E-Repository
 ,O
database,O
(,O
accessed,O
April,O
2018,O
),O
.,O
After,O
extraction,O
of,O
human,O
reads,O
",",O
FASTQ,O
files,O
generated,O
for,O
SARS,O
-,O
CoV-2,O
samples,O
(,O
with,O
and,O
without,O
viral,O
enrichment,O
),O
were,O
uploaded,O
for,O
classification,O
and,O
de,O
novo,O
assembly,O
by,O
the,O
commercial,O
web,O
-,O
based,O
tool,O
Genome,O
Detective,O
v1.120,O
(,O
www.genomedetective.com,O
",",O
accessed,O
2020,O
-,O
05,O
-,O
11,O
),O
[,O
9,O
],O
",",O
using,O
a,O
reference,O
database,O
(,O
generated,O
2019,O
-,O
09,O
-,O
21,O
),O
.,O
In,O
brief,O
",",O
after,O
removal,O
of,O
low,O
-,O
quality,O
reads,O
and,O
trimming,O
by,O
Trimmomatic,O
[,O
24,O
],O
",",O
candidate,O
viral,O
reads,O
were,O
identified,O
using,O
the,O
protein,O
-,O
based,O
alignment,O
method,O
DIAMOND,O
[,O
25,O
],O
in,O
combination,O
with,O
the,O
Swissprot,B-Repository
UniRef,E-Repository
90,O
protein,O
database,O
followed,O
by,O
de,O
novo,O
assembly,O
using,O
metaSPAdes,O
[,O
26,O
],O
.,O
Blastx,O
and,O
Blastn,O
[,O
23,O
],O
were,O
used,O
to,O
search,O
for,O
candidate,O
reference,O
sequences,O
using,O
the,O
NCBI,S-Repository
 ,O
RefSeq,S-Dataset
 ,O
virus,O
database,O
(,O
accessed,O
2019,O
-,O
09,O
-,O
21,O
),O
.,O
To,O
mimic,O
the,O
classification,O
conditions,O
present,O
in,O
the,O
setting,O
of,O
virus,O
discovery,O
",",O
viral,O
metagenomic,O
reference,O
genome,O
databases,O
created,O
before,O
the,O
emergence,O
of,O
SARS,O
-,O
CoV-2,O
",",O
SARS,O
-,O
CoV,O
and,O
MERS,O
-,O
CoV,O
were,O
used,O
for,O
the,O
classification,O
of,O
sequence,O
reads,O
(,O
December,O
2019,O
for,O
the,O
two,O
SARS,O
-,O
CoV-2,O
positive,O
samples,O
",",O
November,O
2002,O
for,O
the,O
SARS,O
-,O
CoV,O
and,O
June,O
2012,O
for,O
the,O
MERS,O
-,O
CoV,O
positive,O
samples,O
),O
.,O
GenomeDetective,O
results,O
of,O
identification,O
of,O
SARS,O
-,O
CoV-2,O
sequences,O
using,O
a,O
database,O
created,O
before,O
the,O
emergence,O
of,O
SARS,O
-,O
CoV-2,O
are,O
shown,O
in,O
Fig,O
.,O
2,O
.,O
In,O
this,O
study,O
",",O
we,O
evaluated,O
the,O
performance,O
of,O
a,O
metagenomic,O
sequencing,O
protocol,O
for,O
the,O
identification,O
of,O
emerging,O
viruses,O
using,O
clinical,O
samples,O
in,O
combination,O
with,O
a,O
simulated,O
reference,O
database,O
.,O
The,O
performance,O
of,O
a,O
viral,O
metagenomic,O
protocol,O
in,O
a,O
clinical,O
setting,O
for,O
the,O
identification,O
of,O
novel,O
coronaviruses,O
was,O
tested,O
using,O
clinical,O
samples,O
containing,O
SARS,O
-,O
CoV-2,O
",",O
SARS,O
-,O
CoV,O
",",O
and,O
MERS,O
-,O
CoV,O
",",O
in,O
combination,O
with,O
databases,O
generated,O
to,O
contain,O
only,O
viruses,O
of,O
before,O
the,O
discovery,O
dates,O
of,O
these,O
coronaviruses,O
",",O
to,O
mimic,O
virus,O
discovery,O
.,O
Recently,O
",",O
Ji,O
et,O
al,O
.,O
[,O
10,O
],O
recommended,O
best,O
practices,O
for,O
processing,O
HIV,O
NGS,O
data,O
",",O
which,O
include,O
reference,O
-,O
based,O
assembly,O
using,O
Bowtie2,O
[,O
11,O
],O
as,O
the,O
short,O
read,O
aligner,O
and,O
HXB2,O
(,O
NCBI,S-Repository
 ,O
accession,O
:,O
K03455,S-AccessionNumber
;,O
[,O
12,O
],O
),O
as,O
the,O
reference,O
sequence,O
for,O
constructing,O
a,O
consensus,O
sequence,O
.,O
For,O
the,O
purposes,O
of,O
this,O
study,O
",",O
we,O
focus,O
on,O
the,O
composition,O
of,O
the,O
consensus,O
sequences,O
",",O
but,O
additionally,O
report,O
haplotype,O
data,O
for,O
the,O
HIV,O
and,O
HCV,O
empirical,O
datasets,O
as,O
validation,O
of,O
HAPHPIPE,O
’s,O
intra,O
-,O
host,O
analytical,O
capabilities,O
.,O
Below,O
",",O
we,O
introduce,O
the,O
three,O
tools,O
that,O
were,O
used,O
in,O
generating,O
consensus,O
sequences,O
",",O
as,O
well,O
as,O
the,O
simulated,O
and,O
empirical,O
datasets,O
used,O
in,O
this,O
study,O
.,O
Briefly,O
",",O
the,O
default,O
parameters,O
included,O
:,O
a,O
minimum,O
of,O
20,O
%,O
frequency,O
for,O
a,O
base,O
to,O
be,O
included,O
in,O
the,O
consensus,O
sequence,O
",",O
the,O
default,O
mutation,O
database,O
—,O
which,O
is,O
the,O
Stanford,O
SDRM,O
2009,O
list,O
of,O
mutations,O
—,O
a,O
target,O
coverage,O
of,O
"10,000",O
reads,O
",",O
a,O
minimum,O
read,O
length,O
of,O
100,O
bp,O
",",O
a,O
minimum,O
average,O
read,O
quality,O
score,O
of,O
30,O
",",O
a,O
sequencing,O
platform,O
error,O
rate,O
of,O
0.0021,O
",",O
a,O
minimum,O
variant,O
quality,O
of,O
30,O
",",O
a,O
minimum,O
read,O
depth,O
of,O
100,O
for,O
a,O
variant,O
call,O
",",O
a,O
minimum,O
allele,O
count,O
of,O
five,O
to,O
be,O
considered,O
a,O
variant,O
",",O
and,O
a,O
minimum,O
amino,O
acid,O
frequency,O
of,O
0.01,O
for,O
a,O
mutation,O
to,O
be,O
considered,O
in,O
the,O
drug,O
-,O
resistant,O
report,O
.,O
These,O
reads,O
were,O
also,O
error,O
-,O
prone,O
",",O
implemented,O
with,O
the,O
integrated,O
Illumina,O
MiSeq,O
platform,O
error,O
profile,O
",",O
which,O
means,O
that,O
the,O
reads,O
contained,O
errors,O
known,O
to,O
be,O
caused,O
by,O
the,O
sequencing,O
platform,O
itself,O
",",O
creating,O
a,O
realistic,O
representation,O
of,O
a,O
standard,O
NGS,O
dataset,O
.,O
All,O
SRA,S-Repository
 ,O
accessions,O
",",O
each,O
representing,O
empirical,O
HIV-1,O
NGS,O
amplicon,O
data,O
from,O
two,O
populations,O
sampled,O
repeatedly,O
over,O
one,O
year,O
",",O
were,O
selected,O
from,O
the,O
BioProject,O
accession,O
PRJNA506879,S-AccessionNumber
 ,O
[,O
63,O
],O
.,O
A,O
total,O
of,O
23,O
SRA,S-Repository
 ,O
accessions,O
of,O
HCV,O
sequence,O
data,O
were,O
selected,O
from,O
Babcock,B-Creator
et,I-Creator
al.,E-Creator
 ,O
[,O
64,O
],O
(,O
accession,O
numbers,O
:,O
SRR1170557,S-AccessionNumber
",",O
SRR1170560,S-AccessionNumber
-,O
SRR1170568,S-AccessionNumber
",",O
SRR1170576,S-AccessionNumber
-,O
SRR1170579,S-AccessionNumber
",",O
SRR1170671,S-AccessionNumber
-,O
SRR1170679,S-AccessionNumber
),O
",",O
each,O
representing,O
HCV,O
viral,O
variants,O
from,O
a,O
patient,O
cohort,O
at,O
several,O
time,O
points,O
spanning,O
two,O
months,O
.,O
For,O
reference,O
-,O
based,O
pipelines,O
",",O
we,O
used,O
the,O
H77,O
HCV,O
reference,O
sequence,O
(,O
accession,O
:,O
NC_004102,S-AccessionNumber
),O
",",O
which,O
is,O
of,O
HCV,O
subtype,O
1a,O
[,O
150,O
],O
.,O
We,O
also,O
reconstructed,O
haplotypes,O
for,O
this,O
dataset,O
",",O
estimated,O
genetic,O
diversity,O
for,O
consensus,O
sequences,O
from,O
each,O
pipeline,O
",",O
and,O
calculated,O
the,O
corresponding,O
genetic,O
distances,O
(,O
p,O
-,O
distance,O
and,O
adjusted,O
p,O
-,O
distance,O
),O
between,O
each,O
of,O
the,O
resulting,O
pipeline,O
consensus,O
sequences,O
and,O
H77,O
.,O
At,O
the,O
time,O
of,O
this,O
study,O
",",O
four,O
high,O
-,O
quality,O
SARS,O
-,O
CoV-2,O
SRA,O
samples,O
were,O
available,O
(,O
accession,O
numbers,O
:,O
SRR11140744,S-AccessionNumber
",",O
SRR11140746,S-AccessionNumber
",",O
SRR11140748,S-AccessionNumber
",",O
SRR11140750,S-AccessionNumber
),O
",",O
and,O
we,O
analyzed,O
each,O
through,O
both,O
HAPHPIPE,O
pipelines,O
and,O
Geneious,O
workflows,O
.,O
We,O
used,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
isolate,O
Wuhan,O
-,O
Hu-1,O
(,O
accession,O
NC_045512,S-AccessionNumber
),O
as,O
the,O
reference,O
sequence,O
[,O
151,O
],O
.,O
We,O
sought,O
to,O
test,O
whole,O
genome,O
assembly,O
",",O
so,O
the,O
entire,O
genome,O
was,O
used,O
(,O
i.e.,O
",",O
no,O
amplicons,O
were,O
assembled,O
for,O
this,O
dataset,O
),O
;,O
this,O
meant,O
that,O
",",O
for,O
the,O
de,O
novo,O
assembly,O
pipeline,O
for,O
HAPHPIPE,O
(,O
haphpipe_assemble_01,O
),O
",",O
we,O
used,O
the,O
numbering,O
0,O
to,O
"29,902",O
for,O
the,O
reference,O
GTF,O
file,O
.,O
Again,O
",",O
we,O
analyzed,O
assembly,O
statistics,O
",",O
genetic,O
distance,O
from,O
reference,O
metrics,O
",",O
and,O
diversity,O
estimates,O
",",O
as,O
with,O
the,O
previously,O
described,O
datasets,O
.,O
Median,O
distance,O
to,O
HXB2,O
was,O
notably,O
greater,O
than,O
distance,O
to,O
the,O
true,O
sequence,O
in,O
all,O
genes,O
for,O
gp120,O
sequences,O
in,O
the,O
simulation,O
dataset,O
(,O
Figure,O
3,O
),O
.,O
Consensus,O
sequences,O
produced,O
for,O
each,O
gene,O
in,O
the,O
empirical,O
HIV,O
dataset,O
showed,O
significant,O
differences,O
in,O
genetic,O
distance,O
to,O
the,O
HIV,O
subtype,O
B,O
reference,O
sequence,O
",",O
HXB2,O
(,O
p,O
<,O
0.001,O
;,O
Table,O
A7,O
),O
.,O
Overall,O
",",O
diversity,O
estimates,O
for,O
Geneious,O
de,O
novo,O
sequences,O
were,O
higher,O
than,O
the,O
other,O
constructed,O
consensus,O
sequences,O
",",O
which,O
could,O
be,O
related,O
to,O
the,O
extreme,O
subsampling,O
for,O
this,O
dataset,O
(,O
Table,O
5,O
),O
.,O
There,O
was,O
no,O
significant,O
difference,O
in,O
genetic,O
distance,O
for,O
the,O
simulated,O
HIV,O
datasets,O
between,O
the,O
HAPHPIPE,O
pipelines,O
",",O
except,O
for,O
the,O
gp120,O
amplicon,O
",",O
in,O
which,O
de,O
novo,O
assembly,O
constructed,O
a,O
consensus,O
sequence,O
genetically,O
closer,O
to,O
the,O
true,O
sequence,O
.,O
However,O
",",O
for,O
more,O
advanced,O
users,O
and,O
those,O
analyzing,O
large,O
-,O
scale,O
datasets,O
",",O
this,O
becomes,O
a,O
hindrance,O
to,O
efficiency,O
.,O
Additionally,O
",",O
storing,O
large,O
-,O
scale,O
NGS,O
datasets,O
locally,O
on,O
the,O
user,O
’s,O
computer,O
as,O
opposed,O
to,O
remotely,O
on,O
a,O
high,O
-,O
performance,O
cluster,O
",",O
may,O
pose,O
limitations,O
for,O
larger,O
studies,O
in,O
using,O
GUIs,O
.,O
We,O
validate,O
and,O
compare,O
the,O
consensus,O
sequence,O
assembly,O
methods,O
of,O
HAPHPIPE,O
to,O
those,O
of,O
two,O
alternative,O
software,O
packages,O
",",O
HyDRA,O
and,O
Geneious,O
",",O
using,O
simulated,O
HIV,O
and,O
empirical,O
HIV,O
",",O
HCV,O
",",O
and,O
SARS,O
-,O
CoV-2,O
datasets,O
.,O
Furthermore,O
",",O
using,O
empirical,O
data,O
from,O
multiple,O
viruses,O
",",O
we,O
demonstrate,O
that,O
HAPHPIPE,O
can,O
analyze,O
larger,O
sequence,O
datasets,O
due,O
to,O
its,O
greater,O
computational,O
speed,O
.,O
A,O
key,O
dataset,O
in,O
the,O
paper,O
is,O
that,O
44,O
%,O
of,O
the,O
patients,O
were,O
virus,O
positive,O
",",O
as,O
contrasted,O
with,O
an,O
overall,O
rate,O
of,O
18,O
%,O
in,O
the,O
state,O
of,O
Massachusetts,O
.,O
The,O
central,O
point,O
to,O
keep,O
in,O
mind,O
",",O
as,O
exemplified,O
by,O
Murphy,O
and,O
colleagues,O
",",O
is,O
that,O
basic,O
science,O
ingenuity,O
and,O
innovation,O
can,O
rapidly,O
be,O
advanced,O
to,O
the,O
actual,O
world,O
of,O
healthcare,O
practice,O
during,O
the,O
current,O
pandemic,O
of,O
COVID-19,O
",",O
but,O
also,O
for,O
other,O
pandemics,O
arising,O
in,O
the,O
future,O
.,O
In,O
this,O
issue,O
of,O
Med,O
",",O
Vanuytsel,O
and,O
colleagues,O
1,O
demonstrate,O
how,O
academic,O
institutions,O
are,O
stepping,O
up,O
to,O
the,O
forefront,O
of,O
SARS,O
-,O
CoV-2,O
testing,O
by,O
rapidly,O
implementing,O
a,O
COVID-19,O
diagnostic,O
test,O
at,O
a,O
large,O
safety,O
net,O
hospital,O
serving,O
an,O
at,O
-,O
risk,O
population,O
",",O
providing,O
a,O
regulatory,O
and,O
logistical,O
roadmap,O
to,O
broaden,O
testing,O
capacity,O
.,O
In,O
this,O
issue,O
of,O
Med,O
",",O
Vanuytsel,O
and,O
colleagues,O
1,O
demonstrate,O
how,O
academic,O
institutions,O
are,O
stepping,O
up,O
to,O
the,O
forefront,O
of,O
SARS,O
-,O
CoV-2,O
testing,O
by,O
rapidly,O
implementing,O
a,O
COVID-19,O
diagnostic,O
test,O
at,O
a,O
large,O
safety,O
net,O
hospital,O
serving,O
an,O
at,O
-,O
risk,O
population,O
",",O
providing,O
a,O
regulatory,O
and,O
logistical,O
roadmap,O
to,O
broaden,O
testing,O
capacity,O
.,O
From,O
March,O
23,O
to,O
May,O
31,O
",",O
2020,O
",",O
Addgene,O
received,O
about,O
"5,300",O
COVID-19,O
plasmid,O
requests,O
(,O
Fig,O
.,O
1A,O
),O
from,O
∼50,O
countries,O
(,O
Fig,O
.,O
1B,O
),O
.,O
Of,O
these,O
",",O
94,O
plasmid,O
requests,O
(,O
from,O
27,O
countries,O
),O
are,O
for,O
CRISPR,O
plasmids,O
that,O
are,O
part,O
of,O
the,O
COVID-19,O
collection,O
.,O
As,O
with,O
the,O
widespread,O
sharing,O
of,O
CRISPR,O
tools,O
in,O
previous,O
years,O
",",O
it,O
's,O
likely,O
that,O
as,O
labs,O
reopen,O
",",O
many,O
will,O
adopt,O
these,O
tools,O
to,O
study,O
coronaviruses,O
and,O
build,O
new,O
diagnostic,O
tools,O
using,O
the,O
reagents,O
from,O
Addgene,O
's,O
COVID-19,O
collection,O
.,O
Since,O
its,O
emergence,O
in,O
on,O
December,O
2019,O
",",O
the,O
COVID-19,O
pandemic,O
has,O
evolved,O
as,O
a,O
global,O
health,O
emergency,O
[,O
1,O
],O
.,O
COVID-19,O
is,O
caused,O
by,O
the,O
novel,O
SARS,O
-,O
CoV-2,O
",",O
a,O
betacoronavirus,O
structurally,O
similar,O
(,O
approximately,O
79,O
%,O
),O
to,O
SARS,O
-,O
CoV,O
[,O
2,O
],O
.,O
Among,O
the,O
first,O
studies,O
to,O
report,O
clinical,O
data,O
on,O
COVID19,O
was,O
a,O
recent,O
publication,O
by,O
Yang,O
and,O
colleagues,O
[,O
6,O
],O
.,O
Their,O
study,O
provided,O
the,O
foundation,O
for,O
a,O
hypothesis,O
put,O
forth,O
by,O
Fang,O
and,O
colleagues,O
indicating,O
that,O
diabetic,O
and,O
hypertensive,O
patients,O
exposed,O
to,O
ACE2,O
inhibitors,O
may,O
be,O
at,O
an,O
increased,O
risk,O
of,O
more,O
severe,O
COVID-19,O
[,O
7,O
],O
.,O
Evidence,O
on,O
COVID-19,O
’s,O
interplay,O
with,O
diabetes,O
is,O
only,O
recently,O
emerging,O
",",O
and,O
can,O
currently,O
only,O
be,O
considered,O
within,O
the,O
context,O
of,O
epidemiological,O
studies,O
",",O
determining,O
diabetes,O
mellitus,O
(,O
DM,O
),O
as,O
frequent,O
comorbidity,O
.,O
Aside,O
from,O
DM,O
",",O
novel,O
hyperglycemia,O
was,O
recently,O
associated,O
with,O
an,O
increased,O
with,O
worse,O
outcomes,O
in,O
COVID-19,O
patients,O
",",O
however,O
this,O
association,O
was,O
not,O
independent,O
of,O
other,O
predictors,O
in,O
the,O
multivariate,O
model,O
[,O
17,O
],O
.,O
Epidemiological,O
associations,O
between,O
COVID-19,O
and,O
lipid,O
metabolism,O
are,O
currently,O
not,O
possible,O
",",O
since,O
even,O
large,O
scale,O
cohorts,O
do,O
not,O
report,O
on,O
relevant,O
measurements,O
[,O
18,O
],O
.,O
On,O
the,O
experimental,O
level,O
",",O
lipid,O
metabolism,O
on,O
the,O
cellular,O
level,O
has,O
been,O
proposed,O
as,O
a,O
treatment,O
target,O
for,O
COVID-19,O
;,O
specifically,O
",",O
both,O
interactions,O
between,O
SARS,O
-,O
CoV,O
’s,O
spike,O
protein,O
with,O
lipid,O
rich,O
membrane,O
compartments,O
",",O
as,O
well,O
as,O
the,O
epigenetic,O
modulations,O
in,O
lipid,O
metabolism,O
were,O
considered,O
as,O
the,O
end,O
-,O
point,O
targets,O
for,O
the,O
development,O
of,O
small,O
molecules,O
",",O
aiming,O
to,O
prevent,O
SARS,O
-,O
CoV-2,O
infection,O
[,O
19,O
],O
.,O
COVID-19,O
",",O
the,O
disease,O
caused,O
by,O
the,O
novel,O
SARS,O
-,O
CoV-2,O
",",O
a,O
betacoronavirus,O
structurally,O
similar,O
to,O
SARS,O
-,O
CoV.,O
Conversely,O
",",O
currently,O
there,O
are,O
only,O
non,O
-,O
causative,O
",",O
observational,O
evidence,O
of,O
worse,O
outcomes,O
for,O
COVID-19,O
patients,O
with,O
comorbid,O
diabetes,O
or,O
hyperglycemia,O
.,O
No,O
study,O
has,O
reported,O
on,O
the,O
lipid,O
profiles,O
of,O
COVID-19,O
patients,O
;,O
however,O
",",O
lipid,O
-,O
targeting,O
molecules,O
have,O
been,O
proposed,O
as,O
agents,O
against,O
SARS,O
-,O
CoV-2,O
.,O
Future,O
studies,O
",",O
reporting,O
on,O
lipid,O
and,O
glucose,O
metabolism,O
of,O
COVID-19,O
patients,O
could,O
help,O
elucidate,O
the,O
disease,O
’s,O
seculae,O
and,O
aid,O
drug,O
design,O
.,O
The,O
virus,O
was,O
tentatively,O
named,O
2019‐nCoV,O
but,O
officially,O
named,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS‐CoV‐2,O
),O
later,O
by,O
the,O
Coronavirus,O
Study,O
Group,O
of,O
the,O
International,O
Committee,O
on,O
Taxonomy,O
of,O
Viruses,O
",",O
and,O
the,O
disease,O
caused,O
by,O
this,O
virus,O
was,O
name,O
COVID‐19,O
by,O
the,O
World,O
Health,O
Organization,O
.,O
",",O
  ,O
Up,O
to,O
March,O
8,O
(,O
24:00,O
GMT,O
),O
",",O
80,O
 ,O
735,O
confirmed,O
cases,O
",",O
have,O
been,O
diagnosed,O
in,O
Mainland,O
China,O
",",O
causing,O
3119,O
deaths,O
.,O
Missed,O
diagnosis,O
and,O
misdiagnosis,O
are,O
currently,O
not,O
uncommon,O
due,O
to,O
these,O
reasons,O
.,O
",",O
 ,O
",",O
The,O
NCBI,S-Repository
 ,O
(,O
http://www.ncbi.nlm.nih.gov/genbank/,S-URL
),O
and,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/,S-URL
),O
databases,O
up,O
to,O
14,O
Feb,O
",",O
2020,O
were,O
searched,O
by,O
using,O
keywords,O
“,O
novel,O
",",O
coronavirus,O
",",O
complete,O
",",O
Wuhan,O
”,O
or,O
“,O
2019‐nCoV.,O
”,O
A,O
total,O
of,O
145,O
sequences,O
were,O
obtained,O
from,O
databases,O
.,O
The,O
reference,O
sequence,O
was,O
constructed,O
by,O
nucleotide,O
sequence,O
alignment,O
(,O
accession,O
number,O
:,O
EPI_ISL_412026,S-AccessionNumber
),O
.,O
Nucleic,O
acid,O
detection,O
is,O
currently,O
the,O
gold,O
standard,O
method,O
for,O
diagnosis,O
of,O
COVID‐19,O
.,O
This,O
might,O
partially,O
explain,O
why,O
false,O
negative,O
results,O
in,O
nucleic,O
acid,O
detection,O
of,O
SARS‐CoV‐2,O
for,O
diagnosis,O
of,O
COVID‐19,O
is,O
currently,O
not,O
uncommon,O
.,O
Abstract,O
 ,O
Starting,O
around,O
December,O
2019,O
",",O
an,O
epidemic,O
of,O
pneumonia,O
",",O
which,O
was,O
named,O
COVID‐19,O
by,O
the,O
World,O
Health,O
Organization,O
",",O
broke,O
out,O
in,O
Wuhan,O
",",O
China,O
",",O
and,O
is,O
spreading,O
throughout,O
the,O
world,O
.,O
In,O
this,O
study,O
",",O
we,O
retrieved,O
95,O
full‐length,O
genomic,O
sequences,O
of,O
SARAS‐CoV‐2,O
strains,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,E-Repository
 ,O
and,O
GISAID,S-Dataset
 ,O
databases,O
",",O
established,O
the,O
reference,O
sequence,O
by,O
conducting,O
multiple,O
sequence,O
alignment,O
and,O
phylogenetic,O
analyses,O
",",O
and,O
analyzed,O
sequence,O
variations,O
along,O
the,O
SARS‐CoV‐2,O
genome,O
.,O
A,O
relevant,O
debate,O
was,O
ongoing,O
concerning,O
the,O
use,O
of,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drugs,O
(,O
NSAIDs,O
),O
to,O
treat,O
patients,O
with,O
Covid-19,O
[,O
"6,7",O
],O
.,O
Following,O
a,O
survey,O
by,O
the,O
French,O
National,O
Agency,O
for,O
Medicines,O
and,O
Health,O
Products,O
Safety,O
(,O
ANSM,O
),O
",",O
US,O
Food,O
and,O
Drug,O
Administration,O
(,O
FDA,O
),O
and,O
European,O
Medicines,O
Agency,O
(,O
EMA,O
),O
are,O
investigating,O
a,O
potential,O
correlation,O
between,O
NSAIDs,O
and,O
increased,O
severity,O
of,O
Covid-19,O
symptomatology,O
",",O
supporting,O
possible,O
negative,O
effects,O
of,O
these,O
drugs,O
to,O
exacerbate,O
Covid-19,O
-,O
related,O
viral,O
and,O
bacterial,O
pulmonary,O
infections,O
",",O
leading,O
to,O
increased,O
hospitalization,O
rates,O
and,O
poor,O
health,O
outcomes,O
.,O
ARBs,O
block,O
the,O
effects,O
of,O
excessive,O
activation,O
of,O
Angiotensin,O
II,O
AT1,O
receptors,O
(,O
AT1R,O
),O
",",O
a,O
major,O
injury,O
factor,O
participating,O
in,O
the,O
development,O
of,O
disorders,O
of,O
the,O
brain,O
",",O
the,O
cardiovascular,O
system,O
",",O
the,O
kidney,O
",",O
lipid,O
and,O
glucose,O
metabolism,O
and,O
the,O
immune,O
system,O
",",O
enhancing,O
inflammation,O
and,O
viral,O
injury,O
in,O
the,O
lung,O
and,O
linearly,O
associated,O
with,O
viral,O
load,O
and,O
lung,O
injury,O
in,O
COVID-19,O
patients,O
[,O
[,O
1,O
],O
",",O
[,O
2,O
],O
",",O
[,O
3,O
],O
",",O
[,O
4,O
],O
",",O
[,O
5,O
],O
],O
.,O
These,O
compounds,O
are,O
well,O
-,O
tolerated,O
in,O
the,O
elderly,O
and,O
successfully,O
used,O
not,O
only,O
as,O
first,O
-,O
line,O
antihypertensives,O
but,O
also,O
in,O
the,O
treatment,O
of,O
diabetes,O
",",O
kidney,O
disease,O
",",O
congestive,O
heart,O
failure,O
and,O
cerebrovascular,O
disorders,O
",",O
which,O
are,O
frequent,O
COVID-19,O
comorbidities,O
[,O
8,O
],O
.,O
These,O
findings,O
are,O
of,O
interest,O
because,O
cerebrovascular,O
complications,O
are,O
frequent,O
in,O
patients,O
affected,O
by,O
COVID-19,O
and,O
their,O
prevalence,O
increases,O
in,O
severe,O
cases,O
and,O
in,O
the,O
elderly,O
[,O
[,O
18,O
],O
",",O
[,O
19,O
],O
",",O
[,O
20,O
],O
",",O
[,O
21,O
],O
",",O
[,O
22,O
],O
",",O
[,O
23,O
],O
],O
.,O
For,O
these,O
reasons,O
it,O
was,O
reasonable,O
to,O
suggest,O
that,O
ARBs,O
could,O
be,O
beneficial,O
for,O
the,O
treatment,O
of,O
COVID-19,O
patients,O
",",O
by,O
ameliorating,O
inflammation,O
",",O
hypertension,O
and,O
other,O
comorbidities,O
and,O
directly,O
protecting,O
the,O
lung,O
and,O
other,O
organs,O
from,O
the,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
Multiple,O
clinical,O
studies,O
are,O
in,O
progress,O
to,O
determine,O
the,O
effect,O
of,O
ARB,O
therapy,O
in,O
COVID-19,O
patients,O
https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=angiotensin+receptor+blockers&cntry=&state=&city=&dist=,O
and,O
preliminary,O
evidence,O
indicates,O
a,O
reduction,O
of,O
critical,O
prognosis,O
and,O
a,O
lower,O
death,O
rate,O
in,O
ARB,O
-,O
treated,O
COVID-19,O
patients,O
[,O
24,O
],O
.,O
Recent,O
transcriptomic,O
analysis,O
of,O
samples,O
from,O
COVID-19,O
patients,O
and,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
primary,O
human,O
alveolar,O
cells,O
revealed,O
unique,O
inflammatory,O
profiles,O
with,O
excessive,O
inflammatory,O
cytokine,O
release,O
",",O
alterations,O
in,O
interferon,O
responses,O
",",O
macrophage,O
and,O
neutrophil,O
infiltration,O
",",O
increased,O
apoptosis,O
and,O
p53,O
signaling,O
associated,O
with,O
lymphopenia,O
[,O
"25,26",O
],O
.,O
We,O
had,O
previously,O
reported,O
that,O
these,O
changes,O
in,O
cultured,O
neurons,O
were,O
strikingly,O
correlated,O
with,O
those,O
observed,O
in,O
aging,O
",",O
one,O
of,O
the,O
most,O
important,O
risk,O
factors,O
for,O
COVID-19,O
",",O
not,O
only,O
in,O
the,O
brain,O
but,O
also,O
in,O
peripheral,O
tissues,O
[,O
"16,17",O
],O
.,O
The,O
recent,O
transcriptome,O
analyses,O
of,O
samples,O
from,O
COVID-19,O
patients,O
[,O
"25,26",O
],O
provided,O
an,O
opportunity,O
to,O
correlate,O
their,O
findings,O
with,O
those,O
obtained,O
earlier,O
reporting,O
ARBs,O
anti,O
-,O
inflammatory,O
and,O
anti,O
-,O
aging,O
protective,O
effects,O
[,O
"16,17",O
],O
.,O
We,O
analyzed,O
our,O
own,O
raw,O
data,O
from,O
a,O
previous,O
experiment,O
(,O
Elkahloun,B-Creator
et,I-Creator
"al.,",I-Creator
2016,E-Creator
),O
submitted,O
to,O
Gene,B-Repository
Expression,I-Repository
Omnibus,I-Repository
(GEO),E-Repository
 ,O
under,O
accession,O
number,O
GSE67036,S-AccessionNumber
.,O
The,O
raw,O
data,O
was,O
submitted,O
to,O
GEO,S-Repository
 ,O
under,O
accession,O
GSE67036,S-AccessionNumber
.,O
We,O
used,O
Gene,O
Set,O
Enrichment,O
Analysis,O
(,O
GSEA,O
),O
[,O
27,O
],O
(,O
http://www.broadinstitute.org/gsea/,O
),O
to,O
compare,O
our,O
data,O
to,O
published,O
datasets,O
[,O
26,O
],O
(,O
GSE147507,S-AccessionNumber
),O
downloaded,O
from,O
the,O
National,B-Repository
Center,I-Repository
for,I-Repository
Biotechnology,I-Repository
Information,I-Repository
(NCBI),E-Repository
 ,O
GEO,S-Repository
 ,O
database,O
",",O
and,O
[,O
25,O
],O
",",O
CRA002390,S-AccessionNumber
 ,O
downloaded,O
from,O
their,O
supplemental,O
data,O
and,O
the,O
Genome,B-Repository
Sequence,I-Repository
Archive,I-Repository
in,I-Repository
BIG,I-Repository
(Beijing,I-Repository
Institute,I-Repository
of,I-Repository
Genomics),I-Repository
Data,I-Repository
Center,E-Repository
 ,O
(,O
https://bigd.big.ac.cn/,S-URL
 ,O
),O
",",O
Chinese,O
Academy,O
of,O
Sciences,O
[,O
28,O
],O
.,O
A,O
complete,O
description,O
of,O
these,O
data,O
sets,O
is,O
summarized,O
in,O
Table,O
1,O
.,O
Ingenuity,O
Pathway,O
Analysis,O
(,O
IPA,O
),O
(,O
http://www.ingenuity.com,O
),O
[,O
33,O
],O
",",O
Gene,O
Ontology,O
(,O
http://geneontology.org/,O
),O
[,O
34,O
],O
",",O
Metascape,O
(,O
https://metascape.org/gp/index.html#/main/step1,O
),O
[,O
35,O
],O
and,O
Jensen,O
Compartments,O
database,O
(,O
https://compartments.jensenlab.org/,O
),O
[,O
36,O
],O
were,O
used,O
to,O
identify,O
gene,O
expression,O
profiles,O
and,O
canonical,O
pathways,O
associated,O
with,O
the,O
differentially,O
expressed,O
genes,O
.,O
Using,O
GSEA,O
",",O
we,O
now,O
asked,O
the,O
question,O
whether,O
this,O
comparison,O
would,O
reveal,O
normalization,O
by,O
Candesartan,O
of,O
gene,O
signatures,O
characteristic,O
of,O
COVID-19,O
.,O
We,O
found,O
a,O
highly,O
statistical,O
positive,O
correlation,O
between,O
the,O
expression,O
of,O
a,O
large,O
number,O
of,O
genes,O
upregulated,O
by,O
glutamate,O
and,O
those,O
genes,O
upregulated,O
in,O
four,O
different,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
human,O
transcriptomes,O
:,O
a,O
normal,O
primary,O
human,O
bronchial,O
epithelial,O
(,O
NHBE,O
),O
cell,O
culture,O
infected,O
with,O
SARS,O
-,O
CoV-2,O
(,O
Table,O
1,O
",",O
Fig,O
.,O
1,O
A,O
),O
",",O
lung,O
tissue,O
post,O
mortem,O
samples,O
from,O
2,O
COVID-19,O
patients,O
and,O
2,O
lung,O
biopsies,O
from,O
healthy,O
controls,O
(,O
Table,O
1,O
",",O
Fig,O
.,O
1B,O
),O
",",O
peripheral,O
blood,O
mononuclear,O
cells,O
(,O
PBMC,O
),O
from,O
3,O
COVID-19,O
patients,O
and,O
3,O
healthy,O
controls,O
(,O
Table,O
1,O
",",O
Fig,O
.,O
1C,O
),O
and,O
bronchoalveolar,O
lavage,O
fluid,O
(,O
BALF,O
),O
from,O
2,O
COVID-19,O
patients,O
and,O
3,O
healthy,O
controls,O
(,O
Table,O
1,O
",",O
Fig,O
.,O
1D,O
),O
.,O
Gene,O
set,O
enrichment,O
plots,O
from,O
representative,O
COVID-19,O
gene,O
sets,O
.,O
The,O
figure,O
represents,O
gene,O
set,O
enrichment,O
analysis,O
plots,O
showing,O
the,O
positive,O
correlations,O
of,O
genes,O
upregulated,O
by,O
glutamate,O
(,O
in,O
red,O
),O
and,O
normalized,O
by,O
Candesartan,O
(,O
in,O
blue,O
),O
in,O
our,O
neuronal,O
cell,O
culture,O
with,O
genes,O
upregulated,O
in,O
primary,O
human,O
bronchial,O
epithelial,O
cells,O
(,O
NHBE,O
),O
infected,O
with,O
SARS,O
-,O
CoV-2,O
(,O
A,O
),O
",",O
lung,O
tissue,O
post,O
mortem,O
samples,O
from,O
COVID-19,O
patients,O
(,O
B,O
),O
",",O
peripheral,O
blood,O
mononuclear,O
cells,O
from,O
COVID-19,O
patients,O
(,O
C,O
),O
and,O
bronchoalveolar,O
lavage,O
fluid,O
(,O
BALF,O
),O
from,O
COVID-19,O
patients,O
(,O
D,O
),O
(,O
see,O
Supplemental,O
Table,O
1,O
for,O
complete,O
GSEA,O
output,O
),O
.,O
Conversely,O
",",O
we,O
found,O
a,O
striking,O
negative,O
correlation,O
between,O
expression,O
of,O
these,O
genes,O
after,O
Candesartan,O
treatment,O
and,O
those,O
genes,O
upregulated,O
in,O
the,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
human,O
transcriptomes,O
.,O
The,O
top,O
20,O
genes,O
with,O
the,O
highest,O
rank,O
metric,O
scores,O
in,O
each,O
enrichment,O
dataset,O
are,O
listed,O
in,O
Table,O
2,O
",",O
that,O
includes,O
many,O
genes,O
related,O
to,O
cytokine,O
and,O
chemokine,O
activity,O
",",O
chemokine,O
receptor,O
binding,O
",",O
cytokine,O
-,O
mediated,O
signaling,O
pathways,O
",",O
NF,O
-,O
κB,O
complex,O
",",O
cellular,O
response,O
to,O
type,O
I,O
interferon,O
",",O
type,O
I,O
interferon,O
signaling,O
pathway,O
",",O
response,O
to,O
interferon,O
γ,O
and,O
response,O
to,O
virus,O
",",O
such,O
as,O
CXCL1,O
",",O
CXCL6,O
",",O
CXCL10,O
",",O
CXCL11,O
",",O
CXCL16,O
",",O
CCL4,O
",",O
IL1RN,O
",",O
IFITM1,O
",",O
RSAD2,O
",",O
PTGS2,O
",",O
BIRC3,O
",",O
AIF1,O
and,O
ASS1,O
.,O
When,O
the,O
top,O
20,O
genes,O
with,O
the,O
highest,O
rank,O
metric,O
scores,O
in,O
each,O
enrichment,O
dataset,O
were,O
compared,O
",",O
each,O
dataset,O
revealed,O
an,O
apparent,O
unique,O
transcriptome,O
signature,O
",",O
the,O
result,O
of,O
different,O
types,O
of,O
cells,O
included,O
in,O
each,O
transcriptome,O
.,O
To,O
reveal,O
the,O
genes,O
most,O
commonly,O
associated,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
we,O
generated,O
a,O
list,O
of,O
210,O
genes,O
consistently,O
upregulated,O
and,O
GSEA,O
enriched,O
in,O
at,O
least,O
2,O
out,O
of,O
the,O
4,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
human,O
transcriptomes,O
",",O
that,O
were,O
also,O
upregulated,O
by,O
glutamate,O
and,O
normalized,O
by,O
Candesartan,O
in,O
our,O
neuronal,O
culture,O
.,O
In,O
addition,O
",",O
Supplemental,O
Table,O
2,O
lists,O
the,O
individual,O
gene,O
associations,O
with,O
their,O
dataset,O
origin,O
",",O
the,O
genes,O
commonly,O
upregulated,O
in,O
NHBE,O
cells,O
and,O
PBMC,O
",",O
BALF,O
and,O
PBMC,O
",",O
and,O
lung,O
autopsies,O
and,O
PBMC,O
databases,O
.,O
From,O
the,O
Jensen,O
Compartments,O
database,O
",",O
we,O
identified,O
50,O
highly,O
significant,O
gene,O
expression,O
profiles,O
",",O
and,O
some,O
of,O
the,O
most,O
significant,O
with,O
highest,O
numbers,O
of,O
genes,O
were,O
the,O
NF,O
-,O
kappa,O
B,O
complex,O
",",O
interferon,O
regulatory,O
factor,O
7,O
",",O
interferon,O
regulatory,O
factor,O
complex,O
",",O
interleukin-12,O
complex,O
",",O
interleukin-23,O
complex,O
",",O
S100A9,O
complex,O
",",O
extracellular,O
space,O
and,O
Bcl-2,O
family,O
protein,O
complex,O
(,O
Table,O
3,O
",",O
Supplemental,O
Table,O
3,O
),O
.,O
Individual,O
analysis,O
of,O
the,O
list,O
of,O
210,O
genes,O
upregulated,O
in,O
at,O
least,O
2,O
out,O
of,O
4,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
human,O
transcriptomes,O
",",O
that,O
were,O
also,O
upregulated,O
by,O
glutamate,O
and,O
normalized,O
by,O
Candesartan,O
in,O
our,O
neuronal,O
culture,O
(,O
Fig,O
.,O
2,O
and,O
Supplemental,O
Tables,O
1,O
and,O
2,O
),O
revealed,O
some,O
genes,O
encoding,O
for,O
pattern,O
recognition,O
receptors,O
(,O
PRRs,O
),O
for,O
viral,O
entry,O
or,O
regulating,O
their,O
function,O
(,O
RIG-1,O
(,O
DDX58,O
),O
",",O
TLR4,O
",",O
MYD88,O
",",O
HERC6,O
),O
.,O
Excessive,O
inflammation,O
with,O
a,O
cytokine,O
storm,O
and,O
innate,O
and,O
adaptive,O
immune,O
alterations,O
are,O
hallmarks,O
of,O
COVID-19,O
[,O
"25,26",O
],O
",",O
a,O
disorder,O
more,O
severely,O
affecting,O
the,O
elderly,O
and,O
involving,O
not,O
only,O
the,O
lung,O
but,O
many,O
other,O
organs,O
",",O
including,O
the,O
brain,O
[,O
37,O
],O
.,O
Because,O
of,O
the,O
above,O
",",O
we,O
asked,O
the,O
question,O
whether,O
the,O
strong,O
anti,O
-,O
inflammatory,O
effects,O
and,O
normalization,O
of,O
the,O
immune,O
response,O
by,O
Candesartan,O
could,O
be,O
in,O
any,O
way,O
related,O
to,O
a,O
relief,O
of,O
the,O
cytokine,O
storm,O
and,O
immune,O
alterations,O
associated,O
with,O
SARS,O
-,O
CoV-2,O
infection,O
",",O
and,O
we,O
compared,O
",",O
using,O
GSEA,O
",",O
our,O
results,O
with,O
the,O
recently,O
reported,O
gene,O
signature,O
samples,O
obtained,O
from,O
SARS,O
-,O
CoV-2,O
infected,O
human,O
cells,O
and,O
COVID-19,O
patients,O
[,O
"25,26",O
],O
.,O
As,O
expected,O
",",O
because,O
of,O
the,O
different,O
source,O
of,O
the,O
materials,O
examined,O
",",O
each,O
of,O
the,O
datasets,O
studied,O
revealed,O
unique,O
transcriptome,O
signatures,O
when,O
only,O
the,O
top,O
20,O
genes,O
with,O
highest,O
rank,O
metric,O
scores,O
in,O
each,O
enrichment,O
dataset,O
were,O
reported,O
(,O
Table,O
2,O
),O
.,O
The,O
NHBE,O
transcriptome,O
included,O
ICAM1,O
",",O
important,O
for,O
recruitment,O
of,O
inflammatory,O
immune,O
cells,O
and,O
participating,O
in,O
the,O
COVID-19,O
response,O
[,O
38,O
],O
",",O
and,O
IL-6,O
",",O
a,O
pro,O
-,O
inflammatory,O
cytokine,O
associated,O
to,O
poor,O
COVID-19,O
response,O
[,O
"39,40",O
],O
.,O
The,O
transcriptome,O
from,O
COVID-19,O
post,O
mortem,O
samples,O
contained,O
CYBB,O
(,O
NOX2,O
),O
[,O
41,O
],O
a,O
super,O
-,O
oxide,O
generating,O
enzyme,O
forming,O
excessive,O
reactive,O
oxygen,O
species,O
(,O
ROS,O
),O
and,O
involved,O
in,O
SARS,O
-,O
CoV-2,O
infection,O
[,O
42,O
],O
and,O
TLR7,O
",",O
a,O
Toll,O
-,O
like,O
receptor,O
essential,O
for,O
antiviral,O
immunity,O
",",O
including,O
the,O
response,O
to,O
SARS,O
-,O
CoV-2,O
[,O
[,O
43,O
],O
",",O
[,O
44,O
],O
",",O
[,O
45,O
],O
],O
.,O
The,O
PBMC,O
transcriptome,O
revealed,O
HMOX1,O
",",O
with,O
anti,O
-,O
inflammatory,O
properties,O
[,O
"46,47",O
],O
",",O
and,O
IL18,O
",",O
a,O
proinflammatory,O
cytokine,O
reported,O
to,O
play,O
an,O
important,O
role,O
in,O
COVID-19,O
[,O
[,O
48,O
],O
",",O
[,O
49,O
],O
",",O
[,O
50,O
],O
],O
.,O
However,O
",",O
when,O
the,O
entire,O
lists,O
of,O
enriched,O
genes,O
were,O
compared,O
(,O
Table,O
1,O
and,O
Supplemental,O
Table,O
2,O
),O
we,O
found,O
hundreds,O
of,O
enriched,O
genes,O
in,O
each,O
of,O
the,O
datasets,O
studied,O
.,O
Individual,O
analysis,O
of,O
the,O
210,O
-,O
gene,O
list,O
revealed,O
many,O
genes,O
playing,O
major,O
roles,O
in,O
COVID-19,O
pathology,O
.,O
MyD88,O
plays,O
an,O
important,O
role,O
in,O
IL-6,O
induction,O
during,O
COVID-19,O
[,O
57,O
],O
.,O
RIG‐I,O
is,O
a,O
PRR,O
sensing,O
RNA,O
virus,O
",",O
upregulated,O
by,O
viral,O
infection,O
[,O
58,O
],O
and,O
has,O
been,O
implicated,O
in,O
the,O
induction,O
of,O
early,O
antiviral,O
immune,O
responses,O
in,O
COVID-19,O
[,O
59,O
],O
.,O
Many,O
genes,O
are,O
associated,O
to,O
the,O
COVID-19,O
cytokine,O
storm,O
.,O
CXCL10,O
is,O
a,O
chemokine,O
attracting,O
macrophages,O
and,O
promoting,O
T,O
cell,O
adhesion,O
in,O
response,O
to,O
interferon,O
[,O
69,O
],O
and,O
is,O
part,O
of,O
the,O
COVID-19,O
cytokine,O
storm,O
[,O
70,O
],O
.,O
STAT1,O
is,O
activated,O
by,O
interferon,O
and,O
IL-6,O
",",O
polarizing,O
the,O
immune,O
response,O
specifically,O
in,O
macrophages,O
",",O
resulting,O
in,O
a,O
worsened,O
COVID-19,O
outcome,O
[,O
[,O
75,O
],O
",",O
[,O
76,O
],O
",",O
[,O
77,O
],O
",",O
[,O
78,O
],O
],O
.,O
Increased,O
TNFα,O
production,O
and,O
release,O
",",O
associated,O
with,O
IL-1α,O
and,O
IL,O
-,O
β,O
and,O
inversely,O
correlated,O
with,O
lymphopenia,O
and,O
decreased,O
IFN,O
-,O
γ,O
expression,O
",",O
is,O
characteristic,O
of,O
severe,O
COVID-19,O
[,O
[,O
79,O
],O
",",O
[,O
80,O
],O
",",O
[,O
81,O
],O
",",O
[,O
82,O
],O
],O
.,O
Their,O
upregulation,O
may,O
play,O
a,O
role,O
in,O
the,O
high,O
risk,O
of,O
thrombosis,O
of,O
COVID-19,O
patients,O
[,O
"103,104",O
],O
.,O
The,O
beneficial,O
effect,O
of,O
ARB,O
treatment,O
may,O
not,O
be,O
limited,O
to,O
acute,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
COVID-19,O
severity,O
but,O
may,O
extend,O
to,O
ameliorate,O
long,O
-,O
term,O
consequences,O
of,O
the,O
disease,O
.,O
Pulmonary,O
fibrosis,O
leading,O
to,O
pulmonary,O
arterial,O
hypertension,O
and,O
irreversible,O
respiratory,O
failure,O
is,O
likely,O
to,O
occur,O
in,O
patients,O
recovered,O
from,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
associated,O
with,O
critically,O
severe,O
COVID-19,O
[,O
"57,129,130",O
],O
.,O
Old,O
age,O
is,O
a,O
major,O
risk,O
factor,O
for,O
COVID-19,O
progression,O
and,O
death,O
[,O
"5,18,138",O
],O
.,O
It,O
has,O
been,O
recently,O
shown,O
that,O
one,O
Alzheimer,O
’s,O
risk,O
gene,O
correlates,O
with,O
risk,O
for,O
severe,O
COVID-19,O
[,O
141,O
],O
.,O
Within,O
our,O
210,O
-,O
gene,O
list,O
",",O
a,O
genetic,O
variant,O
of,O
IFITM3,O
has,O
been,O
recently,O
associated,O
with,O
age,O
-,O
dependent,O
COVID-19,O
severity,O
[,O
142,O
],O
",",O
and,O
ADAP2,O
has,O
been,O
proposed,O
to,O
participate,O
in,O
Alzheimer,O
’s,O
disease,O
progression,O
[,O
143,O
],O
.,O
SARS,O
-,O
CoV-2,O
infection,O
not,O
only,O
affects,O
the,O
lung,O
but,O
extends,O
to,O
many,O
other,O
organs,O
",",O
including,O
the,O
brain,O
",",O
and,O
age,O
-,O
related,O
cerebrovascular,O
disorders,O
such,O
as,O
cerebral,O
hemorrhage,O
and,O
stroke,O
are,O
not,O
only,O
frequent,O
comorbidities,O
but,O
also,O
novel,O
and,O
critical,O
events,O
in,O
the,O
presentation,O
",",O
progress,O
and,O
prognosis,O
of,O
COVID-19,O
[,O
"18,19,[21",O
],O
",",O
[,O
22,O
],O
",",O
[,O
"23],146,147",O
],O
.,O
Our,O
IPA,O
upstream,O
regulator,O
analysis,O
identified,O
many,O
factors,O
that,O
may,O
downregulate,O
COVID-19,O
upregulated,O
genes,O
in,O
our,O
study,O
",",O
including,O
dexamethasone,O
",",O
immunoglobulin,O
",",O
beta,O
-,O
estradiol,O
",",O
and,O
simvastatin,O
.,O
Dexamethasone,O
has,O
been,O
proposed,O
for,O
acutely,O
ill,O
COVID-19,O
patients,O
",",O
but,O
its,O
use,O
carries,O
severe,O
risks,O
and,O
needs,O
to,O
be,O
carefully,O
evaluated,O
[,O
152,O
],O
.,O
Immunoglobulin,O
was,O
reported,O
to,O
be,O
effective,O
in,O
severely,O
ill,O
COVID-19,O
patients,O
[,O
153,O
],O
.,O
Not,O
surprisingly,O
",",O
many,O
proinflammatory,O
cytokines,O
(,O
TNF,O
",",O
IL1B,O
",",O
IL6,O
",",O
IL13,O
),O
",",O
PRRs,O
such,O
as,O
TLR4,O
and,O
TLR7,O
",",O
and,O
inflammation,O
-,O
inducing,O
drugs,O
such,O
as,O
lipopolysaccharide,O
were,O
found,O
to,O
positively,O
correlate,O
with,O
COVID-19,O
upregulated,O
genes,O
.,O
It,O
has,O
also,O
been,O
reported,O
that,O
ARBs,O
ameliorate,O
pneumonia,O
in,O
COVID-19,O
patients,O
[,O
[,O
176,O
],O
",",O
[,O
177,O
],O
",",O
[,O
178,O
],O
",",O
[,O
179,O
],O
],O
",",O
after,O
viral,O
infections,O
[,O
"6,[180",O
],O
",",O
[,O
181,O
],O
",",O
[,O
182,O
],O
",",O
[,O
183,O
],O
",",O
[,O
184,O
],O
",",O
[,O
185,O
],O
",",O
[,O
186,O
],O
],O
",",O
in,O
diabetic,O
patients,O
[,O
187,O
],O
and,O
in,O
chronic,O
obstructive,O
pulmonary,O
disease,O
[,O
[,O
188,O
],O
",",O
[,O
189,O
],O
",",O
[,O
190,O
],O
],O
.,O
Improved,O
clinical,O
outcome,O
after,O
ARB,O
treatment,O
of,O
COVID-19,O
patients,O
is,O
associated,O
with,O
reduced,O
IL-6,O
in,O
peripheral,O
blood,O
",",O
increased,O
CD3,O
and,O
CD8,O
T,O
cell,O
counts,O
and,O
reduced,O
peak,O
viral,O
load,O
[,O
178,O
],O
and,O
lower,O
concentrations,O
of,O
high,O
-,O
sensitivity,O
C,O
-,O
reactive,O
protein,O
(,O
hs,O
-,O
CRP,O
),O
and,O
procalcitonin,O
(,O
PCT,O
),O
[,O
24,O
],O
.,O
These,O
findings,O
support,O
the,O
present,O
correlation,O
of,O
our,O
neuronal,O
transcriptome,O
with,O
that,O
of,O
PBMC,O
in,O
COVID-19,O
patients,O
.,O
However,O
",",O
the,O
role,O
of,O
AT2,O
receptor,O
activation,O
in,O
COVID-19,O
patients,O
has,O
not,O
been,O
studied,O
.,O
•,O
 ,O
Glutamate,O
upregulated,O
genes,O
in,O
neurons,O
positively,O
correlate,O
with,O
COVID-19,O
upregulated,O
genes,O
.,O
•,O
 ,O
Candesartan,O
gene,O
downregulation,O
negatively,O
correlates,O
with,O
COVID-19,O
upregulated,O
genes,O
.,O
•,O
 ,O
Candesartan,O
downregulates,O
genes,O
involved,O
in,O
the,O
COVID-19,O
cytokine,O
storm,O
.,O
Background,O
 ,O
Angiotensin,O
receptor,O
blockers,O
(,O
ARBs,O
),O
reducing,O
inflammation,O
and,O
protecting,O
lung,O
and,O
brain,O
function,O
",",O
could,O
be,O
of,O
therapeutic,O
efficacy,O
in,O
COVID-19,O
patients,O
.,O
Methods,O
 ,O
Using,O
GSEA,O
",",O
we,O
compared,O
our,O
previous,O
transcriptome,O
analysis,O
of,O
neurons,O
injured,O
by,O
glutamate,O
and,O
treated,O
with,O
the,O
ARB,O
Candesartan,O
(,O
GSE67036,S-AccessionNumber
),O
with,O
transcriptional,O
signatures,O
from,O
SARS,O
-,O
CoV-2,O
infected,O
primary,O
human,O
bronchial,O
epithelial,O
cells,O
(,O
NHBE,O
),O
and,O
lung,O
postmortem,O
(,O
GSE147507,S-AccessionNumber
),O
",",O
PBMC,O
and,O
BALF,O
samples,O
(,O
CRA002390,S-AccessionNumber
),O
from,O
COVID-19,O
patients,O
.,O
Results,O
 ,O
Hundreds,O
of,O
genes,O
upregulated,O
in,O
SARS,O
-,O
CoV-2,O
/,O
COVID-19,O
transcriptomes,O
were,O
similarly,O
upregulated,O
by,O
glutamate,O
and,O
normalized,O
by,O
Candesartan,O
.,O
Gene,O
Ontology,O
analysis,O
revealed,O
expression,O
profiles,O
with,O
greatest,O
significance,O
and,O
enrichment,O
",",O
including,O
proinflammatory,O
cytokine,O
and,O
chemokine,O
activity,O
",",O
the,O
NF,O
-,O
kappa,O
B,O
complex,O
",",O
alterations,O
in,O
innate,O
and,O
adaptive,O
immunity,O
",",O
with,O
many,O
genes,O
participating,O
in,O
the,O
COVID-19,O
cytokine,O
storm,O
.,O
This,O
supports,O
the,O
hypothesis,O
of,O
a,O
therapeutic,O
role,O
for,O
ARBs,O
",",O
ameliorating,O
the,O
COVID-19,O
cytokine,O
storm,O
.,O
Finally,O
",",O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
declared,O
it,O
as,O
Corona,O
Viruses,O
Disease,O
2019,O
(,O
COVID-19,O
),O
.,O
Third,O
",",O
this,O
number,O
of,O
peak,O
list,O
associated,O
with,O
the,O
abstract,O
number,O
of,O
peaks,O
obtained,O
by,O
in,O
-,O
silico,O
digestion,O
using,O
various,O
databases,O
.,O
So,O
",",O
we,O
selected,O
a,O
medicinal,O
plant,O
and,O
a,O
drug,O
to,O
check,O
its,O
activity,O
against,O
COVID-19,O
.,O
HCQ,O
is,O
also,O
included,O
in,O
the,O
triallist,O
to,O
treat,O
COVID-19,O
(,O
Liu,O
et,O
 ,O
al,O
.,O
",",O
2020,O
;,O
Wang,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
There,O
is,O
theoretical,O
",",O
experimental,O
",",O
preclinical,O
",",O
and,O
clinical,O
evidence,O
of,O
the,O
effectiveness,O
of,O
hydroxychloroquine,O
in,O
patients,O
affected,O
with,O
COVID-19,O
.,O
The,O
whole,O
genome,O
sequence,O
of,O
novel,O
coronavirus,O
was,O
obtained,O
through,O
NCBI,S-Repository
 ,O
(,O
https://www.ncbi.nlm.nih.gov/,S-URL
),O
with,O
accession,O
no,O
:,O
MN908947.3,S-AccessionNumber
",",O
"29,903bp",O
in,O
length,O
and,O
described,O
as,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
originated,O
from,O
Wuhan,O
-,O
Hu-1,O
on,O
18,O
March,O
2020,O
(,O
Kruse,O
",",O
2020,O
),O
.,O
This,O
server,O
determines,O
the,O
active,O
peptides,O
by,O
comparing,O
the,O
calculated,O
peak,O
lists,O
with,O
already,O
existing,O
masses,O
of,O
peptides,O
in,O
the,O
database,O
",",O
resulting,O
in,O
the,O
active,O
peptides,O
with,O
additional,O
information,O
.,O
We,O
picked,O
Swissprot,S-Repository
 ,O
for,O
the,O
search,O
database,O
because,O
it,O
is,O
nonredundant,O
and,O
fairly,O
small,O
",",O
helpful,O
for,O
statistically,O
meaningful,O
matches,O
(,O
Bairoch,O
and,O
Apweiler,O
",",O
2000,O
),O
.,O
MASCOT,O
database,O
identifies,O
the,O
viruses,O
and,O
proteins,O
which,O
contain,O
the,O
matched,O
peptides,O
sequences,O
along,O
with,O
complete,O
annotation,O
.,O
So,O
",",O
from,O
the,O
aforementioned,O
findings,O
",",O
it,O
is,O
confirmed,O
that,O
the,O
chosen,O
antiviral,O
compounds,O
are,O
effective,O
inhibitors,O
against,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
can,O
help,O
the,O
immune,O
system,O
to,O
fight,O
against,O
COVID-19,O
(,O
Figures,O
5,O
and,O
6,O
),O
.,O
An,O
rare,O
pandemic,O
of,O
viral,O
pneumonia,O
occurs,O
in,O
December,O
2019,O
in,O
Wuhan,O
",",O
China,O
",",O
which,O
is,O
now,O
recognized,O
internationally,O
as,O
Corona,O
Virus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
",",O
the,O
etiological,O
agent,O
classified,O
as,O
Severe,O
Acute,O
Respiratory,O
Syndrome,O
Corona,O
Virus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
.,O
Molecular,O
peptide,O
docking,O
with,O
Moringa,O
oleifera,O
",",O
phytochemicals,O
(,O
aqueous,O
and,O
ethanolic,O
),O
leaf,O
extracts,O
of,O
flavonoids,O
(,O
3.56,O
 ,O
±,O
 ,O
0.03,O
),O
",",O
(,O
3.83,O
 ,O
±,O
 ,O
0.02,O
),O
",",O
anthraquinone,O
(,O
11.68,O
 ,O
±,O
 ,O
0.04,O
),O
",",O
(,O
10.86,O
 ,O
±,O
 ,O
0.06,O
),O
and,O
hydroxychloroquine,O
present,O
therapy,O
of,O
COVID-19,O
in,O
Pakistan,O
for,O
comparative,O
study,O
.,O
In,O
conclusion,O
",",O
it,O
is,O
proposed,O
that,O
these,O
compounds,O
are,O
effective,O
antiviral,O
agents,O
against,O
COVID-19,O
and,O
can,O
be,O
used,O
in,O
clinical,O
trials,O
.,O
A,O
total,O
of,O
24,O
proteins,O
of,O
SARS,O
-,O
CoV-2,O
(,O
Table,O
1,O
),O
were,O
run,O
through,O
our,O
standardized,O
workflow,O
(,O
Fig,O
.,O
1,O
),O
",",O
consisting,O
of,O
protein,O
structure,O
assessment,O
",",O
setting,O
of,O
protein,O
protonation,O
at,O
pH,O
7.4,O
",",O
energy,O
minimization,O
in,O
water,O
with,O
NaCl,O
",",O
20,O
ns,O
of,O
molecular,O
dynamics,O
simulations,O
",",O
analysis,O
of,O
the,O
movement,O
trajectories,O
",",O
sequence,O
identification,O
from,O
the,O
nonredundant,O
(,O
nr,O
),O
database,O
",",O
mapping,O
of,O
conservation,O
onto,O
structure,O
/,O
dynamics,O
",",O
and,O
assessment,O
of,O
interactions,O
with,O
known,O
binding,O
partners,O
.,O
The,O
dynamics,O
and,O
evolution,O
for,O
each,O
protein,O
were,O
integrated,O
together,O
into,O
VIStEDD,S-Repository
",",O
available,O
at,O
RRID,O
:,O
SCR_018793,S-AccessionNumber
.,O
For,O
example,O
",",O
within,O
the,O
nsp10,O
data,O
(,O
RRID,O
:,O
SCR_018793,S-AccessionNumber
",",O
SARS,O
-,O
CoV-2,O
",",O
nsp10,O
),O
",",O
structures,O
of,O
nsp10,O
interacting,O
with,O
either,O
nsp14,O
or,O
nsp16,O
are,O
available,O
",",O
both,O
of,O
which,O
show,O
highly,O
conserved,O
contact,O
sites,O
of,O
interaction,O
.,O
Structural,O
mapping,O
of,O
human,O
variants,O
from,O
"141,456",O
people,O
of,O
the,O
gnomADv2,S-Repository
 ,O
database,O
for,O
ACE2,O
suggests,O
a,O
few,O
possible,O
variants,O
at,O
the,O
interface,O
of,O
S,O
-,O
ACE2,O
interaction,O
(,O
Fig,O
.,O
6C,O
),O
.,O
That,O
database,O
can,O
be,O
used,O
by,O
groups,O
to,O
investigate,O
species,O
where,O
SARS,O
-,O
CoV-2,O
may,O
be,O
able,O
to,O
enter,O
cells,O
",",O
with,O
variants,O
that,O
enhance,O
or,O
inhibit,O
binding,O
.,O
For,O
those,O
proteins,O
without,O
structural,O
homologs,O
",",O
we,O
utilized,O
models,O
that,O
are,O
part,O
of,O
the,O
I,O
-,O
TASSER,O
SARS,O
-,O
CoV-2,O
database,O
(,O
39,O
),O
.,O
We,O
established,O
the,O
Viral,B-Repository
Integrated,I-Repository
Structural,I-Repository
Evolution,I-Repository
Dynamic,I-Repository
Database,I-Repository
(VIStEDD,E-Repository
 ,O
at,O
RRID,O
:,O
SCR_018793,S-AccessionNumber
 ,O
),O
to,O
facilitate,O
future,O
discoveries,O
and,O
educational,O
use,O
.,O
Using,O
this,O
quantitative,O
matrix,O
",",O
we,O
elucidated,O
47,O
potential,O
functional,O
missense,O
variants,O
from,O
genomic,O
databases,O
within,O
ACE2,O
/,O
SLC6A19,O
/,O
transmembrane,O
serine,O
protease,O
2,O
(,O
TMPRSS2,O
),O
",",O
warranting,O
genomic,O
enrichment,O
analyses,O
in,O
SARS,O
-,O
CoV-2,O
patients,O
.,O
We,O
propose,O
that,O
this,O
SARS,O
-,O
CoV-2,O
database,O
may,O
aid,O
research,O
into,O
the,O
ongoing,O
pandemic,O
.,O
Previous,O
reports,O
indicated,O
that,O
the,O
emergence,O
of,O
the,O
novel,O
coronavirus,O
(,O
SARS,O
-,O
CoV-2,O
),O
infection,O
(,O
COVID-19,O
),O
had,O
raised,O
global,O
concern,O
and,O
was,O
characterized,O
as,O
a,O
pandemic,O
event,O
by,O
the,O
World,O
Health,O
Organization,O
on,O
March,O
11,O
",",O
2020.1,O
",",O
2,O
",",O
3,O
Till,O
March,O
18,O
",",O
2020,O
",",O
it,O
has,O
spread,O
to,O
146,O
countries,O
",",O
including,O
Taiwan,O
.,O
People,O
in,O
Taiwan,O
and,O
mainland,O
China,O
travel,O
frequently,O
",",O
which,O
put,O
Taiwan,O
at,O
a,O
great,O
risk,O
of,O
acquiring,O
an,O
epidemic,O
of,O
COVID-19,O
.,O
Taiwan,O
has,O
been,O
on,O
constant,O
alert,O
and,O
react,O
rapidly,O
to,O
epidemics,O
change,O
from,O
China,O
ever,O
since,O
the,O
severe,O
acute,O
respiratory,O
syndrome,O
(,O
SARS,O
),O
epidemic,O
in,O
2003,O
and,O
has,O
done,O
much,O
effort,O
on,O
the,O
containment,O
of,O
COVID-19,O
with,O
success,O
.,O
Till,O
March,O
18,O
",",O
2020,O
",",O
there,O
are,O
only,O
100,O
cases,O
of,O
COVID-19,O
noted,O
in,O
Taiwan,O
",",O
including,O
79,O
imported,O
cases,O
and,O
21,O
cases,O
belonging,O
to,O
seven,O
occasions,O
of,O
limited,O
local,O
transmission,O
(,O
six,O
family,O
clusters,O
and,O
two,O
transmissions,O
in,O
social,O
societies,O
),O
.,O
The,O
most,O
interesting,O
point,O
of,O
this,O
patient,O
is,O
where,O
she,O
contracted,O
her,O
COVID-19,O
.,O
However,O
",",O
despite,O
that,O
the,O
median,O
incubation,O
period,O
of,O
COVID-19,O
was,O
5.1,O
days,O
",",O
it,O
might,O
be,O
as,O
long,O
as,O
more,O
than,O
three,O
weeks,O
in,O
some,O
extreme,O
cases,O
.,O
",",O
The,O
phylogenetic,O
tree,O
was,O
generated,O
and,O
modified,O
for,O
display,O
purposes,O
from,O
Nextstrain,S-Repository
 ,O
(,O
https://nextstrain.org/ncov,S-URL
),O
",",O
which,O
uses,O
genetic,O
sequences,O
and,O
metadata,O
from,O
GISAID,S-Dataset
 ,O
(,O
https://www.gisaid.org/CoV2020/,S-URL
),O
and,O
sequence,O
submission,O
date,O
for,O
the,O
horizontal,O
axis,O
.,O
To,O
our,O
best,O
knowledge,O
",",O
in,O
late,O
February,O
and,O
early,O
March,O
",",O
several,O
foreign,O
 ,O
COVID-19,O
patients,O
who,O
had,O
travel,O
histories,O
to,O
Egypt,O
were,O
reported,O
.,O
Further,O
phylogenetic,O
analysis,O
including,O
viral,O
sequences,O
derived,O
from,O
the,O
45,O
confirmed,O
SARS,O
-,O
CoV-2,O
infections,O
on,O
the,O
quarantined,O
Nile,O
cruise,O
boat,O
will,O
help,O
to,O
delineate,O
the,O
outbreak,O
on,O
Nile,O
tourism,O
boat,O
and,O
its,O
impact,O
on,O
the,O
COVID-19,O
epidemic,O
.,O
In,O
planning,O
for,O
our,O
health,O
system,O
’s,O
anticipated,O
COVID-19,O
pandemic,O
response,O
scenario,O
",",O
our,O
workgroup,O
planned,O
initially,O
to,O
support,O
only,O
low,O
-,O
acuity,O
",",O
non,O
–,O
COVID-19,O
populations,O
requiring,O
oral,O
and/or,O
intramuscular,O
injections,O
;,O
in,O
a,O
stepwise,O
approach,O
to,O
increasing,O
acuity,O
",",O
limited,O
gravity,O
-,O
flow,O
infusions,O
would,O
be,O
supported,O
by,O
the,O
closest,O
hospital,O
pharmacy,O
with,O
sterile,O
compounding,O
capabilities,O
.,O
Our,O
workgroup,O
anticipated,O
that,O
the,O
alternate,O
care,O
site,O
would,O
have,O
limited,O
nurse,O
staffing,O
due,O
to,O
mass,O
deployment,O
for,O
high,O
-,O
acuity,O
",",O
COVID-19,O
–,O
related,O
patient,O
care,O
needs,O
in,O
existing,O
hospitals,O
throughout,O
the,O
health,O
system,O
.,O
Abstract,O
  ,O
Purpose,O
 ,O
Guidance,O
on,O
alternate,O
care,O
site,O
planning,O
based,O
on,O
the,O
experience,O
of,O
a,O
health,O
-,O
system,O
pharmacy,O
department,O
in,O
preparing,O
for,O
an,O
expected,O
surge,O
in,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
cases,O
is,O
provided,O
.,O
In,O
disaster,O
response,O
situations,O
such,O
as,O
the,O
COVID-19,O
pandemic,O
",",O
healthcare,O
institutions,O
may,O
be,O
compelled,O
to,O
transition,O
to,O
a,O
contingency,O
care,O
model,O
in,O
which,O
staffing,O
and,O
supply,O
levels,O
are,O
no,O
longer,O
consistent,O
with,O
daily,O
practice,O
norms,O
and,O
",",O
while,O
usual,O
patient,O
care,O
practices,O
are,O
maintained,O
",",O
establishment,O
of,O
alternate,O
care,O
sites,O
(,O
eg,O
",",O
a,O
convention,O
center,O
),O
may,O
be,O
necessitated,O
by,O
high,O
patient,O
volumes,O
.,O
Available,O
resources,O
to,O
assist,O
hospitals,O
and,O
health,O
systems,O
in,O
alternate,O
care,O
site,O
planning,O
include,O
online,O
guidance,O
posted,O
within,O
the,O
COVID-19,O
resources,O
section,O
of,O
the,O
US,O
Army,O
Corps,O
of,O
Engineers,O
website,O
",",O
which,O
provides,O
recommended,O
medication,O
and,O
supply,O
lists,O
;,O
and,O
the,O
Federal,O
Healthcare,O
Resilience,O
Task,O
Force,O
’s,O
alternate,O
care,O
site,O
toolkit,O
",",O
a,O
comprehensive,O
resource,O
for,O
all,O
aspects,O
of,O
alternate,O
care,O
site,O
planning,O
",",O
including,O
pharmacy,O
services,O
.,O
Overall,O
",",O
these,O
data,O
show,O
the,O
utility,O
of,O
genomics,O
to,O
complement,O
other,O
tools,O
in,O
the,O
response,O
to,O
",",O
and,O
containment,O
of,O
",",O
the,O
COVID-19,O
outbreak,O
.,O
COVID-19,O
cases,O
are,O
slowly,O
increasing,O
in,O
number,O
in,O
Africa,O
and,O
genetic,O
mutations,O
are,O
expected,O
to,O
accumulate,O
as,O
the,O
virus,O
spreads,O
.,O
As,O
well,O
as,O
ongoing,O
mobilisation,O
of,O
resources,O
to,O
support,O
the,O
COVID-19,O
outbreak,O
response,O
",",O
it,O
is,O
crucial,O
for,O
Africa,O
to,O
develop,O
sustainable,O
approaches,O
",",O
with,O
a,O
vision,O
to,O
change,O
the,O
siloed,O
pathogen,O
-,O
specific,O
diagnostics,O
methods,O
and,O
implement,O
digital,O
and,O
genomic,O
transformation,O
in,O
the,O
public,O
health,O
system,O
.,O
SENTINEL,O
",",O
a,O
new,O
international,O
initiative,O
led,O
by,O
the,O
African,O
Centre,O
of,O
Excellence,O
for,O
Genomics,O
of,O
Infectious,O
Diseases,O
(,O
ACEGID,O
),O
in,O
Nigeria,O
and,O
the,O
Broad,O
Institute,O
",",O
is,O
utilising,O
ultra,O
-,O
sensitive,O
genomic,O
technologies,O
to,O
develop,O
a,O
pandemic,O
pre,O
-,O
emption,O
system,O
that,O
detects,O
viral,O
threats,O
in,O
real,O
time,O
.,O
The,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
termed,O
the,O
disease,O
as,O
coronavirus,O
disease-2019,O
(,O
COVID-19,O
),O
on,O
February,O
11,O
",",O
2020,O
[,O
17,O
],O
.,O
With,O
transmission,O
of,O
the,O
virus,O
possible,O
before,O
the,O
onset,O
of,O
clinical,O
signs,O
",",O
the,O
COVID-19,O
outbreak,O
has,O
quickly,O
expanded,O
to,O
worldwide,O
[,O
18–20,O
],O
.,O
As,O
of,O
August,O
18,O
",",O
2020,O
",",O
a,O
total,O
of,O
"21,756,357",O
confirmed,O
cases,O
of,O
COVID-19,O
and,O
"771,635",O
deaths,O
have,O
been,O
reported,O
in,O
more,O
than,O
200,O
countries,O
and,O
territories,O
.,O
The,O
first,O
case,O
of,O
COVID-19,O
in,O
Turkey,O
was,O
confirmed,O
on,O
March,O
112020,O
.,O
The,O
reads,O
were,O
aligned,O
to,O
the,O
previously,O
assembled,O
sequence,O
of,O
the,O
SARS,O
-,O
CoV-2,O
genome,O
(,O
GenBank,S-Repository
 ,O
Accession,O
:,O
MN908947.3,S-AccessionNumber
),O
using,O
the,O
Burrows,O
-,O
Wheeler,O
aligner,O
v.0.7.1,O
with,O
the,O
MEM,O
algorithm,O
[,O
25,O
],O
.,O
For,O
multiple,O
sequence,O
alignment,O
",",O
complete,O
(,O
>,O
"29,000bp",O
),O
and,O
high,O
-,O
coverage,O
genomes,O
(,O
n,O
=,O
3970,O
),O
were,O
used,O
from,O
the,O
GISAID,S-Dataset
 ,O
database,O
.,O
The,O
GISAID,S-Dataset
 ,O
strain,O
genomes,O
including,O
the,O
genome,O
of,O
our,O
strain,O
were,O
aligned,O
using,O
the,O
MAFFT,O
v7.450,O
tool,O
[,O
28,O
],O
.,O
The,O
whole,O
genome,O
sequence,O
was,O
submitted,O
to,O
GenBank,S-Repository
 ,O
(,O
ID,O
:,O
MT327745.1,S-AccessionNumber
),O
and,O
GISAID,S-Dataset
 ,O
(,O
ID,O
:,O
EPI_ISL_424366,S-AccessionNumber
),O
and,O
the,O
raw,O
data,O
deposited,O
on,O
SRA,S-Repository
 ,O
(,O
SAMN15062833,S-AccessionNumber
),O
.,O
Taken,O
together,O
",",O
these,O
results,O
suggest,O
that,O
a,O
SARS,O
-,O
CoV-2,O
strain,O
named,O
hCoV-19,O
/,O
Turkey,O
/,O
ERAGEM-001/2020,O
was,O
successfully,O
isolated,O
from,O
the,O
nasopharyngeal,O
sample,O
of,O
a,O
patient,O
in,O
Turkey,O
with,O
confirmed,O
COVID-19,O
.,O
According,O
to,O
published,O
case,O
reports,O
and,O
GISAID,S-Dataset
 ,O
metadata,O
entries,O
",",O
at,O
least,O
9,O
SARS,O
-,O
CoV-2,O
samples,O
in,O
the,O
nearby,O
clusters,O
had,O
a,O
recent,O
travel,O
history,O
to,O
Iran,O
[,O
30,O
],O
.,O
The,O
GISAID,S-Dataset
 ,O
had,O
only,O
one,O
full,O
genome,O
sequence,O
of,O
SARS,O
-,O
CoV-2,O
from,O
Iran,O
",",O
which,O
also,O
included,O
the,O
two,O
key,O
mutations,O
(,O
G1397A,O
and,O
G29742,O
T,O
),O
.,O
In,O
addition,O
",",O
analysis,O
of,O
the,O
NP,O
partial,O
gene,O
sequences,O
of,O
the,O
Iranian,O
samples,O
in,O
GISAID,S-Dataset
 ,O
showed,O
that,O
all,O
of,O
the,O
Iranian,O
partial,O
sequences,O
(,O
n,O
=,O
15,O
),O
also,O
contain,O
the,O
T28688C,O
",",O
which,O
is,O
another,O
key,O
single,O
nucleotide,O
polymorphism,O
(,O
SNP,O
),O
of,O
this,O
clade,O
.,O
Our,O
strain,O
also,O
contained,O
G23876A,O
",",O
a,O
non,O
-,O
synonymous,O
mutation,O
in,O
the,O
S,O
gene,O
",",O
which,O
was,O
not,O
observed,O
in,O
any,O
other,O
full,O
genome,O
sequences,O
in,O
GISAID,S-Dataset
.,O
In,O
this,O
study,O
",",O
we,O
isolated,O
the,O
SARS,O
-,O
CoV-2,O
from,O
the,O
nasopharyngeal,O
sample,O
of,O
a,O
patient,O
in,O
Turkey,O
with,O
confirmed,O
COVID-19,O
.,O
Lastly,O
",",O
we,O
have,O
compared,O
the,O
whole,O
genome,O
of,O
hCoV-19,O
/,O
Turkey,O
/,O
ERAGEM-001/2020,O
with,O
a,O
dataset,O
of,O
3970,O
available,O
SARS,O
-,O
CoV-2,O
complete,O
genomes,O
from,O
different,O
countries,O
retrieved,O
from,O
GISAID,S-Dataset
.,O
The,O
reason,O
for,O
the,O
high,O
fraction,O
of,O
Australian,O
cases,O
in,O
this,O
cluster,O
was,O
possibly,O
due,O
to,O
the,O
high,O
number,O
of,O
submitted,O
sequences,O
",",O
as,O
Australia,O
was,O
the,O
third,O
country,O
that,O
had,O
the,O
most,O
sequences,O
submitted,O
to,O
GISAID,S-Dataset
 ,O
by,O
April,O
2020,O
.,O
Interestingly,O
",",O
hCoV-19,O
/,O
Turkey,O
/,O
ERAGEM-001/2020,O
has,O
the,O
G23876A,O
mutation,O
on,O
the,O
S,O
gene,O
",",O
which,O
is,O
not,O
found,O
in,O
any,O
other,O
full,O
genome,O
sequences,O
in,O
GISAID,S-Dataset
",",O
including,O
the,O
Australian,O
cluster,O
.,O
Coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
caused,O
by,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
and,O
associated,O
with,O
severe,O
respiratory,O
illness,O
emerged,O
in,O
Wuhan,O
",",O
China,O
",",O
in,O
late,O
2019,O
.,O
Currently,O
",",O
there,O
are,O
no,O
specific,O
treatments,O
or,O
licensed,O
vaccines,O
available,O
for,O
COVID-19,O
.,O
We,O
isolated,O
SARS,O
-,O
CoV-2,O
from,O
the,O
nasopharyngeal,O
sample,O
of,O
a,O
patient,O
in,O
Turkey,O
with,O
confirmed,O
COVID-19,O
.,O
COVID-19,O
infects,O
mainly,O
elderly,O
and,O
people,O
with,O
cardiovascular,O
risk,O
",",O
such,O
as,O
hypertension,O
(,O
Guan,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Every,O
clinician,O
recognizes,O
that,O
the,O
virus,O
does,O
not,O
cause,O
disease,O
similar,O
to,O
influenza,O
",",O
which,O
carries,O
the,O
risk,O
that,O
designing,O
targeted,O
therapies,O
based,O
on,O
the,O
pathogenesis,O
of,O
influenza,O
might,O
fail,O
in,O
COVID-19,O
.,O
Research,O
on,O
Sars,O
-,O
CoV,O
pathogenesis,O
which,O
might,O
be,O
very,O
similar,O
to,O
Sars,O
-,O
CoV-2,O
pathogenesis,O
has,O
focused,O
the,O
discussion,O
on,O
ACE,O
inhibitors,O
",",O
recombinant,O
ACE2,O
",",O
 ,O
and,O
ARBs,O
and,O
how,O
they,O
could,O
fit,O
in,O
the,O
pathogenesis,O
of,O
COVID-19,O
",",O
since,O
these,O
pathways,O
were,O
extensively,O
studied,O
in,O
SARS,O
(,O
Fang,O
et,O
al,O
.,O
",",O
2020,O
;,O
 ,O
Batlle,O
et,O
al,O
.,O
",",O
2020,O
),O
.,O
Here,O
",",O
we,O
describe,O
the,O
clinical,O
observations,O
that,O
brought,O
the,O
clues,O
for,O
explaining,O
the,O
potential,O
pathophysiological,O
mechanisms,O
",",O
and,O
offer,O
a,O
rationale,O
for,O
targeted,O
treatment,O
at,O
different,O
stages,O
of,O
COVID-19,O
.,O
In,O
contrast,O
to,O
patients,O
with,O
common,O
forms,O
of,O
ARDS,O
",",O
approximately,O
70,O
%,O
of,O
patients,O
with,O
severe,O
COVID-19,O
show,O
an,O
only,O
slightly,O
decreased,O
pulmonary,O
compliance,O
(,O
L,O
-,O
type,O
),O
(,O
Gattinoni,O
et,O
al,O
.,O
",",O
2020a,O
),O
.,O
We,O
propose,O
it,O
all,O
starts,O
with,O
ACE2,O
and,O
its,O
role,O
in,O
the,O
kallikrein,O
-,O
kinin,O
system,O
",",O
which,O
to,O
date,O
has,O
not,O
been,O
 ,O
investigated,O
in,O
the,O
pathogenesis,O
of,O
SARS,O
or,O
COVID-19,O
.,O
The,O
clinical,O
picture,O
of,O
COVID-19,O
is,O
in,O
line,O
with,O
a,O
single,O
-,O
organ,O
failure,O
of,O
the,O
lung,O
that,O
is,O
due,O
to,O
edema,O
at,O
the,O
site,O
of,O
inflammation,O
.,O
In,O
addition,O
",",O
complement,O
activation,O
has,O
been,O
described,O
and,O
could,O
play,O
a,O
role,O
in,O
this,O
stage,O
of,O
disease,O
",",O
and,O
this,O
might,O
be,O
amendable,O
to,O
C5,O
blockade,O
with,O
eculizimab,O
with,O
which,O
a,O
randomized,O
trial,O
in,O
COVID-19,O
is,O
being,O
performed,O
(,O
NCT04288713,S-AccessionNumber
),O
.,O
COVID-19,O
patients,O
can,O
present,O
with,O
pulmonary,O
edema,O
early,O
in,O
disease,O
.,O
Here,O
",",O
we,O
hypothesize,O
that,O
a,O
kinin,O
-,O
dependent,O
local,O
lung,O
angioedema,O
via,O
B1R,O
and,O
eventually,O
B2R,O
is,O
an,O
important,O
feature,O
of,O
COVID-19,O
.,O
We,O
propose,O
that,O
blocking,O
the,O
B2R,O
and,O
inhibiting,O
plasma,O
kallikrein,O
activity,O
might,O
have,O
an,O
ameliorating,O
effect,O
on,O
early,O
disease,O
caused,O
by,O
COVID-19,O
and,O
might,O
prevent,O
acute,O
respiratory,O
distress,O
syndrome,O
(,O
ARDS,O
),O
.,O
The,O
COVID-19,O
pandemic,O
represents,O
an,O
unprecedented,O
threat,O
to,O
global,O
health,O
.,O
Common,O
symptoms,O
include,O
a,O
fever,O
and,O
persistent,O
cough,O
and,O
COVID-19,O
patients,O
also,O
often,O
experience,O
an,O
excess,O
of,O
fluid,O
in,O
the,O
lungs,O
",",O
which,O
makes,O
it,O
difficult,O
to,O
breathe,O
.,O
The,O
SARS,O
-,O
CoV-2,O
virus,O
",",O
which,O
causes,O
COVID-19,O
",",O
enters,O
the,O
lining,O
of,O
the,O
lungs,O
via,O
an,O
enzyme,O
called,O
the,O
ACE2,O
receptor,O
",",O
which,O
is,O
present,O
on,O
the,O
outer,O
surface,O
of,O
the,O
lungs,O
’,O
cells,O
.,O
As,O
a,O
result,O
",",O
much,O
attention,O
has,O
turned,O
to,O
the,O
potential,O
link,O
between,O
this,O
hormone,O
system,O
in,O
relation,O
to,O
COVID-19,O
.,O
This,O
led,O
van,O
de,O
Veerdonk,O
et,O
al,O
.,O
to,O
propose,O
that,O
the,O
excess,O
of,O
fluid,O
in,O
the,O
lungs,O
seen,O
in,O
COVID-19,O
patients,O
may,O
be,O
because,O
kinins,O
are,O
not,O
being,O
neutralized,O
due,O
to,O
the,O
shortage,O
of,O
the,O
ACE2,O
receptor,O
.,O
If,O
this,O
hypothesis,O
is,O
correct,O
",",O
it,O
would,O
mean,O
that,O
directly,O
inhibiting,O
the,O
receptor,O
for,O
the,O
kinins,O
(,O
or,O
the,O
proteins,O
that,O
they,O
come,O
from,O
),O
may,O
be,O
the,O
only,O
way,O
to,O
stop,O
fluid,O
leaking,O
into,O
the,O
lungs,O
of,O
COVID-19,O
patients,O
in,O
the,O
early,O
stage,O
of,O
disease,O
.,O
If,O
that,O
work,O
provides,O
a,O
proof,O
of,O
concept,O
",",O
it,O
means,O
that,O
existing,O
treatments,O
and,O
registered,O
drugs,O
could,O
potentially,O
help,O
patients,O
with,O
COVID-19,O
",",O
by,O
preventing,O
the,O
need,O
for,O
mechanical,O
ventilation,O
and,O
saving,O
many,O
lives,O
.,O
Severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
(,O
SARS,O
-,O
CoV-2,O
),O
",",O
the,O
causative,O
agent,O
of,O
coronavirus,O
disease-19,O
(,O
COVID-19,O
),O
",",O
has,O
infected,O
millions,O
of,O
people,O
worldwide,O
since,O
its,O
identification,O
in,O
December,O
2019,O
",",O
resulting,O
in,O
more,O
than,O
400,O
000,O
deaths,O
to,O
date,O
.,O
Despite,O
the,O
substantial,O
reach,O
of,O
the,O
COVID-19,O
pandemic,O
in,O
areas,O
with,O
high,O
HIV,O
prevalence,O
",",O
there,O
are,O
very,O
limited,O
data,O
regarding,O
the,O
clinical,O
impact,O
of,O
SARS,O
-,O
CoV-2,O
infection,O
on,O
PLWH,O
.,O
COVID-19,O
also,O
leads,O
to,O
marked,O
immune,O
dysregulation,O
",",O
with,O
severe,O
cases,O
manifesting,O
a,O
dramatic,O
hyperinflammatory,O
syndrome,O
that,O
causes,O
respiratory,O
failure,O
and,O
multiorgan,O
dysfunction,O
[,O
4,O
],O
.,O
Lack,O
of,O
knowledge,O
regarding,O
the,O
interaction,O
of,O
HIV-,O
and,O
COVID-19,O
–,O
related,O
immune,O
dysfunction,O
have,O
led,O
to,O
uncertainty,O
regarding,O
appropriate,O
clinical,O
and,O
policy,O
guidance,O
for,O
the,O
management,O
and,O
counseling,O
of,O
PLWH,O
during,O
the,O
SARS,O
-,O
CoV-2,O
pandemic,O
.,O
We,O
identified,O
405,O
patients,O
not,O
living,O
with,O
HIV,O
",",O
matching,O
1,O
PLWH,O
to,O
up,O
to,O
5,O
patients,O
by,O
age,O
(,O
±2.5,O
years,O
),O
",",O
sex,O
",",O
race,O
/,O
ethnicity,O
",",O
and,O
calendar,O
week,O
of,O
infection,O
(,O
to,O
account,O
for,O
temporally,O
associated,O
changes,O
in,O
COVID-19,O
management,O
and,O
differences,O
in,O
follow,O
-,O
up,O
time,O
),O
.,O
Oxygen,O
supplementation,O
requirements,O
on,O
admission,O
were,O
collected,O
",",O
verified,O
via,O
chart,O
review,O
",",O
and,O
used,O
to,O
categorize,O
COVID-19,O
severity,O
using,O
published,O
criteria,O
[,O
6,O
],O
.,O
Each,O
of,O
these,O
biomarkers,O
was,O
also,O
ascertained,O
",",O
when,O
available,O
",",O
after,O
the,O
diagnosis,O
of,O
COVID-19,O
.,O
We,O
also,O
stratified,O
baseline,O
laboratory,O
measures,O
by,O
COVID-19,O
severity,O
for,O
PLWH,O
",",O
testing,O
for,O
differences,O
in,O
measures,O
by,O
severity,O
category,O
using,O
ordinal,O
logistic,O
regression,O
.,O
To,O
compare,O
cumulative,O
incidence,O
of,O
death,O
by,O
HIV,O
status,O
accounting,O
for,O
potential,O
confounding,O
factors,O
",",O
we,O
fit,O
a,O
multivariable,O
survival,O
model,O
using,O
Fine,O
-,O
Grey,O
competing,O
risk,O
methods,O
",",O
including,O
demographics,O
",",O
COVID-19,O
severity,O
",",O
comorbid,O
conditions,O
",",O
and,O
laboratory,O
values,O
that,O
differed,O
by,O
HIV,O
status,O
[,O
8,O
],O
.,O
Of,O
the,O
4402,O
patients,O
hospitalized,O
for,O
COVID-19,O
during,O
the,O
study,O
period,O
",",O
88,O
(,O
2,O
%,O
),O
were,O
PLWH,O
.,O
The,O
median,O
age,O
of,O
PLWH,O
hospitalized,O
with,O
COVID-19,O
was,O
61,O
years,O
(,O
Table,O
1,O
;,O
interquartile,O
range,O
[,O
IQR,O
],O
",",O
54–67,O
),O
",",O
and,O
most,O
PLWH,O
were,O
black,O
(,O
40,O
%,O
),O
or,O
Hispanic,O
/,O
Latino,O
(,O
30,O
%,O
),O
.,O
PLWH,O
and,O
uninfected,O
persons,O
had,O
similar,O
COVID-19,O
severity,O
on,O
admission,O
as,O
measured,O
by,O
oxygen,O
supplementation,O
requirements,O
(,O
P,O
=,O
.15,O
),O
.,O
Higher,O
CRP,O
values,O
were,O
present,O
in,O
PLWH,O
with,O
more,O
severe,O
COVID-19,O
on,O
admission,O
(,O
Supplementary,O
Table,O
2,O
;,O
P,O
=,O
.005,O
),O
.,O
Concern,O
that,O
COVID-19,O
might,O
be,O
more,O
severe,O
in,O
persons,O
with,O
immunodeficiency,O
or,O
immune,O
dysregulation,O
has,O
been,O
raised,O
since,O
the,O
emergence,O
of,O
the,O
earliest,O
cases,O
[,O
10,O
],O
.,O
However,O
",",O
outcomes,O
analyses,O
for,O
PLWH,O
during,O
the,O
COVID-19,O
pandemic,O
have,O
been,O
limited,O
",",O
consisting,O
of,O
small,O
case,O
reports,O
or,O
series,O
[,O
12,O
],O
.,O
A,O
single,O
center,O
in,O
Spain,O
reported,O
outcomes,O
for,O
5,O
males,O
living,O
with,O
HIV,O
hospitalized,O
with,O
COVID-19,O
.,O
Larger,O
uncontrolled,O
series,O
from,O
New,O
Jersey,O
(,O
13,O
hospitalized,O
patients,O
),O
",",O
New,O
York,O
City,O
(,O
31,O
hospitalized,O
patients,O
),O
",",O
and,O
Madrid,O
",",O
Spain,O
(,O
28,O
hospitalized,O
patients,O
),O
also,O
subsequently,O
demonstrated,O
COVID-19,O
outcomes,O
for,O
PLWH,O
similar,O
to,O
those,O
described,O
for,O
the,O
general,O
population,O
[,O
14–16,O
],O
.,O
This,O
is,O
broadly,O
consistent,O
with,O
our,O
finding,O
that,O
respiratory,O
failure,O
that,O
requires,O
mechanical,O
ventilation,O
and,O
death,O
were,O
not,O
more,O
frequent,O
in,O
PLWH,O
when,O
compared,O
with,O
demographically,O
similar,O
persons,O
with,O
COVID-19,O
.,O
The,O
lack,O
of,O
outcome,O
differences,O
is,O
even,O
more,O
striking,O
when,O
it,O
is,O
noted,O
that,O
COPD,O
",",O
cancer,O
",",O
and,O
smoking,O
",",O
which,O
were,O
identified,O
as,O
risk,O
factors,O
linked,O
to,O
worse,O
COVID-19,O
outcomes,O
in,O
several,O
previous,O
studies,O
",",O
were,O
far,O
more,O
prevalent,O
in,O
PLWH,O
in,O
our,O
cohort,O
than,O
in,O
comparator,O
patients,O
[,O
17,O
",",O
18,O
],O
.,O
Several,O
factors,O
have,O
supported,O
theoretical,O
risks,O
of,O
worse,O
COVID-19,O
in,O
PLWH,O
",",O
including,O
incomplete,O
immune,O
reconstitution,O
and,O
evidence,O
of,O
persistent,O
immune,O
activation,O
in,O
many,O
patients,O
prior,O
to,O
the,O
pandemic,O
[,O
19,O
",",O
20,O
],O
.,O
Furthermore,O
",",O
increased,O
IL-6,O
and,O
D,O
-,O
dimer,O
measures,O
have,O
been,O
independently,O
associated,O
with,O
chronic,O
HIV,O
infection,O
[,O
21,O
",",O
22,O
],O
and,O
have,O
also,O
been,O
closely,O
linked,O
with,O
COVID-19,O
severity,O
in,O
data,O
mostly,O
from,O
persons,O
not,O
living,O
with,O
HIV,O
[,O
23,O
",",O
24,O
],O
.,O
Neither,O
biomarker,O
differed,O
on,O
presentation,O
for,O
patients,O
by,O
HIV,O
status,O
nor,O
was,O
either,O
associated,O
with,O
COVID-19,O
severity,O
at,O
presentation,O
for,O
PLWH,O
.,O
Among,O
PLWH,O
",",O
CD4,O
decline,O
was,O
noted,O
in,O
the,O
majority,O
of,O
patients,O
with,O
available,O
data,O
",",O
consistent,O
with,O
existing,O
immunologic,O
data,O
on,O
COVID-19,O
natural,O
history,O
",",O
but,O
the,O
decrease,O
in,O
CD4,O
percentage,O
was,O
not,O
large,O
[,O
25,O
],O
.,O
We,O
did,O
not,O
find,O
evidence,O
of,O
associations,O
between,O
immunologic,O
measures,O
(,O
either,O
decreases,O
from,O
pre,O
–,O
COVID-19,O
values,O
or,O
low,O
values,O
at,O
the,O
time,O
of,O
presentation,O
),O
and,O
adverse,O
COVID-19,O
outcomes,O
for,O
PLWH,O
.,O
Antiretroviral,O
medications,O
have,O
been,O
evaluated,O
for,O
treatment,O
of,O
COVID-19,O
[,O
26,O
],O
.,O
There,O
are,O
limited,O
data,O
regarding,O
the,O
clinical,O
impact,O
of,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
on,O
people,O
living,O
with,O
human,O
immunodeficiency,O
virus,O
(,O
PLWH,O
),O
.,O
In,O
this,O
study,O
",",O
we,O
compared,O
outcomes,O
for,O
PLWH,O
with,O
COVID-19,O
to,O
a,O
matched,O
comparison,O
group,O
.,O
We,O
identified,O
88,O
PLWH,O
hospitalized,O
with,O
laboratory,O
-,O
confirmed,O
COVID-19,O
in,O
our,O
hospital,O
system,O
in,O
New,O
York,O
City,O
between,O
12,O
March,O
and,O
23,O
April,O
2020,O
.,O
PLWH,O
hospitalized,O
with,O
COVID-19,O
had,O
high,O
proportions,O
of,O
HIV,O
virologic,O
control,O
on,O
antiretroviral,O
therapy,O
.,O
There,O
was,O
no,O
difference,O
in,O
COVID-19,O
severity,O
on,O
admission,O
by,O
HIV,O
status,O
(,O
P,O
=,O
.15,O
),O
.,O
We,O
found,O
no,O
differences,O
in,O
adverse,O
outcomes,O
associated,O
with,O
HIV,O
infection,O
for,O
hospitalized,O
COVID-19,O
patients,O
compared,O
with,O
a,O
demographically,O
similar,O
patient,O
group,O
.,O
There,O
are,O
limited,O
data,O
on,O
coronavirus,O
disease,O
2019,O
(,O
COVID-19,O
),O
clinical,O
outcomes,O
for,O
people,O
living,O
with,O
human,O
immunodeficiency,O
virus,O
(,O
PLWH,O
),O
.,O
We,O
report,O
outcomes,O
for,O
a,O
cohort,O
of,O
hospitalized,O
PLWH,O
with,O
COVID-19,O
compared,O
with,O
demographically,O
matched,O
comparators,O
.,O
Fifty,O
-,O
five,O
sera,O
from,O
convalescent,O
COVID-19,O
patients,O
and,O
18,O
control,O
sera,O
(,O
Supplementary,O
Table,O
 ,O
2,O
),O
were,O
screened,O
on,O
the,O
peptide,O
microarray,O
for,O
both,O
IgG,O
and,O
IgM,O
responses,O
(,O
Fig,O
.,O
 ,O
1a,O
and,O
Supplementary,O
Fig,O
.,O
For,O
IgG,O
",",O
COVID-19,O
patients,O
were,O
completely,O
separated,O
from,O
controls,O
",",O
and,O
distinct,O
and,O
specific,O
signals,O
were,O
shown,O
for,O
some,O
peptides,O
.,O
IgG,O
antibodies,O
against,O
this,O
epitope,O
can,O
be,O
detected,O
in,O
~90,O
%,O
of,O
COVID-19,O
patients,O
",",O
indicating,O
that,O
it,O
is,O
an,O
extremely,O
dominant,O
epitope,O
.,O
The,O
peptide,O
microarray,O
data,O
are,O
deposited,O
in,O
the,O
Protein,B-Repository
Microarray,I-Repository
Database,E-Repository
 ,O
(,O
http://www.proteinmicroarray.cn,S-URL
),O
under,O
the,O
accession,O
number,O
PMDE242,S-AccessionNumber
.,O
Analysis,O
of,O
binding,O
to,O
dimeric,O
human,O
ACE2,O
",",O
incorporating,O
avidity,O
effects,O
",",O
was,O
also,O
analyzed,O
for,O
the,O
RBDs,O
that,O
did,O
not,O
bind,O
monomeric,O
ACE2,O
(,O
D,O
-,O
F,O
",",O
right,O
),O
.,O
To,O
assess,O
the,O
phenotypic,O
impacts,O
of,O
mutations,O
that,O
have,O
appeared,O
in,O
the,O
SARS,O
-,O
CoV-2,O
RBD,O
to,O
date,O
",",O
we,O
downloaded,O
all,O
 ,O
"31,570",O
spike,O
sequences,O
available,O
from,O
GISAID,S-Dataset
 ,O
(,O
Elbe,B-Creator
and,I-Creator
"Buckland-Merrett,",I-Creator
2017,E-Creator
),O
on,O
May,O
27,O
",",O
2020,O
and,O
identified,O
RBD,O
amino,O
acid,O
mutations,O
present,O
in,O
high,O
-,O
quality,O
clinical,O
isolates,O
.,O
For,O
each,O
threshold,O
of,O
GISAID,S-Dataset
 ,O
observation,O
counts,O
",",O
1,O
million,O
random,O
sub,O
-,O
samples,O
of,O
single,O
-,O
nucleotide,O
-,O
accessible,O
amino,O
acid,O
changes,O
were,O
generated,O
at,O
the,O
same,O
sample,O
size,O
as,O
the,O
true,O
mutation,O
set,O
(,O
n,O
 ,O
=,O
 ,O
98,O
",",O
42,O
",",O
and,O
13,O
for,O
the,O
≥,O
1,O
",",O
≥,O
2,O
",",O
and,O
≥,O
6,O
thresholds,O
),O
.,O
A,O
P,O
-,O
value,O
was,O
determined,O
as,O
the,O
fraction,O
of,O
sub,O
-,O
samples,O
with,O
median,O
mutational,O
effect,O
on,O
binding,O
or,O
expression,O
equal,O
to,O
or,O
greater,O
than,O
that,O
of,O
the,O
actual,O
GISAID,S-Dataset
 ,O
mutation,O
set,O
(,O
dashed,O
vertical,O
line,O
),O
.,O
The,O
observation,O
that,O
the,O
set,O
of,O
mutations,O
observed,O
in,O
GISAID,S-Dataset
 ,O
have,O
a,O
more,O
favorable,O
median,O
mutational,O
effect,O
on,O
binding,O
and,O
expression,O
than,O
randomly,O
sampled,O
mutations,O
indicates,O
the,O
action,O
of,O
purifying,O
selection,O
for,O
ACE2,O
binding,O
and,O
RBD,O
stability,O
.,O
Random,O
sub,O
-,O
samples,O
were,O
generated,O
as,O
in,O
(,O
B,O
),O
",",O
and,O
the,O
maximum,O
affinity,O
-,O
enhancing,O
effect,O
of,O
mutations,O
in,O
each,O
sub,O
-,O
sample,O
was,O
compared,O
to,O
that,O
in,O
the,O
actual,O
GISAID,S-Dataset
 ,O
mutation,O
set,O
.,O
A,O
P,O
-,O
value,O
was,O
determined,O
as,O
the,O
fraction,O
of,O
sub,O
-,O
samples,O
with,O
a,O
maximum,O
effect,O
on,O
binding,O
equal,O
to,O
or,O
greater,O
than,O
in,O
the,O
actual,O
GISAID,S-Dataset
 ,O
mutation,O
set,O
(,O
vertical,O
dashed,O
line,O
),O
.,O
We,O
do,O
not,O
see,O
evidence,O
for,O
selection,O
for,O
enhanced,O
ACE2,O
binding,O
",",O
as,O
randomly,O
sampled,O
mutations,O
generally,O
contain,O
mutations,O
with,O
stronger,O
affinity,O
-,O
enhancing,O
effects,O
than,O
observed,O
in,O
the,O
GISAID,S-Dataset
 ,O
mutation,O
set,O
.,O
Last,O
",",O
we,O
validated,O
our,O
deep,O
mutational,O
scanning,O
for,O
mutations,O
that,O
are,O
especially,O
prevalent,O
among,O
naturally,O
occurring,O
sequences,O
in,O
GISAID,S-Dataset
.,O
The,O
Spike,O
receptor,O
binding,O
domain,O
(,O
RBD,O
),O
from,O
SARS,O
-,O
CoV-2,O
(,O
isolate,O
Wuhan,O
-,O
Hu-1,O
",",O
GenBank,S-Repository
 ,O
:,O
MN908947,S-AccessionNumber
",",O
residues,O
N331,O
-,O
T531,O
),O
and,O
additional,O
sarbecovirus,O
homologs,O
(,O
RaTG13,O
",",O
GenBank,S-Repository
:,O
MN996532,S-AccessionNumber
;,O
GD,O
-,O
Pangolin,O
consensus,O
from,O
Lam,O
et,O
 ,O
al,O
.,O
(,O
2020,O
),O
;,O
SARS,O
-,O
CoV-1,O
 ,O
Urbani,O
",",O
GenBank,S-Repository
:,O
AY278741,S-AccessionNumber
;,O
WIV1,O
",",O
GenBank,S-Repository
:,O
KF367457,S-AccessionNumber
 ,O
(,O
identical,O
RBD,O
sequence,O
to,O
WIV16,O
),O
;,O
LYRa11,O
",",O
GenBank,S-Repository
:,O
KF569996,S-AccessionNumber
;,O
Rp3,O
",",O
GenBank,S-Repository
:,O
DQ071615,S-AccessionNumber
;,O
HKU3,O
-,O
1,O
",",O
GenBank,S-Repository
:,O
DQ022305,S-AccessionNumber
;,O
Rf1,O
",",O
GenBank,S-Repository
:,O
DQ412042,S-AccessionNumber
;,O
ZXC21,O
",",O
GenBank,S-Repository
:,O
MG772934,S-AccessionNumber
;,O
ZC45,O
",",O
GenBank,S-Repository
:,O
MG772933,S-AccessionNumber
;,O
and,O
BM48,O
-,O
31,O
",",O
GenBank,S-Repository
:,O
NC014470,S-AccessionNumber
),O
were,O
ordered,O
as,O
yeast,O
codon,O
-,O
optimized,O
gBlocks,O
(,O
IDT,O
),O
and,O
cloned,O
into,O
the,O
pETcon,O
yeast,O
surface,O
-,O
display,O
expression,O
vector,O
.,O
All,O
"31,570",O
spike,O
sequences,O
on,O
GISAID,S-Dataset
 ,O
as,O
of,O
27,O
May,O
2020,O
were,O
downloaded,O
and,O
aligned,O
via,O
mafft,O
(,O
Katoh,O
and,O
Standley,O
",",O
2013,O
),O
.,O
All,O
amino,O
-,O
acid,O
mutations,O
among,O
GISAID,S-Dataset
 ,O
sequences,O
were,O
enumerated,O
.,O
We,O
excluded,O
any,O
mutation,O
from,O
our,O
curated,O
set,O
of,O
GISAID,S-Dataset
 ,O
mutations,O
if,O
it,O
was,O
solely,O
observed,O
on,O
sequence,O
backgrounds,O
containing,O
at,O
least,O
one,O
undetermined,O
X,O
character,O
in,O
the,O
RBD,O
sequence,O
;,O
however,O
",",O
sequences,O
with,O
X,O
characters,O
were,O
allowed,O
to,O
contribute,O
to,O
observations,O
of,O
mutation,O
count,O
for,O
mutations,O
that,O
were,O
observed,O
on,O
at,O
least,O
one,O
other,O
high,O
-,O
coverage,O
RBD,O
sequence,O
.,O
To,O
characterize,O
patterns,O
of,O
selection,O
on,O
amino,O
-,O
acid,O
mutations,O
observed,O
among,O
GISAID,S-Dataset
 ,O
sequences,O
",",O
we,O
conducted,O
permutation,O
tests,O
as,O
described,O
in,O
the,O
Figure,O
 ,O
S7,O
legend,O
.,O
We,O
acknowledge,O
all,O
GISAID,S-Dataset
 ,O
contributors,O
for,O
their,O
sharing,O
of,O
sequencing,O
data,O
(,O
https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS/blob/master/data/alignments/Spike_GISAID/gisaid_hcov-19_acknowledgement_table.xls,O
),O
.,O
The,O
full,O
sequence,O
of,O
this,O
plasmid,O
is,O
available,O
at,O
https://github.com/jbloomlab/SARS-CoV-2-RBD_DMS/blob/master/data/plasmid_maps/2736_HDM_IDTSpike_EcoKozak.gb,S-URL
.,O
We,O
present,O
an,O
interactive,O
visualization,O
and,O
open,O
analysis,O
pipeline,O
to,O
facilitate,O
use,O
of,O
our,O
dataset,O
for,O
vaccine,O
design,O
and,O
functional,O
annotation,O
of,O
mutations,O
observed,O
during,O
viral,O
surveillance,O
.,O
The,O
work,O
identifies,O
structurally,O
constrained,O
regions,O
of,O
the,O
spike,O
RBD,O
that,O
would,O
be,O
ideal,O
targets,O
for,O
COVID-19,O
countermeasures,O
and,O
demonstrates,O
that,O
mutations,O
in,O
the,O
virus,O
that,O
enhance,O
ACE2,O
affinity,O
can,O
be,O
engineered,O
but,O
have,O
not,O
",",O
to,O
date,O
",",O
been,O
naturally,O
selected,O
during,O
the,O
pandemic,O
.,O
COVID-19,O
(,O
coronavirus,O
disease,O
2019,O
),O
has,O
become,O
a,O
global,O
pandemic,O
",",O
fueled,O
by,O
the,O
rapid,O
spread,O
of,O
the,O
coronavirus,O
SARS,O
-,O
CoV-2,O
(,O
severe,O
acute,O
respiratory,O
syndrome,O
coronavirus,O
2,O
),O
",",O
a,O
positive,O
-,O
strand,O
RNA,O
virus,O
(,O
Wu,O
et,O
 ,O
al,O
.,O
",",O
2020a,O
;,O
Sanche,O
et,O
 ,O
al,O
.,O
",",O
2020,O
),O
.,O
While,O
large,O
-,O
scale,O
comparisons,O
are,O
not,O
currently,O
feasible,O
due,O
to,O
lack,O
of,O
datasets,O
measuring,O
viral,O
transcript,O
localization,O
",",O
this,O
example,O
provides,O
some,O
reassurance,O
that,O
RNA,O
-,O
GPS,O
’,O
predicted,O
viral,O
residencies,O
are,O
reasonable,O
.,O
(,O
B,O
),O
To,O
evaluate,O
the,O
effect,O
of,O
the,O
potentially,O
noisy,O
mitochondrial,O
examples,O
in,O
our,O
APEX,O
-,O
seq,O
training,O
set,O
on,O
predicted,O
SARS,O
-,O
CoV-2,O
residencies,O
",",O
we,O
trained,O
a,O
“,O
denoised,O
”,O
variant,O
of,O
RNA,O
-,O
GPS,O
on,O
a,O
subsetted,O
dataset,O
that,O
excludes,O
these,O
examples,O
.,O
For,O
additional,O
analysis,O
of,O
the,O
mitochondrial,O
dataset,O
and,O
predictions,O
",",O
see,O
Figure,O
 ,O
S1,O
.,O
To,O
ensure,O
that,O
our,O
results,O
have,O
not,O
been,O
driven,O
by,O
potentially,O
noisy,O
data,O
in,O
this,O
regime,O
",",O
we,O
excluded,O
nuclear,O
-,O
encoded,O
",",O
“,O
noncanonical,O
”,O
mitochondrial,O
matrix,O
transcripts,O
with,O
relatively,O
low,O
APEX,O
-,O
seq,O
enrichment,O
signal,O
(,O
lowest,O
20,O
%,O
of,O
log,O
-,O
fold,O
-,O
change,O
enrichment,O
scores,O
),O
and,O
retrained,O
RNA,O
-,O
GPS,O
on,O
this,O
adjusted,O
dataset,O
.,O
This,O
“,O
denoised,O
”,O
model,O
recapitulates,O
the,O
same,O
SARS,O
-,O
CoV-2,O
residency,O
toward,O
the,O
mitochondrial,O
matrix,O
and,O
nucleolus,O
(,O
Figure,O
 ,O
2B,O
),O
",",O
suggesting,O
that,O
our,O
predictions,O
are,O
robust,O
to,O
potential,O
noise,O
in,O
the,O
training,O
data,O
.,O
We,O
used,O
“,O
RNA,O
subcellular,O
residency,O
”,O
rather,O
than,O
“,O
RNA,O
localization,O
”,O
to,O
describe,O
RNA,O
-,O
GPS,O
prediction,O
results,O
",",O
as,O
this,O
is,O
more,O
reflective,O
of,O
the,O
underlying,O
APEX,O
-,O
seq,O
training,O
data,O
and,O
its,O
inherent,O
differences,O
compared,O
with,O
viral,O
transcripts,O
.,O
SARS,O
-,O
CoV-2,O
viral,O
genomes,O
were,O
programmatically,O
queried,O
from,O
the,O
NCBI,S-Repository
 ,O
GenBank,S-Repository
 ,O
online,O
database,O
using,O
the,O
BioPython,O
library,O
’s,O
Entrez,O
module,O
(,O
Cock,O
et,O
 ,O
al,O
.,O
",",O
2009,O
),O
.,O
The,O
model,O
was,O
implemented,O
in,O
PyTorch,O
and,O
was,O
trained,O
to,O
minimize,O
a,O
binary,O
cross,O
-,O
entropy,O
loss,O
using,O
the,O
Adam,O
optimizer,O
(,O
Kingma,O
and,O
Ba,O
",",O
2014,O
),O
with,O
a,O
batch,O
size,O
of,O
1,O
",",O
with,O
early,O
stopping,O
based,O
on,O
validation,O
set,O
area,O
under,O
the,O
receiver,O
operating,O
characteristic,O
(,O
AUROC,O
),O
.,O
Localization,O
within,O
this,O
dataset,O
is,O
expressed,O
as,O
an,O
enrichment,O
score,O
compared,O
to,O
the,O
rest,O
of,O
the,O
cell,O
.,O
As,O
is,O
conventional,O
",",O
the,O
validation,O
set,O
was,O
used,O
for,O
hyperparameter,O
tuning,O
and,O
model,O
architecture,O
tuning,O
.,O
We,O
use,O
a,O
database,O
of,O
102,O
RNA,O
binding,O
protein,O
binding,O
motifs,O
(,O
Ray,O
et,O
 ,O
al,O
.,O
",",O
2013,O
),O
.,O
Genes,O
were,O
compared,O
in,O
an,O
overrepresentation,O
test,O
against,O
a,O
reference,O
list,O
of,O
all,O
genes,O
in,O
the,O
Homo,O
sapiens,O
database,O
using,O
Fisher,O
’s,O
Exact,O
test,O
",",O
with,O
false,O
discovery,O
rate,O
correction,O
.,O
It,O
is,O
worth,O
mentioning,O
that,O
each,O
Baltimore,O
’s,O
group,O
is,O
represented,O
in,O
the,O
human,O
",",O
non,O
-,O
human,O
primate,O
",",O
avian,O
and,O
fish,O
viral,O
sequence,O
data,O
sets,O
",",O
albeit,O
in,O
different,O
proportions,O
(,O
Fig,O
3A,O
),O
.,O
This,O
depletion,O
is,O
shared,O
in,O
all,O
viral,O
datasets,O
while,O
the,O
NTC,O
depletion,O
is,O
specific,O
to,O
a,O
subpopulation,O
of,O
human,O
and,O
non,O
-,O
human,O
primate,O
viral,O
sequences,O
.,O
The,O
APOBEC,O
family,O
of,O
genes,O
also,O
counts,O
the,O
AID,O
(,O
or,O
AICDA,O
),O
",",O
APOBEC1,O
",",O
APOBEC2,O
and,O
APOBEC4,O
genes,O
.,O
AID,O
is,O
critical,O
for,O
somatic,O
hypermutation,O
and,O
class,O
switch,O
recombination,O
by,O
editing,O
the,O
immunoglobulin,O
loci,O
in,O
B,O
cells,O
[,O
39,O
],O
.,O
Importantly,O
",",O
APOBEC1,O
and,O
AID,O
appear,O
also,O
to,O
participate,O
to,O
the,O
restriction,O
of,O
viruses,O
and,O
retroelements,O
[,O
"1,42",O
],O
.,O
Evidence,O
for,O
AID,O
and,O
APOBEC1,O
evolutionary,O
footprints,O
were,O
investigated,O
by,O
looking,O
for,O
the,O
depletion,O
of,O
their,O
favored,O
motifs,O
",",O
respectively,O
WRC,O
for,O
AID,O
[,O
43,O
],O
and,O
WCW,O
for,O
APOBEC1,O
[,O
44,O
],O
.,O
The,O
distributions,O
of,O
the,O
WRC,O
and,O
NNGYWN,O
ratios,O
do,O
not,O
point,O
towards,O
viruses,O
significantly,O
footprinted,O
by,O
AID,O
at,O
the,O
whole,O
genome,O
level,O
(,O
S10B,O
Fig,O
),O
.,O
Nevertheless,O
",",O
putatively,O
AID,O
-,O
footprinted,O
genes,O
were,O
identified,O
in,O
several,O
double,O
strand,O
DNA,O
viruses,O
",",O
notably,O
the,O
B,O
-,O
cell,O
-,O
infecting,O
virus,O
EBV,O
(,O
S10C,O
Fig,O
),O
.,O
Finally,O
",",O
we,O
identified,O
several,O
AID,O
-,O
footprinted,O
genes,O
in,O
the,O
EBV,O
genome,O
which,O
supports,O
recent,O
observations,O
made,O
by,O
Martinez,O
et,O
al,O
.,O
[,O
33,O
],O
.,O
Those,O
genes,O
are,O
not,O
spatially,O
clustered,O
and,O
further,O
investigation,O
would,O
be,O
necessary,O
to,O
link,O
the,O
detected,O
footprint,O
to,O
AID,O
activity,O
.,O
We,O
downloaded,O
complete,O
viral,O
genomes,O
from,O
the,O
“,O
NCBI,B-Repository
Virus,E-Repository
”,O
database,O
(,O
https://www.ncbi.nlm.nih.gov/labs/virus/vssi/#/,S-URL
),O
as,O
released,O
in,O
April,O
2020,O
.,O
We,O
retrieved,O
non,O
-,O
human,O
primate,O
viruses,O
by,O
selecting,O
“,O
Primate,O
”,O
for,O
the,O
criterion,O
“,O
Host,O
”,O
and,O
by,O
deducting,O
the,O
human,O
viruses,O
from,O
this,O
data,O
set,O
.,O
The,O
dataset,O
of,O
Human,O
viruses,O
was,O
supplemented,O
by,O
manually,O
curated,O
human,O
virus,O
complete,O
genome,O
sequences,O
from,O
the,O
“,O
NCBI,B-Repository
nucleotide,E-Repository
”,O
database,O
.,O
GenBank,S-Repository
 ,O
accession,O
ID,O
’s,O
are,O
treated,O
as,O
unique,O
and,O
listed,O
in,O
the,O
S1,O
",",O
S2,O
and,O
S3,O
Tables,O
.,O
Coronavirus,O
Disease,O
2019,O
(,O
COVID-19,O
),O
was,O
first,O
described,O
in,O
2019,O
in,O
Wuhan,O
city,O
of,O
Hubei,O
state,O
",",O
China,O
",",O
as,O
a,O
pneumonia,O
caused,O
by,O
a,O
previously,O
unknown,O
pathogen,O
.,O
The,O
International,O
Coronavirus,O
Study,O
Group,O
named,O
the,O
responsible,O
virus,O
initially,O
as,O
2019,O
-,O
nCoV,O
and,O
later,O
as,O
SARS,O
-,O
CoV-2,O
.,O
World,O
Health,O
Organization,O
(,O
WHO,O
),O
",",O
named,O
the,O
disease,O
caused,O
by,O
SARS,O
-,O
CoV-2,O
as,O
COVID-19,O
[,O
1,O
],O
",",O
[,O
2,O
],O
.,O
There,O
is,O
no,O
specific,O
antiviral,O
drug,O
for,O
treatment,O
of,O
COVID-19,O
.,O
On,O
the,O
other,O
hand,O
",",O
severe,O
COVID-19,O
patients,O
have,O
elevated,O
levels,O
of,O
pro,O
-,O
inflammatory,O
cytokines,O
IL-6,O
",",O
IL-1β,O
",",O
IL-2,O
",",O
IL-8,O
",",O
IL-17,O
",",O
G,O
-,O
CSF,O
",",O
GM,O
-,O
CSF,O
",",O
M,O
-,O
CSF,O
",",O
IP10,O
",",O
MCP1,O
",",O
MIP1α,O
(,O
CCL3,O
),O
and,O
TNF,O
-,O
α,O
in,O
their,O
sera,O
[,O
19,O
],O
",",O
[,O
20,O
],O
",",O
this,O
burst,O
of,O
cytokines,O
is,O
defined,O
as,O
cytokine,O
release,O
syndrome,O
(,O
CRS,O
),O
and,O
is,O
also,O
common,O
during,O
CAR,O
T,O
cell,O
therapies,O
",",O
macrophage,O
activation,O
syndrome,O
(,O
MAS,O
),O
or,O
hemophagocytic,O
lymphohistiocytosis,O
(,O
HLH,O
),O
[,O
21,O
],O
",",O
[,O
22,O
],O
",",O
[,O
23,O
],O
",",O
COVID-19,O
pathology,O
mainly,O
consists,O
of,O
pulmonary,O
lesions,O
",",O
and,O
thus,O
",",O
presents,O
similar,O
characteristics,O
with,O
interferonopathies,O
which,O
root,O
from,O
intrinsic,O
hyperactive,O
IFN,O
response,O
.,O
Indeed,O
",",O
neutralizing,O
IL-6,O
(,O
via,O
tocilizumab,O
),O
showed,O
promise,O
in,O
severe,O
COVID-19,O
patients,O
[,O
24,O
],O
",",O
[,O
25,O
],O
",",O
IL-1β,O
or,O
TNF,O
-,O
α,O
blockers,O
are,O
considered,O
or,O
planned,O
for,O
clinical,O
trials,O
[,O
19,O
],O
",",O
[,O
22,O
],O
",",O
[,O
23,O
],O
",",O
Herein,O
",",O
we,O
discuss,O
the,O
potential,O
use,O
of,O
TLR7,O
agonists,O
in,O
the,O
early,O
stages,O
of,O
COVID-19,O
treatment,O
.,O
The,O
rHCoVs,O
-,O
OC43,O
50,O
%,O
tissue,O
culture,O
infectious,O
dose,O
(,O
TCID50,O
),O
was,O
determined,O
by,O
indirect,O
immunofluorescence,O
assay,O
(,O
IFA,O
),O
according,O
to,O
a,O
previously,O
described,O
method,O
(,O
Reed,O
",",O
1938,O
),O
.,O
Additionally,O
",",O
rOC43,O
-,O
ns2DelRluc,O
(,O
100,O
TCID50,O
),O
showed,O
pathogenicity,O
in,O
BALB,O
/,O
c,O
mice,O
",",O
which,O
exhibited,O
neurological,O
symptoms,O
identical,O
to,O
those,O
caused,O
by,O
the,O
parental,O
virus,O
after,O
intracerebral,O
inoculation,O
(,O
Shen,O
et,O
al,O
.,O
",",O
2016,O
),O
.,O
Therefore,O
",",O
these,O
two,O
mouse,O
strains,O
were,O
infected,O
with,O
104,O
TCID50,O
of,O
rOC43,O
-,O
ns2DelRluc,O
or,O
HCoV,O
-,O
OC43,O
-,O
WT,O
by,O
intranasal,O
inoculation,O
in,O
order,O
to,O
determine,O
its,O
infection,O
of,O
the,O
respiratory,O
tract,O
in,O
vivo,O
.,O
However,O
",",O
in,O
the,O
present,O
study,O
",",O
we,O
found,O
that,O
both,O
BALB,O
/,O
c,O
or,O
C57BL/6,O
suckling,O
mice,O
(,O
<,O
12,O
-,O
days,O
old,O
),O
infected,O
with,O
HCoV,O
-,O
OC43,O
at,O
a,O
dose,O
of,O
104,O
TCID50,O
showed,O
100,O
%,O
mortality,O
and,O
similar,O
sensitivity,O
.,O
To,O
confirm,O
these,O
observations,O
and,O
the,O
dissemination,O
of,O
the,O
recombinant,O
virus,O
",",O
the,O
viral,O
load,O
in,O
different,O
tissues,O
was,O
determined,O
using,O
an,O
IFA,O
in,O
BHK-21,O
 ,O
cells,O
or,O
real,O
-,O
time,O
qRT,O
-,O
PCR,O
at,O
6,O
dpi,O
via,O
intranasal,O
inoculation,O
of,O
104,O
TCID50,O
of,O
rOC43,O
-,O
ns2DelRluc,O
.,O
To,O
perform,O
BLI,O
of,O
rOC43,O
-,O
ns2DelRluc,O
in,O
vivo,O
",",O
BALB,O
/,O
c,O
and,O
C57BL/6,O
mice,O
were,O
intranasally,O
inoculated,O
with,O
104,O
TCID50,O
of,O
rOC43,O
-,O
ns2DelRluc,O
or,O
HCoV,O
-,O
OC43,O
-,O
WT,O
",",O
monitored,O
over,O
time,O
",",O
and,O
bioluminescence,O
intensity,O
was,O
determined,O
(,O
Fig,O
.,O
3,O
),O
.,O
Briefly,O
",",O
individual,O
BALB,O
/,O
c,O
mice,O
were,O
either,O
inoculated,O
intracerebrally,O
with,O
100,O
TCID50,O
or,O
intranasally,O
with,O
104,O
TCID50,O
of,O
rOC43,O
-,O
ns2DelRluc,O
and,O
monitored,O
over,O
time,O
.,O
Mice,O
were,O
intracerebrally,O
infected,O
with,O
100,O
TCID50,O
of,O
rOC43,O
-,O
ns2DelRluc,O
",",O
and,O
bioluminescence,O
intensity,O
was,O
measured,O
daily,O
(,O
Fig,O
.,O
5,O
),O
.,O
Both,O
the,O
WHO,O
and,O
European,O
Centre,O
for,O
Disease,O
Prevention,O
and,O
Control,O
(,O
ECDC,O
),O
have,O
recommended,O
the,O
evaluation,O
of,O
convalescent,O
plasma,O
for,O
the,O
prevention,O
and,O
treatment,O
of,O
the,O
COVID-19,O
disease,O
in,O
controlled,O
trials,O
(,O
WHO,O
/,O
HEO,O
/,O
R&D,O
Blueprint,O
(,O
nCoV)/2020.1,O
),O
[,O
11,O
],O
.,O
Indeed,O
",",O
several,O
trials,O
have,O
shown,O
that,O
convalescent,O
plasma,O
reduced,O
the,O
viral,O
load,O
and,O
was,O
safe,O
for,O
the,O
treatment,O
of,O
patients,O
with,O
COVID-19,O
[,O
"12,13",O
],O
.,O
We,O
have,O
recently,O
reviewed,O
and,O
summarized,O
the,O
information,O
on,O
dozens,O
of,O
safe,O
-,O
in,O
-,O
man,O
BSAAs,O
in,O
the,O
freely,O
accessible,O
database,O
(,O
https://drugvirus.info/,S-URL
),O
[,O
"17,18,19",O
],O
.,O
Additionally,O
",",O
clinical,O
investigations,O
have,O
started,O
recently,O
into,O
the,O
effectiveness,O
of,O
BSAAs,O
such,O
as,O
lopinavir,O
",",O
ritonavir,O
",",O
remdesivir,O
",",O
hydroxychloroquine,O
and,O
arbidol,O
against,O
COVID-19,O
(,O
NCT04252664,S-AccessionNumber
",",O
NCT0425487,S-AccessionNumber
",",O
NCT04255017,S-AccessionNumber
",",O
NCT04261517,S-AccessionNumber
 ,O
and,O
NCT04260594,S-AccessionNumber
),O
.,O
We,O
reviewed,O
the,O
current,O
landscape,O
of,O
the,O
available,O
diagnostic,O
tools,O
",",O
as,O
well,O
as,O
the,O
emerging,O
treatment,O
and,O
prophylactic,O
options,O
for,O
the,O
SARS,O
-,O
CoV-2,O
pandemic,O
and,O
have,O
summarized,O
the,O
information,O
in,O
a,O
database,O
that,O
can,O
be,O
freely,O
accessed,O
at,O
https://sars-coronavirus-2.info,O
.,O
The,O
information,O
in,O
the,O
database,O
was,O
obtained,O
from,O
PubMed,S-Repository
",",O
clinicaltrials.gov,S-Repository
",",O
DrugBank,S-Repository
",",O
DrugCentral,S-Repository
",",O
the,O
Chinese,B-Repository
Clinical,I-Repository
Trials,I-Repository
Register,I-Repository
(ChiCTR),E-Repository
 ,O
and,O
EU,B-Repository
Clinical,I-Repository
Trials,I-Repository
Register,E-Repository
 ,O
databases,O
[,O
"28,29,30",O
],O
",",O
as,O
well,O
as,O
other,O
public,O
sources,O
.,O
The,O
COVID-19,O
statistics,O
are,O
automatically,O
exported,O
from,O
the,O
COVID-19,B-Repository
Data,I-Repository
Repository,E-Repository
 ,O
by,O
the,O
Center,B-Creator
for,I-Creator
Systems,I-Creator
Science,I-Creator
and,I-Creator
Engineering,I-Creator
(CSSE),E-Creator
 ,O
at,O
Johns,O
Hopkins,O
University,O
(,O
https://github.com/CSSEGISandData/COVID-19,S-URL
),O
.,O
We,O
isolated,O
seven,O
SARS,O
-,O
CoV-2,O
strains,O
from,O
22,O
NPS,O
samples,O
of,O
COVID-19,O
patients,O
using,O
Vero,O
-,O
E6,O
cells,O
.,O
We,O
evaluated,O
the,O
neutralization,O
capacity,O
of,O
seven,O
serum,O
samples,O
obtained,O
from,O
patients,O
recovered,O
from,O
COVID-19,O
.,O
Five,O
samples,O
from,O
patients,O
recovered,O
from,O
COVID-19,O
had,O
serum,O
sensitivity,O
scores,O
(,O
SSS,O
),O
>,O
5,O
and,O
rescued,O
>,O
50,O
%,O
cells,O
from,O
virus,O
-,O
mediated,O
death,O
at,O
1,O
mg,O
/,O
mL,O
(,O
Figure,O
2a,O
",",O
b,O
),O
.,O
Altogether,O
",",O
these,O
results,O
suggest,O
that,O
patients,O
diagnosed,O
with,O
COVID-19,O
produce,O
different,O
immune,O
responses,O
to,O
the,O
SARS,O
-,O
CoV-2,O
infection,O
and,O
that,O
the,O
neutralization,O
capacity,O
of,O
convalescent,O
sera,O
declines,O
with,O
time,O
.,O
Through,O
the,O
literature,O
review,O
",",O
we,O
made,O
a,O
database,O
to,O
summarize,O
safe,O
-,O
in,O
-,O
man,O
BSAAs,O
(,O
https://drugvirus.info/,S-URL
),O
.,O
Our,O
results,O
suggest,O
that,O
COVID-19,O
patients,O
respond,O
differently,O
to,O
the,O
SARS,O
-,O
CoV-2,O
infection,O
.,O
Thus,O
",",O
the,O
neutralization,O
test,O
allowed,O
us,O
to,O
identify,O
the,O
most,O
potent,O
sera,O
from,O
patients,O
recovered,O
from,O
COVID-19,O
for,O
the,O
treatment,O
of,O
SARS,O
-,O
CoV-2,O
-,O
infected,O
patients,O
.,O
However,O
",",O
the,O
recent,O
safety,O
study,O
on,O
5000,O
hospitalized,O
patients,O
transfused,O
under,O
the,O
U.S.,O
Food,O
and,O
Drug,O
Administration,O
’s,O
national,O
Expand,O
Access,O
Program,O
for,O
COVID-19,O
revealed,O
no,O
toxicity,O
(,O
https://doi.org/10.1101/2020.05.12.20099879,O
),O
.,O
Therefore,O
",",O
drug,O
repositioning,O
for,O
COVID-19,O
provides,O
unique,O
translational,O
opportunities,O
",",O
including,O
a,O
substantially,O
higher,O
probability,O
of,O
success,O
to,O
the,O
market,O
as,O
compared,O
with,O
developing,O
new,O
virus,O
-,O
specific,O
drugs,O
and,O
vaccines,O
",",O
as,O
well,O
as,O
significantly,O
reduced,O
costs,O
and,O
timelines,O
to,O
clinical,O
availability,O
[,O
"26,46,47",O
],O
.,O
Finally,O
",",O
we,O
developed,O
a,O
website,O
to,O
disseminate,O
the,O
knowledge,O
on,O
available,O
and,O
emerging,O
treatments,O
of,O
COVID-19,O
.,O
It,O
was,O
called,O
SARS,O
-,O
CoV-2,O
(,O
causing,O
the,O
coronavirus,O
disease,O
2019,O
",",O
COVID-19,O
),O
and,O
rapidly,O
spread,O
from,O
animals,O
(,O
pangolins,O
or,O
bats,O
as,O
possible,O
sources,O
),O
to,O
humans,O
.,O
While,O
the,O
diagnosis,O
of,O
COVID-19,O
is,O
based,O
on,O
the,O
amplification,O
of,O
the,O
viral,O
genome,O
in,O
real,O
-,O
time,O
PCR,O
with,O
specific,O
probes,O
",",O
the,O
current,O
treatment,O
of,O
affected,O
individuals,O
is,O
limited,O
to,O
a,O
mixture,O
of,O
a,O
broad,O
-,O
spectrum,O
of,O
antiviral,O
drugs,O
[,O
6,O
],O
.,O
The,O
interaction,O
between,O
the,O
drug,O
and,O
protein,O
was,O
obtained,O
using,O
the,O
Matador,S-Repository
 ,O
and,O
DGIdb,S-Repository
 ,O
database,O
[,O
"29,30",O
],O
.,O
Eighty,O
-,O
three,O
percent,O
of,O
the,O
genes,O
(,O
435/526,O
),O
that,O
correlated,O
with,O
ACE2,O
in,O
TCGA,S-Repository
 ,O
were,O
also,O
correlated,O
in,O
at,O
least,O
one,O
of,O
the,O
other,O
three,O
independent,O
datasets,O
(,O
GSE994,S-AccessionNumber
",",O
GSE17913,S-AccessionNumber
 ,O
and,O
GTEx,S-Dataset
",",O
p,O
-,O
value,O
<,O
0.05,O
),O
(,O
Figure,O
3,O
),O
.,O
Among,O
the,O
top,O
10,O
most,O
significant,O
genes,O
correlated,O
to,O
ACE2,O
in,O
TCGA-LUAD,S-Dataset
 ,O
dataset,O
(,O
Table,O
1,O
),O
",",O
two,O
genes,O
(,O
CRIP2,O
and,O
ACACA,O
),O
were,O
also,O
found,O
in,O
GSE994,S-AccessionNumber
",",O
ACSL5,O
was,O
found,O
in,O
GSE17913,S-AccessionNumber
 ,O
and,O
LRRK2,O
",",O
HSD17B4,O
",",O
EPHX1,O
",",O
MCCC2,O
",",O
GSTA4,O
",",O
HGD,O
",",O
and,O
ROS1,O
were,O
found,O
in,O
GTEx,S-Dataset
 ,O
dataset,O
.,O
Starting,O
from,O
7338,O
drugs,O
originated,O
by,O
the,O
Matador,O
and,O
DGIdb,O
database,O
",",O
we,O
evaluated,O
if,O
drug,O
target,O
genes,O
were,O
overrepresented,O
in,O
the,O
network,O
.,O
Although,O
several,O
recent,O
papers,O
have,O
come,O
out,O
on,O
the,O
possible,O
drug,O
treatment,O
options,O
for,O
COVID-19,O
and,O
several,O
clinical,O
trials,O
are,O
proposing,O
different,O
compounds,O
for,O
the,O
treatment,O
",",O
we,O
have,O
n’t,O
found,O
any,O
drugs,O
among,O
those,O
that,O
we,O
’d,O
propose,O
",",O
either,O
in,O
clinical,O
trials,O
or,O
in,O
other,O
publications,O
.,O
Recently,O
",",O
an,O
in,O
silico,O
approach,O
enlarged,O
to,O
all,O
possible,O
gene,O
networks,O
altered,O
by,O
COVID-19,O
disease,O
found,O
several,O
potential,O
therapeutic,O
molecules,O
[,O
53,O
],O
",",O
and,O
although,O
they,O
found,O
some,O
compounds,O
with,O
anti,O
-,O
inflammatory,O
properties,O
",",O
none,O
of,O
them,O
were,O
common,O
with,O
the,O
ones,O
that,O
we,O
found,O
.,O
Nimesulide,O
belongs,O
to,O
the,O
class,O
of,O
sulphonamides,O
;,O
it,O
is,O
a,O
non,O
-,O
steroidal,O
anti,O
-,O
inflammatory,O
drug,O
(,O
NSAID,O
),O
",",O
which,O
preferentially,O
inhibits,O
the,O
enzyme,O
cyclooxygenase-2,O
(,O
COX-2,O
),O
.,O
The,O
induction,O
by,O
estrogen,O
and,O
androgen,O
of,O
ACE2,O
",",O
and,O
possibly,O
of,O
IL2RA,O
",",O
established,O
a,O
negative,O
correlation,O
between,O
ACE2,O
expression,O
",",O
age,O
of,O
the,O
subjects,O
and,O
COVID-19,O
fatality,O
at,O
both,O
population,O
and,O
molecular,O
levels,O
[,O
62,O
],O
.,O
Specifically,O
",",O
we,O
used,O
the,O
gene,O
expression,O
profiles,O
from,O
public,O
datasets,O
including,O
The,B-Dataset
Cancer,I-Dataset
Genome,I-Dataset
Atlas,E-Dataset
",",O
Gene,B-Repository
Expression,I-Repository
Omnibus,E-Repository
 ,O
and,O
Genotype-Tissue,B-Dataset
Expression,E-Dataset
",",O
Gene,B-Dataset
Ontology,E-Dataset
 ,O
and,O
pathway,O
enrichment,O
analysis,O
to,O
investigate,O
the,O
main,O
functions,O
of,O
ACE2,O
-correlated,O
genes,O
.,O
